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Abstract 
Chemical modifications on mRNA have recently garnered attention as major regulators of 
cell behavior in embryonic development and many types of disease. In particular, N6-adenosine 
(m6A), is an abundant mRNA modification that mediates mRNA fate. Through distinct reader 
protein binding, m6A promotes various processing events such as mRNA degradation, alternative 
splicing, nuclear export, and translation initiation.  While we have known of the existence of m6A 
for many years, the recent discovery of m6A demethylases has spurred interest in this dynamic 
modification as a regulatory system. In vitro work showed that m6A appears to be especially 
important in stem cell biology, where knockout of the m6A methyltransferase complex components 
causes major impairments in stem cell self-renewal and differentiation. In vivo work has been 
severely limited by the fact that full knockout of Mettl3 or Mettl14, which are central parts of the 
m6A methyltransferase complex, is embryonic lethal. We therefore used conditional knockout mice 
in which Mettl14 is knocked out in neural stem cells. My thesis has focused on the role of m6A in 
in vivo brain development, with studies on m6A in mammalian development and Fragile X 
Syndrome. We showed that m6A promotes mRNA degradation of transcripts that regulate the 
balance between stem cell self-renewal and neurogenesis. Loss of m6A slows the tempo of 
neurogenesis and also revealed that neural stem cells are normally pre-patterned with transcription 
of neural genes prior to differentiation. In parallel, I studied the role of m6A in hypoxic breast 
cancer cells because hypoxia induces the m6A demethylase, ALKBH5, to drive global changes in 
m6A methylation patterns. In this system, m6A promotes translation of modified transcripts to 
promote global translation, cell division, and oxidative metabolism.  The study of m6A in multiple 
systems reveals the incredible cell-type specificity and dynamic nature of m6A.   
Primary Reader and Advisor: Hongjun Song 
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Introduction: the epitranscriptome in stem cell 




Foreword: This work was written as part of a review Neurobiology of Disease – Special Issue: 
Frontiers in Neuroepigenetics, which will be published in 2020. The text in this thesis introduction 
includes some additional information beyond the review work. This represents the development of 
the field of epitranscriptomics up to its current status in December 2019.  
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The blossoming field of epitranscriptomics has recently garnered attention across many fields by 
showing that chemical modifications on RNA have immense biological consequences.  
Methylation of bases in RNA, including N6-methyladenosine (m6A), 2-O-dimethyladenosine 
(m6Am), N1-methyladenosine (m1A), and 5-methylcytosine (m5C) and isomerization of uracil to 
make pseudouridine (Ψ), dynamically regulate gene expression, are critical for developmental 
processes, and contribute to disease states. The role of the epitranscriptome is especially relevant 
in stem cell biology and neurobiology. In particular, m6A occurs at the highest levels in the brain 
compared to any other tissue and plays major roles in embryonic stem cell differentiation, brain 
development, and neurodevelopmental disorders. However, studies in these areas have published 
conflicting results on epitranscriptomic regulation of stem cell pluripotency and mechanisms in 
neural development. In this review we will provide an overview of the current understanding of 
several RNA modifications and disentangle the various findings on epitranscriptomic regulation of 




I. Introduction / Modifications of Particular Interest (Figure 1): 
 
N6-methyladenosine: m6A 
Epitranscriptomic detection technologies have been focused on m6A, making it one of the 
best-studied modifications to date. m6A occurs in various types of RNA, including tRNA, rRNA, 
non-coding RNA (ncRNA), and mRNA. In 2012, two groups independently published m6A RIP-
Seq (MeRIP-Seq) techniques [1, 2]. Subsequent mapping of m6A in the transcriptome showed that 
it is most commonly added at a defined consensus sequence of DRACH (D=A,U or G; R=G or C; 
H=A, U, or C). m6A can occur in the coding region, but is especially enriched in the 3’UTR and 
5’UTR [1, 2].  While m6A does not alter Watson-Crick-Franklin base pairing, it can modify protein 
binding and affect mRNA secondary structure [3, 4].  Numerous m6A binding proteins, or readers, 
have been identified. Individual readers confer unique downstream fates on m6A-modified mRNA, 
including altered mRNA stability, translation, localization, and splicing. m6A methylation patterns 
in the transcriptome appear to be tissue-specific and species-specific [5]. On a global level, 0.2 to 
0.5% of all adenines are m6A modified [6]. The highest levels occur in the brain, where up to 30% 
of all transcripts are modified [7]. Since m6A is the focus of most epitranscriptomics studies 
described in this review, we will briefly review the proteins involved in m6A dynamics. 
 
m6A Methyltransferase Complex  
An increasing list of proteins form the methyltransferase complex that adds m6A onto 
mRNA. This complex includes a core heterodimer unit of METTL3 and METTL14, both of which 
are necessary for successful m6A addition to RNA [8]. Additional proteins in the mammalian 
complex include WTAP [8, 9], KIAA1429 [10], and RBM15/B [11]. These accessory proteins 
contribute to RNA binding, target specificity, and nuclear localization of the complex. The complex 
acts co-transcriptionally, meaning that the dynamics of m6A are likely due to demethylase activity 
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and changes in initial transcript methylation, but not new methylation of mature transcripts [12, 
13]. Notably, knockout of either METTL3 or METTL14 is embryonic lethal [14-17]. 
 
m6A Demethylases 
There are two known m6A demethylases, ALKBH5 and FTO [18, 19]. ALKBH5 co-
localizes with nuclear speckles, indicating that both methylation and demethylation occur in the 
nucleus. On the other hand, FTO can act in the nucleus and cytoplasm. However, the in vivo activity 
of FTO as an m6A demethylase has recently been questioned, with the suggestion that it may instead 
act on m6Am [10, 20-22].  Still, one recent study reported that FTO can demethylate m6A, m6Am, 
and m1A.  The specificity of FTO remains a major hurdle in the field of m6A; confirming its target 
is critically important so as not to mis-attribute a phenotype or biological function to the wrong 
epitranscriptomic mark. Finally, full knockouts of either ALKBH5 or FTO are not lethal, though 
they appear to be especially important in the cellular stress response [20, 23, 24].   
 
m6A Reader Proteins 
The highly variable functions of m6A can be attributed to its many distinct reader proteins. 
The central group of readers is the YTH-domain-containing family of proteins, which bind directly 
to m6A. These readers have recently been reviewed elsewhere [25, 26]. Briefly, YTHDC1 is found 
in the nucleus and regulates splicing, while YTHDF1, YTHDF2, YTHDF3, and YTHDC2 are 
cytoplasmic with various functions. YTHDF1 promotes translation, YTHDF2 promotes mRNA 
degradation, and YTHDF3 seems to promote either translation or degradation in a context-specific 
manner. Finally, the binding specificity and function of YTHDC2 remain unclear and may only be 




Unlike the internal m6A modification, N6,2’-O-dimethyladenosine (m6Am) occurs in the 
mRNA terminus at the first nucleotide following the N7-methylguanosine (m7G) cap. 
Approximately 0.0036% to 0.0169% of all adenines are m6Am modified when averaged across 
multiple human tissue types, corresponding to 526 to 1,028 unique transcripts, depending on the 
tissue type [5]. The number of m6Am-modified transcripts were previously thought to be much 
higher, but improved detection sensitivity has led to the viewpoint that m6Am is only moderately 
abundant [27].  FTO can remove m6Am from mRNA, though it also acts on other modifications like 
m6A. In contrast, three independent studies in 2019 confirmed that the cap-specific m6Am 
methyltransferase is phosphorylated C-terminal domain (CTD)-interacting factor 1 (PCIF1), which 
is thought to be unique to m6Am and targets newly transcribed mRNA by associating with RNA 
Polymerase II [28-30]. By knocking out PCIF1 in various cell lines, Boulias et al. found that m6Am 
most strongly correlates with high expression and increased transcript stability [30]. However, this 
was not universally true for all m6Am-modified transcripts, leaving the regulatory capacity of m6Am 
up for debate.  
Liu et al. analyzed the m6Am profile across tissues in both mice and humans and found that 
the m6Am methylome pattern is more clearly resolved in the brain than any other tissue. 
Furthermore, different brain regions (cerebellum, hypothalamus, and brainstem) are distinguishable 
from one another based on their m6Am patterns. Next, Liu et al. found a negative correlation 
between m6Am-modified mRNA and protein levels [5], which seemingly conflicts with the previous 
result that m6Am  promotes mRNA stability [30]. Nonetheless, the highly specific m6Am pattern in 
brain tissue suggests it may play a regulatory role in neural mRNA processing. Finally, Sendinc et 
al. found that m6Am decreases cap-dependent translation but does not affect mRNA stability [31]. 
The field would greatly benefit from identification of m6Am reader proteins that could help 




m1A is steadily gaining attention as sequencing becomes easier, yet the abundance of m1A 
remains under debate. Some studies found that 0.015% to 0.16% of adenines are m1A modified, 
corresponding with over 4,000 mRNA transcripts (about 20% of the transcriptome) [32, 33]. Others 
claim that only about 400 total m1A sites exist in mRNA [34, 35]. m1A also occurs in tRNA, which 
may be functionally distinct from m1A in mRNA. Though our understanding of the modification is 
limited, major progress was made through identification of putative m1A methyltransferases. 
Namely, TRMT6 and TRMT61A form a complex in the cytosol, and TRMT10C and TRMT61B 
complex in the mitochondria [36]. Currently, ALKBH3 is the only known m1A mRNA 
demethylase, though it also acts on DNA and m3C in RNA [37-39].  However, ALKBH1 can 
demethylate m1A in tRNA to impair translation initiation and elongation [40]. In mRNA, m1A is 
also thought to promote translation: it primarily exists in the 5’UTR near the translation initiation 
site (TIS), and its positive charge can induce changes in secondary mRNA structure [32, 36]. To 
our knowledge, no studies of m1A in the brain have been performed, leaving a major gap in 
knowledge that will undoubtedly be explored in the coming years.  
 
5-methylcytosine: m5C  
 m5C is added to tRNA, rRNA, and mRNA by a variety of methyltransferases with specific 
RNA targets [41]. DNMT2 and especially NSUN2 are the most well-characterized m5C 
methyltransferases that act on both tRNA and mRNA [42-44]. NSUN2-mediated m5C mRNA 
methylation promotes mRNA nuclear export through ALYREF, a nuclear m5C reader protein [43]. 
Additionally, m5C may cooperate with m6A to enhance translation of particular transcripts like p21 
[42]. Finally, m5C addition to a subset of ncRNAs called vault RNAs (vtRNAs) reduces 
downstream miRNA production [45]. Though no m5C direct demethylases has been identified, ten-
eleven translocation (Tet) enzymes can oxidize m5C to 5-hydroxymethylcytosine (hm5C) and then 
unmodified cytosine [46]. The frequency of hm5C is about one hm5C per 5000 m5C [47]. This is 
slightly enriched in mRNA, with hm5C occurring on ~7x10-6 of the total cytosines [48]. In 
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Drosophila, hm5C was shown to preferentially mark mRNAs in coding regions and promote their 
translation [47, 49]. However, no RNA hm5C reader proteins have been identified and its 
downstream function in mammals remains unclear.  
 
7-methylguanosine: m7G 
 In addition to m7G modification of the cap in mRNA, which promotes translation and 
protects mRNA from degradation [50], two independent studies identified m7G internally in 
miRNAs [51] and mRNA [52]. These 2019 studies by Pandolfini et al. and Zhang et al., 
respectively, show that m7G disrupts secondary structures of G-quadruplexes to mediate miRNA 
processing and promotes translation of modified mRNA. Both groups showed that a complex 
between METTL1 and WDR4 catalyzes m7G addition to RNA in mammals [51, 52]. This is the 
same enzymatic complex that adds m7G to tRNA to regulate translation [53], while WBSCR22 
regulates m7G addition to rRNA [54]. To date, no m7G demethylases have been identified.  
 
Pseudouridine: Ψ 
While pseudouridine (Ψ) is one of the most abundant modifications in ncRNA, it’s 
existence in mRNA is a recent finding [55, 56]. PUS1 and PUS7 enzymes isomerize uridine to 
pseudouridine [57] in an mRNA structure-dependent manner [58]. Other PUS-family proteins add 
Ψ to other types of RNA. On the other hand, no direct readers or removal enzymes have been 
identified, indicating Ψ may be irreversible. Some downstream effects of Ψ include weakening 
interactions between mRNA and Pumilio family proteins (PUFs) [59] and stabilizing RNA 
structure by improved base stacking and increased hydrogen bonding [55, 60, 61]. Ψ has also been 
hypothesized to promote translation efficiency, though this remains to be proven [55].  
 
 




The ability to detect epitranscriptomics marks is necessary to understand the biology. 
Development of sensitive and accurate sequencing techniques is an ongoing process that is central 
to progression of the field as a whole. Due to this importance, we will provide a brief overview of 
the current technologies available for detection of m6A and highlight the rapid progress made in 
the past two years.   
 
RIP and CLIP-seq 
The first method developed to detect m6A was methylated RNA immunoprecipitation (IP) 
and sequencing (MeRIP-seq, m6A-seq) using an antibody against m6A. This method calculates 
enrichment of mRNA fragments after m6A IP relative to total input mRNA using peak-calling 
methods like MACS. However, peaks represent an accumulation of aligned sequencing reads and 
do not provide single-base resolution. Furthermore, current m6A antibodies cannot distinguish 
between m6A and m6Am, meaning m6A sites identified by meRIP-seq likely contain significant 
false positives or inaccuracies. Nonetheless, as the first method developed, meRIP-seq was 
fundamental in establishing the field of epitranscriptomics and revolutionized our understanding of 
m6A biology. MeRIP-seq was further improved by UV-induced RNA-antibody crosslinking that 
allows for single base resolution. A number of methods using UV crosslinking have been 
developed, including photoactivatable ribonucleoside-enhanced crosslinking and 
immunoprecipitation (PAR-CLIP), UV crosslinking and immunoprecipitation (UV CLIP), and 
m6A individual-nucleotide-resolution crosslinking and immunoprecipitation (miCLIP). These and 
other antibody-based methods have been reviewed in-depth elsewhere [62].  
 
Enzymatic Detection of m6A  
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In 2019, two antibody-free methods for global m6A detection were published. These 
techniques overcome the limitations of antibody specificity and the large quantities of RNA 
necessary for successful RIP-Seq methods and reduce the difficulty of library preparation. First, 
Garcia-Campos*, Edelheit* et al. developed a technique for RNA digestion via m6A sensitive 
RNase (MAZTER-seq), which uses the bacterial RNase MazF to detect m6A. MazF cleaves RNA 
upstream of “ACA” sites, but not “m6A-CA” sites. Therefore, by fragmenting mRNA with MazF, 
ligating adapters and reverse transcribing, and finally amplifying and sequencing, MAZTER-seq 
can identify m6A sites as read-through ACA sites that are not at the terminal end of a read. In 
contrast, unmodified ACA sites occur at either end of every read. However, MAZTER-seq is 
limited by the fact that it can only detect m6A in ACA sites, which represents a mere 16% of all 
m6A sites in mammals. Furthermore, MazF digestion led to only 50-60% of reads beginning and 
ending with ACA, suggesting that MazF cleavage of ACA sites is fairly limited. Still, for the sites 
that are quantifiable by MAZTER-seq, the method provides high sensitivity, single nucleotide 
resolution, and rough quantification of the percent of a particular gene transcript that is m6A 
modified [63].  
 The second enzymatic technique developed in 2019 entails deamination adjacent to RNA 
modification targets (DART-seq). This method utilizes APOBEC1, a cytosine deaminase that 
induces cytosine-to-uracil (C-to-U) editing in both DNA and RNA. By fusing APOBEC to the YTH 
domain of m6A-binding proteins, K. Meyer targeted the base editing system to m6A sites. This in 
turn allows for transcriptome-wide mapping of m6A with only 10 ng of input mRNA and 
comparable sensitivity to antibody-based approaches. More specifically, APOBEC1 deaminates 
the cytidine immediately following m6A in the DRACH motif. C-to-U editing analysis of DART-
seq reads detected m6A sites with 64% overlap with m6A sites identified by MeRIP-seq. This 
percentage could be interpreted as the sensitivity of DART-seq, or as the promiscuity of MeRIP-
seq in identifying marks besides m6A. Furthermore, 91.4% of C-to-U editing sites are preceded by 
an A, confirming the specificity of APOBEC1-YTH for cytidines directly adjacent to m6A. DART-
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seq has several major advantages over other available techniques: it can be used as an indicator of 
m6A abundance on individual RNAs, it distinguishes between m6A and m6Am, and it can be 
combined with long-read PacBio sequencing to identify isoform-specific methylation patterns [64]. 
Overall, DART-seq provides an exciting platform to improve the ease and accuracy of 
transcriptome-wide identification of m6A and holds great potential for pushing the field of 
epitranscriptomics forward.   
 
Nanopore Direct RNA Sequencing 
Direct RNA sequencing is one of the most recently developed methods for detection of 
mRNA modifications. Using Oxford Nanopore Technology (ONT) sequencing, Lorenz et al. 
developed a software to identify m6A sites from in vitro HEK293T RNA. This m6A Identification 
using Nanopore Sequencing (MINES) was able to use nanopore electric current data to predict 
previously reported m6A sites from CLIP-seq data with about 80% accuracy, though this only 
represented about 35% of the total reported CLIP sites and requires the m6A site to be in the 
DRACH consensus motif. However, MINES still depends on averaging signal deviations at every 
predicted m6A site, meaning it currently cannot be used for single molecule detection that would 
determine the percentage of reads methylated at a particular site [65]. In an independent study, Liu 
et al. also used current intensity changes in ONT sequencing to create an algorithm that can detect 
m6A methylation with up to 88-91% accuracy by combining information on base quality, mismatch, 
and deletion frequency. However, this algorithm also depends on averaging of reads for one site 
and therefore cannot predict the modification status of individual transcripts [66].  Current ONT 
sequencing also cannot differentiate between m6A and m1A, which hinders its utility as the field of 
epitranscriptomics moves toward more in-depth analysis of distinct modifications. Still, direct 
RNA m6A nanopore sequencing provides an exciting avenue for future detection strategies, 
particularly because the software tools can be applied to any nanopore RNA sequencing and does 
not require additional processing to detect m6A. 
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Detection of other mRNA modifications 
Pseudouridine can be identified through chemo-selective alteration of the modified base 
followed by sequencing. Specifically, Ψ can be selectively modified by N-cyclohexyl-N′-β-(4-
methylmorpholinium)ethylcarbodiimide (CMC) to form a covalent adduct that arrests reverse 
transcription. Therefore, recurrent reverse transcription termination sites have been used to map Ψ 
at single-nucleotide resolution [55-57, 67]. This method was further improved by using N3-CMC, 
a derivative of CMC that contains an azide, which allows for biotinylation of Ψ-N3-CMC adducts 
and streptavidin enrichment (CeU-seq). This increased the sensitivity of Ψ detection nearly 10-fold, 
with 2,084 Ψ sites identified in HEK293T cells [68].  
m1A mapping has been a major challenge due to its extremely low stoichiometries, with 
estimates ranging from only about 50 modified mRNA transcripts [35] up to about a thousand [33]. 
However, m1A can also occur on tRNA, lncRNA, and rRNA, and total stoichiometry does not 
necessarily correlate with functional power. Transcriptome-wide mapping of m1A was first 
performed using and antibody pull-down method (m1A-seq) [32, 33]. More recently, multiple 
independent studies generated single base-resolution methods that use misincorporation patterns 
upon reverse transcription of m1A-containing RNA, which depends on m1A disrupting Watson-
Crick-Franklin base pairing [34, 36, 69]. Most recently, Khoddami et al. published a method that 
can detect m5C, Ψ, and m1A at single-base resolution in a modified RNA bisulfite sequencing 
method named RBS-Seq [44]. However, this study found significantly different epitranscriptomics 
patterns than previous work; it remains difficult to tell if new methods are more specific or less 
sensitive than previous methods. In upcoming years, we expect rapid progression in single 
experiment combined mapping of multiple modifications, in particular those that disrupt base 




III. Epitranscriptomics in stem cell biology:  
 
 Epitranscriptomics appears to be especially important in stem cell biology, as it contributes 
to self-renewal and differentiation capacity. m6A is by far the most studied RNA modification in 
stem cells, particularly in embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).     
 
Embryonic Stem Cells (ESCs) 
Early reports of m6A in ESCs were somewhat conflicting. In 2014, Wang et al. found that 
knockdown of Mettl3 and Mettl14 reduces m6A abundance and impairs stem cell self-renewal [15]. 
In contrast, Batista et al. then reported that Mettl3 knockout in mESCs improves self-renewal but 
blocks differentiation [16]. However, both of these studies examined mESC in vitro, which 
muddies our understanding of the exact stage the ESCs are in and what m6A might do to drive 
embryonic development in vivo. This gap was addressed by Geula et al., who performed one of the 
first major studies of m6A in naïve pluripotent mouse ESCs. Naïve mESCs exist in a distinct 
molecular state compared to more advanced, “primed” epiblast stem cells (EpiSC). By knocking 
out Mettl3, they identified m6A as a key driver of termination of the naïve state and entry into the 
primed state, which is necessary for proper lineage differentiation at the post-implantation 
embryonic stage. The effects of impaired differentiation are so drastic that loss of m6A causes early 
embryonic lethality [6]. Importantly, this study further clarified that m6A regulates the genes 
governing both naïve and primed states, and that loss of m6A causes upregulation of whichever 
genes are modified in that particular stem cell state. So, naïve mESCs show enhanced pluripotency 
upon Mettl3 knockdown, whereas primed EpiSC show increased stability of lineage-commitment 
genes upon loss of m6A [6, 70]. Mechanistically, this study and others determined that m6A 
primarily functions in development by reducing mRNA stability, which allows for the rapid 
clearance of key naïve pluripotency-promoting transcripts or pro-differentiation transcripts, 
depending on the stem cell stage [6, 15, 16, 71].  
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In addition to the traditional Mettl3/Mettl14-mediated addition of m6A to mRNA, several 
other m6A methyltransferases were thought to exist. In particular, METTL16 was identified in 
human cells as an m6A methyltransferase that primarily targets small nuclear RNA (snRNA), 
specifically U6 snRNA, and other non-coding RNAs [72]. Additionally, METTL16 regulates 
expression of the SAM synthetase MAT2A [73], which is highly consequential for all 
modifications that use SAM as a methyl donor. To this end, Mendel et al. found that METTL16-
mediated modification of Mat2a mRNA is necessary for proper embryonic development of mouse 
blastocysts, and homozygous knockout of Mettl16 is embryonic lethal. Analysis of E2.5 Mettl16 
KO mouse blastocysts showed that only 20 genes are differentially expressed relative to the WT, 
with Mat2a showing the most significant downregulation. However, by E3.5 the global 
transcriptome was massively dysregulated [74]. The role of this non-canonical m6A pathway in 
embryonic development suggests that m6A in snRNA is uniquely regulated and has distinct 
functions at different stages of development. While the more common Mettl3/Mettl14-mediated 
pathway has garnered the most attention, understanding the complexities of the epitranscriptome 
as it changes during development will be necessary to accurately characterize the many roles of 
m6A.  
 
m5C in mESCs 
 The overwhelming focus of research in ESCs has been centered around m6A, but there is 
also one published study on m5C in mESCs. In 2017, Amort*, Rieder* et al. identified 12,492 m5C 
sites in nuclear mESC mRNA. Modified mRNAs were enriched for gene ontologies corresponding 
to cell cycle, RNA processing, chromatin modification, and developmental processes. Though the 
functionality of m5C in mESCs was not shown, a correlation between m5C sites and RNA binding 
protein (RBP) sites was identified. Approximately 29% of m5C sites in mESCs overlap with known 
RBP sites. More specifically, the largest overlaps correspond to UPF1 binding, which regulates 
nonsense-mediated RNA decay. Additionally, SRSF3 and SRSF3 splicing factors and the PRC2 
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subunit EZH2 have binding sites that significantly overlap with m5C sites. This led to the hypothesis 
that m5C may contribute to RBP binding and functionality, though this requires further validation 
[75]. As detection of diverse mRNA modifications continues to improve and orphan 
methyltransferase targets are identified, we expect our understanding of epitranscriptomics 
regulation of stem cells to grow rapidly. Notably, the low stoichiometry of some modifications 
relative to m6A should not decrease their perceived importance, as the power of the modification is 
derived from the strength of its downstream effects, which vary widely among reader proteins.  
 
tRNA epitranscriptomic regulation of ESCs 
Finally, modification of ncRNA, especially tRNA, also regulates ESC self-renewal and 
differentiation. For example, m7G on tRNA in mESCs promotes translation of mRNAs crucial for 
cell cycle progression and neural differentiation [50]. Similarly, NSUN3-mediated addition of m5C 
to mitochondrial tRNA promotes mESC proliferation and balances differentiation into mesoderm, 
endoderm, and neuroectoderm [76].  
 
Induced Pluripotent Stem Cells (iPSCs) 
 The understanding that m6A contributes to pluripotency and differentiation drove studies 
of its regulatory capacity in iPSCs. In 2015, Chen et al. showed that high abundance of m6A 
increases the reprogramming efficiency of mouse embryonic fibroblasts (MEFs) to pluripotent 
stem cells, in part by altering expression of key pluripotency factors like Oct4, Sox2, and Nanog. 
This study further found an interplay between microRNA (miRNA) binding to mRNA and 
enhanced METTL3 binding to mRNA to promote de novo addition of m6A [17]. This concept of 
m6A interplay with noncoding RNAs has been explored with contrasting conclusions, and has been 
reviewed in-depth elsewhere. [77]. Furthermore, Chen et al. found that Mettl3 knockdown reduces 
iPSC colony formation [17]. However, Geula et al. found that Mettl3 knockdown does not impair 
reprogramming efficiency, but rather slows proliferation of iPSCs in early reprogramming [6]. 
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Finally, in 2019, Wu et al. found that Mettl3 knockdown decreases the proliferation rate of porcine 
iPSCs (piPSCs) and impairs expression of key pluripotency genes, though they did not test for 
reprogramming efficiency. This study further identified that m6A promotes YTHDF1-mediated 
translation of JAK2 in piPSCs, while promoting degradation of SOCS3 via YTHDF2 [78]. Both of 
these mechanisms lead to upregulation of the JAK2-STAT3 signaling pathway, which is known to 
promote stem cell self-renewal by increasing expression of the core pluripotency genes Klf4 and 
Sox2 [78, 79].  
 Overall, m6A clearly regulates the pluripotency of iPSCs, but its role in reprogramming 
likely depends on the cellular context of the starting material or the stage of reprogramming. As 
was the case in ESCs, m6A may alter expression of the gene transcripts already present. Still, further 
investigation is needed to identify the fate of m6A-modified transcripts. While m6A-mediated 
mRNA degradation appears to be a major mechanism, expression of other reader proteins suggests 
a more complex system. Understanding how m6A reader proteins selectively bind particular mRNA 
targets will be a major step forward in further elucidating the mechanisms of m6A action in iPSCs.  
    
Regulation of Stem Cell Epitranscriptomes 
 Upstream regulation of m6A deposition or differential expression of the writers, readers, 
and erasers contributes to the function of m6A in stem cells. For example, in 2015 Aguilo et al. 
showed that zinc finger protein 217 (ZFP217) coordinates epigenetic regulation with m6A 
deposition. More specifically, ZFP217 is a transcription factor that directly activates transcription 
of several key pluripotency genes, then blocks m6A modification of these genes by sequestering 
METTL3 in mESCs and iPSCs. ZFP217 knockdown causes global increases in m6A levels, which 
correlates with a decreased half-life of Nanog, Sox2, c-Myc, and Klf4 mRNA transcripts. This in 
turn impairs pluripotency and reprogramming [80].  
 Next, in 2018 Wen et al. found that another zinc-finger protein, Zc3h13, is critical for m6A 
deposition, and Zc3h13 knockdown significantly impairs self-renewal and maintenance of 
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pluripotency in mESCs [81]. This study was based on the finding that Zc3h13 can form a complex 
with WTAP, Virilizer (Kiaa1429), and Hakai, which also contribute to the METTL3-METTL14 
m6A methylation complex [82, 83]. Wen et al. then showed that Zc3h13 knockdown in mESCs 
decreases global m6A levels to about 30-40% of m6A levels in the control, and confirmed m6A 
dependency on Zc3h13 through MeRIP-seq. More specifically, Zc3h13 promotes m6A deposition 
by localizing the Zc3h13-WTAP-Virilizer-Hakai complex to nuclear speckles; loss of Zc3h13 
causes these complex components, as well as Mettl3/Mettl14, to significantly shift to localization 
in the cytoplasm. Functionally, Zc3h13 knockdown impairs mESC self-renewal, decreases 
expression of pluripotency genes, and increases expression of differentiation markers in correlation 
with differential m6A modification of these gene transcripts [81].  The conclusion that m6A 
promotes self-renewal is consistent with previous studies [15], and the consequences on 
pluripotency correspond to studies performed under similar conditions in mESCs [6]. The two 
studies described here on zinc finger proteins are important examples of how m6A may be regulated 
or targeted to individual transcripts in stem cells. This connection between transcription factors and 
epitranscriptomic regulation remains an interesting avenue for further research.  
 In addition to individual transcription factors, Bertero et al. showed in 2018 that the TGFβ 
signaling pathway contributes to m6A-mediated regulation of pluripotency in human pluripotent 
stem cells (hPSCs). Activin and NODAL are members of the TGFβ signaling pathway that regulate 
cell fate decisions via downstream transcription factors SMAD2 and SMAD3 (SMAD2/3). Bertero 
et al. showed that SMAD2/3 interacts with the METTL3-METTL14-WTAP complex in hESCs and 
hiPSCs to increase methylation of SMAD2/3 target genes, and that this interaction is dependent on 
phosphorylation of SMAD2/3, which requires activin-NODAL signaling. Inhibition of activin-
NODAL signaling decreases m6A levels, particularly in genes that are bound by SMAD2/3 and 
regulate stem cell exit from pluripotency (especially NANOG). In this study, m6A was found to 
promote degradation of modified transcripts to allow for rapid degradation of pluripotency genes, 
meaning it promotes the ability of hPSCs to rapidly differentiate upon receiving extracellular cues 
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[84]. This contrasts with the finding from Geula et al. that m6A promotes pluripotency in mESCs 
[6], but may also be caused by differences in human and mouse stem cells. Nonetheless, Bertero et 
al. provide the first example of how extracellular signaling can induce dynamic changes in m6A to 
regulate cell fate through the epitranscriptome.  
 Finally, a single study has found a direct connection between histone methylation and sites 
of m6A deposition. This 2019 study by Huang et al. showed that histone H3 trimethylation at lysine-
36 (H3K36me3) drives m6A methylation by recruiting and promoting interactions between the m6A 
methyltransferase complex and its target mRNA. More specifically, METTL14 binds to 
H3K36Me3, chromatin, and RNA, thereby promoting co-transcriptional addition of m6A to genes 
with H3K36Me3 epigenetic marks. Knockdown of the H3K36Me3 methyltransferase, SETD2, 
impairs binding of the m6A methyltransferase complex to sites that lose H3K36Me3 and globally 
reduces m6A levels. In mESCs, SETD2 knockdown induces higher expression of pluripotency 
factors (OCT4, SOX2, NANOG) and prevents increased m6A methylation during differentiation. 
This suggests that H3K36Me3 drives m6A modification to destabilize pluripotency genes and 
promote differentiation, and loss of either H3K36Me3 or METTL14 promotes pluripotency over 
differentiation [85].  This corresponds with previous reports that m6A is necessary for proper 
differentiation of mESCs [6, 16], and provides the first evidence that m6A addition may be directed 
by epigenetic marks.  
While a few studies have identified how the epitranscriptome may be regulated, over 100 
putative METTL3 or METTL14 binding proteins have been identified, suggesting there is much 
left to be learned about upstream regulation of m6A [86]. Both a better understanding of how the 
methyltransferase complex and demethylases target specific gene transcripts and an understanding 
of how writer, reader, and eraser expression are regulated will drive the field forward. 
 
 
IV. Epitranscriptomics in Neural Development: 
 18 
 
 Recent work has shown that the epitranscriptome, in particular m6A, is especially important 
for neural development and brain function. Lence et al. performed one of the first breakthrough 
studies of m6A in the brain, using Drosophila melanogaster as a model organism. This study showed 
that m6A is enriched in the nervous system and that knockout of the methyltransferase components 
causes reduced lifespan, severe behavioral defects, and global changes in neural gene expression 
[87]. While this work was important for understanding m6A in vivo, it contrasted with mammalian 
studies in that loss of m6A methyltransferases is not embryonic lethal in flies. The next major 
breakthrough came by conditional knockout of the m6A methyltransferase complex, which allowed 
for the study of the epitranscriptome in mammalian brain development. Below we provide an in-
depth overview of the epitranscriptome in mammalian neural development.  
 
Cortical Development 
 In 2017, our lab showed that conditional knockdown (cKO) of Mettl14 in mice and 
subsequent loss of m6A in neural progenitor cells (NPCs) drastically impairs brain development in 
vivo. Loss of m6A impairs NPC differentiation, slows cell cycle progression, and elongates the 
timing of cortical neurogenesis into postnatal stages. Mechanistically, m6A-modified genes are 
significantly enriched for gene ontologies that correlate with regulation of transcription, neuron 
differentiation, cell cycle, and stem cell differentiation. These modified transcripts have a shorter 
half-life than their corresponding unmodified transcripts in Mettl14 cKO mouse forebrains, 
suggesting that m6A normally destabilizes mRNA in the developing brain. By modifying both 
pluripotency and differentiation promoting transcripts, the m6A system allows for rapid changes in 
gene expression that are necessary for the harmonious progression of NPCs through the distinct 
phases of embryonic cortical neurogenesis. To this end, we found that Mettl14 cKO NPCs co-
express stem cell and neural markers, and that rapid degradation of neural markers in WT NPCs 
allow for pre-patterning of differentiation by allowing transcription of pro-neural genes but 
 19 
preventing significant protein production. Finally, we used iPSC-derived human brain organoids to 
confirm that m6A also regulates NPC proliferation and differentiation in humans. We then 
compared m6A-seq analysis between human post-conception week 11 embryonic brain tissue and 
E13.5 mice. While many gene transcripts were m6A-modified in both species, the human-specific 
modifications correlated strongly with disease ontologies for human-specific mental disorders like 
autism and schizophrenia [88]. This work provided the first in vivo analysis of m6A in mammalian 
brain development and highlighted the possibility that m6A may contribute to psychiatric or 
neurodevelopmental disorders in humans. 
 Shortly thereafter, an independent study by Wang et al. knocked out Mettl14 in the 
developing forebrain, and also found that loss of m6A slows NPC cell cycle progression. In vitro 
analysis of Mettl14 cKO NPCs showed that loss of m6A can cause premature differentiation, and 
in vivo analysis showed that Mettl14 cKO mice had reduced numbers of Pax6+ NPCs and reduced 
numbers of Satb2+ late-born neurons. This led the authors to suggest that depletion of the NPC 
pool causes a reduction in neurogenesis [89]. This contrasted with our study, which showed an 
increase in Pax6+ cells in Mettl14 cKO forebrains, but a similar decrease in late-born neurons; we 
therefore proposed that m6A is necessary for the timely differentiation of NPCs, and loss of m6A 
causes a build-up of Pax6+ NPCs [88]. These differences may stem from different methodologies 
or antibodies. Nonetheless, the studies agree that m6A regulates mRNA stability to alter gene 
expression and NPC fate. Next, Wang et al. identified genome-wide changes in histone 
modifications upon Mettl14 knockout. Specifically, cKO NPCs show increases in histone H3 
acetylation at lysine 27 (H3K27ac), histone H3 trimethylation at lysine 4 (H3K4me3), and histone 
H3 trimethylation at lysine 27 (H3K27me3). Chemically blocking these epigenetic marks partially 
rescues cKO NPC proliferation defects. The changes in histone modification were partially 
attributed to m6A-mediated stability of CBP and p300 transcripts, which are stabilized upon loss of 
m6A. However, this did not apply to transcripts in the PRC2 complex, suggesting there are also 
other mechanisms at play [89]. Overall, the connection between the epitranscriptome and 
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epigenetics in the developing brain is highly intriguing. As single transcript m6A editing techniques 
are developed, it would be pertinent to edit only CBP and p300 mRNA to quantify the degree to 
which their methylation contributes to the Mettl14 cKO phenotype, as opposed to the sum of many 
modified transcripts. 
 Finally, a third study conditionally knocked out Ythdf2 in the developing forebrain to show 
that m6A largely functions through YTHDF2-mediated mRNA degradation during cortical 
development. In this study, Li et al. showed that Ythdf2 KO mice have a very similar phenotype to 
Mettl14 cKO mice. In particular, loss of Ythdf2 impairs NPC proliferation and differentiation, and 
causes delays in cortical neurogenesis. They also found that Ythdf2-/- NPCs create fewer primary 
neurites per neuron and shorter neurites overall when differentiated in vitro, suggesting that m6A 
also regulates neuron maturation during the differentiation process [90]. This study was necessary 
to confirm that m6A regulation of cortical development functions primarily through YTHDF2-
mediated mRNA degradation and that m6A promotes NPC proliferation and differentiation.  
 
Cerebellar Development 
 The complexity of the brain suggests that epitranscriptomic regulatory systems may have 
distinct functions in different parts of the brain. Indeed, Chang et al. showed that m6A levels are 
increased in the adult mouse cerebellum compared to the cerebral cortex, and that there are region-
specific methylation patterns [7]. Even within the cerebellum, methylation patters change over 
developmental time. In 2018, Ma et al. showed that methylation targets change across postnatal 
day 7 (P7), P14, P21, and P60 mouse cerebella. There are 12,452 m6A peaks that are turned “ON” 
(emerge at a later stage) over time, and 11,192 that are turned “OFF” (disappear in later stages). 
The groups of transcripts methylated at each timepoint correspond with the developmental 
processes happening at that time. For example, gene transcripts in which m6A is turned OFF from 
P7 to P14 have gene ontologies enriched for cell cycle. On the other hand, gene transcripts in which 
m6A is turned ON at P14, P21, or P60 have gene ontologies enriched for signal transduction, cell 
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adhesion, learning, and synaptic plasticity. Overall, m6A modification patterns strongly correlate 
with the progression from proliferating cells at P7 to mature neuronal activities at P60. This study 
also examined changes in expression of METTL3, METTL14, WTAP, FTO, AND ALKBH5. 
Though cerebellar expression of all of these genes decreased on average over time, there was a 
specific reduction in internal granular layers but elevated expression in Purkinje cells. Lentiviral 
Mettl3 knockdown at P7 lowers the number of Purkinje cells and impairs their organization along 
the outer surface of the inner granule cell layer. On the other hand, Alkbh5-KO mice had no 
observable phenotype in the cerebellum under normal conditions, which may be due to redundant 
action by FTO. After stressing the developing brain with hypobaric hypoxia, Alkbh5-KO mice had 
significantly smaller cerebella and fewer mature neurons, yet significantly more proliferating cells. 
This suggests that ALKBH5 is critical for promoting cerebellar neurogenesis under stress. Finally, 
this study showed that several important gene transcripts are differentially localized in the 
cytoplasm over nucleus in Alkbh5-KO cerebella, indicating that m6A promotes nuclear export in 
this tissue [24].   
 In contrast, Wang et al. used a Mettl3 cKO mouse model to show that m6A promotes 
mRNA degradation and alternative splicing in the cerebellum. Mettl3 cKO mice have drastically 
smaller cerebella, significantly fewer cerebellar granule cells (CGCs) in the internal granular layer 
(IGL), and disordered Purkinje cell organization relative to WT controls. Furthermore, loss of m6A 
causes significantly increased levels of apoptosis of newborn granule cells, which explains the 
depletion of CGCs. Again, loss of m6A increases mRNA stability; m6A modification on apoptosis-
associated gene transcripts normally restricts their expression. Notably, m6A-mediated regulation 
of apoptosis appears to be specific to the cerebellum, as these transcripts are not stabilized in the 
cortex of Mettl3 cKO mice. Finally, Wang et al. identified an additional mechanism of m6A-
mediated alternative splicing in the cerebellum. Exon exclusion occurs more frequently upon m6A 
depletion, especially in transcripts that are normally methylated in the WT. These alternatively 
spliced transcripts are enriched for gene ontologies in synapse-associated pathways and 
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neurotransmitter receptors. Further analysis showed that increases in intracellular calcium 
concentration in Mettl3 cKO CGCs contributes to their increased apoptosis [91]. This work 
highlights the fact that epitranscriptomics regulation is highly cell-type specific with unique roles 
in different parts of the brain. How this specificity is regulated will be an interesting avenue of 
future research.  
 
Adult neurogenesis 
 The m6A demethylase FTO has been implicated in numerous pathways in the mature brain, 
from cancer [92] to psychiatric and neurodegenerative diseases [93-97] to regulation of adult neural 
stem cells [98, 99]. However, understanding the role of FTO remains difficult due to its multiple 
functions in DNA and RNA demethylation. In fact, the first study on FTO in neurogenesis was 
published in 2010, before FTO was even identified as an m6A demethylase [18, 98]. In 2010, Gao 
et al. generated whole-body and neural-specific Fto KO mice, and found that the two have very 
similar phenotypes, indicating that the majority of FTO function occurs in the nervous system [98]. 
In 2017, Li*, Zang*, Zhang* et al. showed that FTO is expressed in adult NSCs (aNSCs) and in 
mature neurons and increases over postnatal time. Fto KO mice show reduced proliferation and 
aNSC differentiation, which functionally impairs learning and memory. Furthermore, loss of FTO 
results in slightly higher (~15%) levels of m6A, though only 363 genes are both m6A modified and 
differentially expressed upon loss of FTO (out of 5635 m6A-modified genes and 1862 FTO-
dependent genes) [99]. While FTO does seem to regulate adult neurogenesis, the degree to which 
this is enacted through m6A remains in question, especially considering FTO can act on multiple 
targets in vivo.  
 Next, Chen et al. found that Mettl3 knockdown impairs both proliferation and 
differentiation of aNSCs cultured in vitro. m6A sequencing showed that the m6A landscape is 
dynamic between proliferating and differentiating cultured aNSCs; transcripts modified only in 
proliferating aNSCs correlate with cell cycle, while transcripts modified only in differentiating 
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aNSCs are enriched for protein localization, signaling, and synapse organization [100]. This study 
is slightly more direct in studying m6A in adult neurogenesis by knocking down Mettl3, but the use 
of cultured aNSCs limits the conclusions that can be drawn; aNSCs exist in highly specialized 
niches in vivo that are difficult to recapitulate in vitro [101, 102].  
 Finally, a 2019 study by Cao*, Zhuang* et al. found that Fto cKO in aNSCs decreases 
aNSC proliferation and differentiation into NeuN+ neurons at 4 weeks after FTO knockout. While 
the fate of m6A-modified transcripts was not tested, individual mRNA transcripts in the Stat3 
signaling pathway, Socs5 and Pdgfrα, were shown to play important roles in FTO-mediated 
regulation of aNSCs. However, Socs5 mRNA and protein decrease in Fto cKO aNSCs, while 
Pdgfrα mRNA and protein increase [23]. Therefore, the involvement of m6A and mechanisms of 
m6A-mediated regulation in aNSC remain unclear. In multiple studies, effects of Fto or Mettl3 KD 
appear stronger in in vitro cultured cells than in vivo aNSCs. The highly dynamic nature of m6A in 
response to signaling and stress stimuli suggest that culturing systems need to be incredibly 
carefully controlled to maintain an accurate representation of the epitranscriptome in in vivo 
aNSCs.      
 
V. Epitranscriptomics in Neurodevelopmental Disease: 
 
 In accordance with its powerful role in neural development, m6A has been linked to 
neurodevelopmental defects as well. To date, m6A in Fragile X Syndrome is the best-characterized 
interaction. Additionally, emerging genome-wide association studies and human genetics studies 
have linked mutations in epitranscriptomic enzymes with intellectual disability.  
 
Fragile X Syndrome 
 Fragile X mental retardation protein (FMRP), encoded by FMR1, is an RNA-binding 
protein that is best known for negatively regulating the translation of its target mRNAs [103, 104] 
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and trafficking mRNA granules [105].  Loss-of-function mutations in FMR1 cause Fragile X 
Syndrome, which is marked by intellectual disability and delayed development. In 2017, Arguello 
et al. identified FMRP as an m6A binding protein in vitro [106]. Zhang et al. then showed that 
FMRP target genes are enriched for m6A marks in the mouse cerebral cortex, and that FMRP 
binding to m6A-modified mRNAs followed by interaction with YTHDF2 promotes degradation of 
FMRP target genes [107].  Next, Edens et al. showed that FMRP promotes nuclear export of m6A-
modified mRNA by interaction with the CRM1 nuclear export protein. Additionally, Fmr1 KO 
mice phenocopy Mettl14 cKO mice in terms of delayed neurogenesis and impaired NPC 
proliferation. In both of these mouse models, FMRP target mRNAs are retained in the nucleus 
[108]. The binding affinity of FRMP for m6A-modified mRNA and role in nuclear export was 
recently confirmed by Hsu et al [109]. 
 
Intellectual Disability 
 Four recent studies identified correlations between epitranscriptomic modifications and 
intellectual disability. First, Shaheen et al. found that mutations in human PUS3, a 
pseudouridinylation enzyme, correlates with intellectual disability and microcephaly in three 
affected siblings. The affected individuals also have a significant reduction in Ψ-modified tRNA 
relative to healthy controls in purified lymphoblastoid cells. The PUS3 deficiency phenotype in 
humans is largely brain-specific, suggesting that PUS3-mediated tRNA Ψ modification is 
especially important for cognitive function [110].  
 Next, both de Brouwer et al. and Shaheen et al. identified mutations in PUS7, a tRNA and 
mRNA pseudouridinylation enzyme, that cause intellectual disability, microcephaly, speech delay, 
and aggressive behavior [111, 112]. Ψ at position 13 in tRNA and PUS7 target mRNAs were 
significantly reduced in affected individuals compared to healthy controls. Additionally, Pus7 
knockout in Drosophila recapitulates the cognitive impairment phenotype and the molecular loss 
of Ψ at particular target sites [111]. This provides exciting evidence that Ψ modification of mRNA 
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and tRNA is not only highly conserved across species, but is critical in neural development. 
Additional studies using mouse models to disseminate the exact mechanism of Ψ in neural 
development will be an exciting next step.  
 Finally, Richard et al. identified frameshift mutations in METTL5, which putatively adds 
m6A to 18S rRNA [113], that cause autosomal-recessive intellectual disability and microcephaly. 
METTL5 is expressed in the human brain from early development and into adulthood, particularly 
in the cerebellar cortex, hippocampus, and striatum. Analysis in rodents confirmed ubiquitous 
METTL5 expression in the brain, with increased staining in neural soma and nuclei, as well as in 
pre- and post-synaptic regions. Finally, mettl5 knockout in zebrafish recapitulates the microcephaly 
phenotype and specifically causes decreases in forebrain and midbrain size [114]. While METTL5 
methyltransferase action and specificity are not well characterized, this genetic evidence suggests 
that it is yet another epitranscriptomics modifier that is crucial for proper brain development. 
 
VI. Concluding Remarks and Future Outlook: 
 
 The field of epitranscriptomics has reached a point where the power of various mRNA 
modifications has become widely accepted, but the specific mechanisms of their action remain 
under debate. It is becoming increasingly important to perform extremely careful experiments to 
detect and validate epitranscriptomics marks to prevent further confusion regarding their 
downstream functions. Furthermore, expression of multiple reader proteins and multiple published 
functions of m6A in a single cell type suggest that m6A may differentially regulate various gene 
transcripts within a single cell. Several important strategies to further elucidate the regulatory 
capacities of m6A in stem cells and neural development include (1) improved detection techniques 
for higher sensitivity and accuracy, (2) studies on how reader proteins selectively bind a subset of 
m6A-modified mRNAs, and (3) considerate analysis of data to prevent over-drawing conclusions 
that will hinder future studies.       
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 In addition to clarifying studies on m6A, we are especially excited by the prospects of other 
epitranscriptomics marks in neural development and disease. Careful mapping of m1A, m5C, m7G, 
m6Am, and Ψ in the brain alongside generating animal knockouts of their respective modifying 
enzymes will greatly expand the breadth of knowledge in the field of epitranscriptomics. With an 
increasing number of scientists working in this field, we expect the next five years to be full of new 







Figure 1: Summary of the most-studied epitranscriptomic modifications. This includes m6A 
(top center, pink), m7G (top right, green), m1A (bottom right, yellow), Ψ (bottom center, lime), 
m6Am (bottom left, blue), and m5C (top left, purple). Each panel shows the known methyltransferase 
components and demethylases, as well as any known reader proteins and functions of the 




Figure 2: Summary of epitranscriptomic marks in embryonic stem cell biology. Top: known 
modifications identified in mouse embryonic stem cells (ESCs)  include m6A on mRNA, m7G on 
tRNA, m6A on snRNA, m5C on nuclear mRNA, and m5C on mitochondrial tRNA. Bottom: 
Multiple studies showed that m6A promotes mRNA degradation in ESCs. In naïve ESCs, 
pluripotency-promoting gene transcripts are m6A modified. In primed ESCs, lineage-commitment 
gene transcripts are modified. Knocking out Mettl3 stabilizes these different sets of gene transcripts 




Figure 3: m6A in neural development. Top: m6A in cortical development regulates the 
progression of neurogenesis over developmental time by promoting mRNA degradation of key 
gene transcripts. Middle: m6A in cerebellar development regulates inner granule layer (IGL) neuron 
organization and apoptosis and Purkinje cell layer (PCL) organization, but does not seem to effect 
external granule layer (ECL) organization. m6A promotes mRNA degradation and alternative 
splicing. Bottom: in vitro adult neurogenesis studies show that knockdown of either the 
demethylase Fto or the methyltransferase Mettl3 impairs adult neural stem cell proliferation and 
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Foreword: This work stemmed from my first two years of graduate school and was performed 
entirely in the lab of Hongjun Song. We initially tried to generate brain-specific Mettl14 conditional 
knockout mice in order to study adult neurogenesis, but found that even conditional knockout mice 
died before reaching adulthood. We therefore shifted our focus to the role of m6A in the developing 
brain and were excited by the drastic phenotype of Mettl14 cKO mice. This work was published in 
Cell (PMCID: PMC5679435) and I am a co-first author.   
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N6-methyladenosine (m6A), installed by the Mettl3/Mettl14 methyltransferase complex, is the most 
prevalent internal mRNA modification. Whether m6A regulates mammalian brain development is 
unknown. Here we show that Mettl14 deletion in the embryonic mouse brain diminishes m6A 
content, prolongs cell cycle progression of radial glia cells, and extends cortical neurogenesis into 
postnatal stages. Mettl3 knockdown also prolongs neural progenitor cell cycle and promotes radial 
glia cell maintenance. m6A-sequencing of the embryonic mouse cortex reveals enrichment of 
mRNAs related to transcription factors, neurogenesis, cell cycle and neuronal differentiation, and 
m6A-tagging promotes their decay. Notably, Mettl14-/- radial glia cells precociously express 
neuronal proteins. Further analysis uncovers previously unappreciated transcriptional pre-
patterning in cortical neural stem cells. Comparison of m6A-mRNA landscapes between mouse and 
human cortical neurogenesis reveals enrichment of human-specific m6A-tagging of transcripts 
related to brain disorder risk genes. Our study identifies an epitranscriptomic mechanism in 
heightened transcriptional coordination during mammalian cortical neurogenesis.  
 
HIGHLIGHTS 
• m6A depletion leads to prolonged cell cycle progression of cortical neural progenitors 
• m6A promotes decay of transcripts related to cell cycle, neurogenesis, and neuronal 
differentiation in neural progenitors 
• Mettl14 deletion uncovers transcriptional pre-patterning for normal cortical neurogenesis 
• m6A-seq reveals conserved and unique m6A mRNA methylation landscapes in mouse and 




Proper development of the nervous system is critical for its function, and deficits in neural 
development have been implicated in many brain disorders, such as microcephaly, autistic 
spectrum disorders, and schizophrenia [115-117]. In the embryonic mouse cortex, radial glia cells 
(RGCs) function as neural stem cells, sequentially giving rise to neurons residing in different 
cortical layers and then switching to glial production before their depletion during early postnatal 
stages [116, 118]. Such a precise and predictable developmental schedule requires a highly 
coordinated genetic program [119]. Indeed, previous studies have revealed transcriptional cascades 
that orchestrate the dynamics of mammalian cortical neurogenesis [120-127]. Recent discoveries 
of widespread mRNA chemical modifications [128, 129] raise the question of whether this 
mechanism plays any regulatory role in cortical neurogenesis.  
 Modified nucleotides in mRNAs were initially discovered over 40 years ago, but little was 
known about the extent, transcript identities, and potential functions of various reversible chemical 
modifications until very recently [128, 129]. High-throughput sequencing approaches have 
revealed a dynamic “epitranscriptome” landscape for many mRNA modifications in various 
organisms, including N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5-methylcytosine 
(m5C), 5-hydroxymethylcytosine (hm5C), pseudouridine (Ψ), and 2’-O-methylnucleotides [62]. 
Among these modifications, m6A is the most abundant internal modification in mRNAs of 
eukaryotic cells [130]. m6A profiling has so far mostly been performed with cell lines and bulk 
tissues due to the need for a substantial amount of input mRNAs. These studies revealed m6A sites 
in over 25% of human transcripts, with enrichment in long exons, and near transcription start sites 
and stop codons [1, 2, 131, 132]. In mammals, m6A is installed by the methyltransferase complex 
consisting of Mettl3 (methyltransferase-like 3), Mettl14, Wtap (Wilms tumor 1-associated protein), 
KIAA1429, RBM15 (RNA-binding motif protein 15) and its paralogue (RBM15B) [11], whereas 
its removal is mediated by demethylases Fto (fat mass and obesity-associated) and Alkbh5 (alkB 
homolog 5) [129, 133]. Recent in vitro studies have identified multiple functions of m6A in mRNA 
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metabolism, from processing in the nucleus to translation and decay in the cytoplasm [129]. The 
field has just started to investigate physiological functions of m6A. For example, Mettl3 or Mettl14 
knockdown reduces m6A levels and decreases self-renewal of primed mouse embryonic stem cells 
(mESCs) [15], whereas Mettl3 knockout naïve mESCs exhibit improved self-renewal and impaired 
differentiation, due to dysregulated decay of m6A-tagged transcripts, such as Nanog [6, 16].  
  Identification of the molecular machinery mediating m6A mRNA methylation provides an 
entry point to explore physiological functions of this pathway in vivo. Studies of Drosophila 
development showed that m6A methylation regulates sex determination and neuronal functions by 
modulating mRNA splicing [134, 135]. In Zebrafish embryos, m6A-tagging promotes clearance of 
maternal mRNAs and maternal-to-zygotic transition [136]. In mice, germline Mettl3 deletion 
results in early embryonic lethality [6]. The function of m6A methylation in the intact mammalian 
system remains elusive; almost nothing is known about its role in mammalian embryonic brain 
development. Here we used the Mettl14 conditional knockout mouse as a model to examine m6A 
function in embryonic cortical neurogenesis in vivo. We further investigated underlying cellular 
and molecular mechanisms of how m6A tagged transcripts are processed. Finally, we extended our 
analysis to human embryonic cortical neurogenesis using induced pluripotent stem cell (iPSC)-
derived forebrain organoids and compared m6A-mRNA landscapes between mouse and human 
cortical neurogenesis. Together, our results reveal critical epitranscriptomic control of mammalian 
cortical neurogenesis and provide novel insight into mechanisms underlying this highly 
coordinated developmental program.   
 
III. RESULTS 
Nervous system Mettl14 deletion extends cortical neurogenesis into postnatal stages 
We first investigated the expression pattern of molecular players mediating m6A signaling during 
mouse embryonic cortical neurogenesis. Mining the recently published single-cell RNA-seq dataset 
of RGCs and their progeny [127] revealed that Mettl14 exhibits the highest expression in RGCs, 
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whereas other m6A methyltransferase components (Mettl3, Wtap), demethylases (Fto, Alkbh5) and 
m6A readers (Ythdf2, Ythdf3) exhibited relatively constant levels during neurogenesis (Figure 
S1A). To examine the functional role of m6A methylation during cortical development in vivo, we 
conditionally deleted Mettl14 in the developing mouse nervous system using the Nestin-
Cre;Mettl14f/f conditional knockout (cKO) model (Figure S1B). We confirmed Mettl14 deletion at 
the protein level with Western blot analysis of E17.5 brains (Figure S1B). The cKO animals were 
smaller in size by P5 compared to wildtype (WT) littermates, and all cKO animals died before P25 
(Figure S1C-D). Thus, the function of m6A molecular machinery in the nervous system is 
indispensable for life in the mammalian system.  
 
 We next examined cortical structures at P5. cKO mice exhibited enlarged ventricles with 
an adjacent dense layer of cells that resembled the embryonic germinal zone (Figure 1A). 
Immunohistological analysis showed the presence of Pax6+ and Nestin+ cells with radial fibers 
along the ventricle in cKO mice, but not in WT mice (Figure 1A-B). During mouse cortical 
development, Pax6+ RGCs are largely depleted by P5 [137]. In contrast, a substantial number of 
Pax6+ cells were present in cKO mice at P5 (Figure 1C). Neurogenic Pax6+ RGCs give rise to 
intermediate progenitor cells (IPCs) expressing Tbr2/Eomes [138]. The presence of Pax6+ cells in 
cKO mice was accompanied by Tbr2+ IPCs, which were absent in WT mice by P5 (Figure 1D-E). 
To confirm that cortical neurogenesis continued postnatally, we pulsed animals with EdU at P5 and 
analyzed 2 days later. Significant numbers of EdU+Pax6+ proliferating RGCs, EdU+Tbr2+ IPCs, 
and EdU+Tbr2+TuJ1+ neuroblasts were present in cKO mice, but very few in WT littermates (Figure 
1F-G). These results indicate that cKO mice maintain neurogenic RGCs with extended cortical 
neurogenesis into postnatal stages.  
 To further characterize the impact of Mettl14 deletion on cortical development, we 
examined neuronal subtype and glia production. We pulsed animals with EdU at E15.5 and 
examined them at P5. Compared to WT littermates, cKO mice exhibited a significantly decreased 
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number of EdU+Satb2+ neurons, suggesting a deficit in producing late-born upper-layer neurons 
(Figure 1H-I). Direct measurement of the number of different cortical neuron subtypes also showed 
a reduced number of Satb2+ upper-layer neurons, but comparable numbers of Tbr1+ and 
Ctip2/Bcl11b+ lower-layer early-born neurons in P5 cKO mice (Figure S1E-F). On the other hand, 
analysis of Ctip2+ neurons at E17.5 showed reduced numbers in cKO mice, suggesting a delay in 
the production of neuron subtypes of different cortical layers, rather than differentiation deficits 
(Figure S1G-H). In addition, we observed a significant decrease in the number of s100 + astrocytes 
in cKO mice at P5 (Figure 1J-K). Together, these results indicate that Mettl14 function is critical 
for proper temporal progression of neurogenesis and gliogenesis during mouse cortical 
development in vivo.  
 
Mettl14 deletion in neural progenitor cells leads to protracted cell cycle progression  
Given the well-defined temporal progression of cortical neurogenesis from RGCs [119], we 
suspected that there could be RGC deficits during embryonic stages in cKO mice. Interkinetic 
nuclear migration (INM), the periodic movement of the cell nucleus in phase with cell-cycle 
progression, is a common feature of developing neuroepithelia [116, 139]. We pulsed animals with 
EdU at E17.5 to label cells in S-phase and followed positions of nuclei in EdU+Pax6+ RGCs (Figure 
2A). While there was no difference at 0.5 hr after EdU labeling, nuclei of labeled RGCs were 
positioned further away from the ventricular surface at 6 hr in cKO mice compared to WT (Figure 
2B), suggesting delayed INM and potential cell cycle deficits. To directly examine the S to M phase 
transition of the cell cycle, we analyzed expression of phospho-Histone 3 (pH3), an M phase 
marker, 2 hr after EdU labeling (Figure 2C). We found a significant decrease in the percentage of 
EdU+pH3+Pax6+ cells among all pH3+Pax6+ cells in cKO mice, suggesting a prolonged S to M 
phase transition of RGCs (Figure 2D). To examine cell cycle exit of proliferating neural 
progenitors, we analyzed expression of Ki67, a proliferation marker, 24 hr after EdU labeling 
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(Figure 2E). We found a significant decrease in the percentage of Ki67 negative cells among EdU+ 
cells in cKO mice, indicating a delay in cell cycle exit (Figure 2F).  
 To address the cell intrinsic effect of Mettl14 deletion on cell cycle progression, we 
performed time-lapse imaging of individual cortical neural progenitor cells (NPCs) cultured from 
E13.5 mouse cortex. We used a dual reporter system with nuclear localized H2B-mCherry and a 
GFP-tagged Cdk2 substrate, DNA Helicase B (DHB) [140]. Cdk2 becomes active during the G1-S 
transition and phosphorylates DHB-GFP, which is then translocated from nucleus to cytoplasm. 
Therefore, the presence of GFP in the mCherry+ nucleus indicates cells in G1 phase, whereas 
translocation to the cytoplasm indicates S phase initiation, and continual buildup of cytoplasmic 
GFP occurs until mitosis (Figure S2A). Quantification of the length between sequential mitoses 
showed an increase of the total cell cycle length in Mettl14 cKO NPCs (Figure 2G-H; Movie S1 
and S2). Further analysis of different cell cycle phases revealed a specific increase of the S-G2-M 
phases in the absence of Mettl14, but no difference in the G1 phase (Figure 2I-J).   
 To quantify cell cycle characteristics at the population level, we pulsed NPCs with EdU 
for 30 min and performed flow cytometry analysis 0 or 5 hr later (Figure S2B). We found a 
significant decrease in the percentage of EdU+ cells that divided in Mettl14 cKO NPCs compared 
to WT at 5 hr, confirming a delay in cell cycle progression (Figure S2C-D).  
 
Mettl3 regulates embryonic cortical neurogenesis  
Consistent with the finding that Mettl14 is a critical component of the m6A methyltransferase 
complex [141], Mettl14 deletion led to a significant reduction of m6A levels in mRNAs from both 
embryonic mouse cortex in vivo and cultured cortical NPCs (Figure 3A-B). To further assess our 
model that m6A methylation regulates cortical neurogenesis, we compared the phenotype of 
Mettl14 cKO to knockdown of Mettl3, another critical component of the m6A methyltransferase 
complex [141].  
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 We first confirmed effective Mettl3 knockdown (KD) with Q-PCR and diminished m6A 
content in mRNAs from Mettl3 KD cells with dot blot analysis (Figure S3A-C and Table S1). We 
next performed population cell cycle analysis with EdU pulse-chase and flow cytometer 
quantification (Figure S3D). We found a significant reduction in the percentage of GFP+EdU+ 
NPCs that divided upon Mettl3 KD (Figure 3C-D), similar to the effect of Mettl14 cKO (Figure 
S2C-D).  
To examine the impact of Mettl3 KD on RGC behavior in vivo, we electroporated plasmids 
co-expressing GFP and the shRNA against mouse Mettl3, or the control shRNA, in utero at E13.5 
and analyzed GFP+ cells at E17.5. Newborn neurons normally migrate toward the cortical plate 
(CP) through the intermediate zone (IZ), whereas self-renewing RGCs remain in the ventricular 
zone (VZ) and subventricular zone (SVZ) [116]. Compared to the control group, GFP+ cells with 
Mettl3 KD were more abundant in the VZ and SVZ and less abundant in the CP (Figure 3E-F), 
similar to the result from EdU fate mapping in Mettl14 cKO mice (Figure 1H). There was also a 
significant increase in the percentage of GFP+Pax6+ cells among all GFP+ cells with Mettl3 KD 
compared to the control group (Figure 3G).  
Together, these results indicate that decreasing m6A levels by either Mettl14 cKO or Mettl3 
KD leads to consistent phenotypes of protracted cell cycle progression of cortical NPCs and 
reduced differentiation of RGCs during mouse embryonic cortical neurogenesis.  
 
m6A tags transcripts related to transcription factors, cell cycle, and neurogenesis, and 
promotes their decay  
To gain insight into the molecular mechanism underlying m6A regulation of cortical neurogenesis, 
we performed m6A-seq of mouse forebrain at E13.5, a stage enriched for neural stem cells. We 
identified 4,055 high confidence m6A peaks corresponding to 2,059 gene transcripts (Figure S4A 
and Table S2). Similar to previous findings from cell lines [1, 2, 131, 132], our in vivo analysis 
showed enriched distribution of m6A sites near stop codons (Figure S4B). We found no correlation 
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between transcript levels and m6A-tagging (Figure S4C). Notably, many transcripts encoding 
transcription factors were m6A-tagged, such as Pax6, Sox1, Sox2, Emx2, and Neurog2/ Neurogenin 
2 (Figure 4A-B). Gene ontology (GO) and Wikipathways analyses of m6A-tagged transcripts 
revealed enrichment of genes related to cell cycle, stem cell, and neuronal differentiation (Figure 
4A-C and Table S3). We observed similar m6A-tagging for a group of transcripts in cortical NPCs 
derived from E13.5 mouse cortex (Figure S4D and Table S1).  
 To determine the functional consequence of m6A-tagging on mRNAs, we explored whether 
Mettl14 deletion affects decay of m6A-tagged transcripts with an RNA stability assay [6, 71]. 
Cortical NPCs derived from E13.5 WT and Mettl14 cKO mice were treated with Actinomycin D 
to halt de novo transcription, and RNA-seq was performed 0 and 5 hr later to obtain the ratio of 
mRNA levels for each gene in order to measure their stability (Figure S4E). Across the 
transcriptomes, m6A-tagged transcripts exhibited significantly lower stability compared to non 
m6A-tagged transcripts in the WT NPCs, and this difference was reduced in cKO NPCs (Figure 4D 
and Table S4). Direct comparison of WT and Mettl14 cKO NPCs showed that m6A-tagged 
transcripts exhibited a larger increase in their stability compared to non-tagged transcripts upon 
Mettl14 deletion; one m6A tag per transcript was sufficient to increase stability and there was a 
minimal additional effect of more tagging sites (Figure 4E). It should be noted that our m6A-seq 
method could not determine whether multiple sites are simultaneously methylated in the same 
transcript. We confirmed our result with the direct measurement of the half-life of a selected group 
of transcripts (Figure 4F and S4F; Table S1).  
 All together, these results support a model that m6A methylation of mRNAs related to cell 
cycle and neurogenesis confers their rapid turnover during the dynamic progress of cortical 
neurogenesis; a lack of m6A-tagging attenuates the decay of these mRNAs, resulting in deficits in 
temporal specification and cell cycle progression of NPCs.  
 
Mettl14 deletion uncovers transcriptional pre-patterning for normal cortical neurogenesis  
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Among the 2,059 m6A-tagged genes in the E13.5 mouse cortex, two major GO terms were 
generation of neurons and neuronal differentiation (Figure 4C). For example, IPC marker Tbr2 and 
Neurog2, and neuronal markers Neurod1 and Neurod2 [142], were m6A-tagged in E13.5 forebrain 
in vivo (Figure 5A) and in cultured cortical NPCs (Figure S4D). Q-PCR analysis of total mRNA 
showed increased levels of Tbr2, Neurog2, Neurod1, and Neurod2, but not non tagged Rad17, in 
Mett14 cKO NPCs compared to WT NPCs (Figure 5B and Table S1). This result raised the 
possibility that neuronal lineage genes are already expressed in neural stem cells and their levels 
are actively suppressed post-transcriptionally by m6A-dependent decay; alternatively, Mettl14 
deletion may transcriptionally upregulate these neuronal genes.  
To differentiate between these two possibilities, we quantified the levels of nascent mRNA 
using the metabolic labeling approach with 4-thiouridine (4sU) [143, 144]. We found comparable 
and even lower levels of nascent mRNA of neuronal lineage genes, such as Tbr2, Neurog2, and 
Neurod2, in Mettl14-/- NPCs in comparison to WT NPCs (Figure 5B and Table S1). The lower 
levels of nascent mRNA observed for some neuronal lineage genes in Mettl14 cKO NPCs could be 
explained by a negative feedback loop at the level of transcription, originating from elevated 
expression of stem cell genes, such as Emx2 and Sox1 (Figure 5B). Similarly, we found comparable 
levels of pre-mRNA for neuronal lineage genes in Mettl14 cKO compared to WT NPCs (Figure 
S5A and Table S1), suggesting that the increase in the total mRNA of neuronal lineage genes in 
Mettl14 cKO NPCs is not due to transcriptional upregulation. Together, these results support that 
neuronal lineage genes are already expressed in neural stem cells under normal cortical 
neurogenesis. Consistent with our result, mining the published single-cell RNA-seq dataset [127] 
revealed expression of neuronal lineage genes, such as Tbr2, Neurog2, Neurod6 and Tubb3/Tuj1, 
in individual RGCs in the embryonic mouse cortex in vivo (Figure S5B).  
We next examined Tbr2 and Neurod1 protein levels in RGCs in vivo. Pax6+Tbr2+ cells 
were localized in the SVZ in WT at E17.5, but extended into the VZ in Mettl14 cKO mice (Figure 
5C-D). Pax6+Neurod1+ cells were rare, but detectable just above the SVZ in WT cortices. In 
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contrast, cKO mice exhibited a significantly increased number of Pax6+Neurod1+ cells with a much 
broader distribution, including in the SVZ and VZ (Figure 5E-F). To specifically examine 
expression in RGCs, we pulse-labeled juxtaventricular newborn cells by FlashTag (FT) [127]. We 
found a significantly increased number of FT+Pax6+Tbr2+ and FT+Pax6+Neurod1+ cells in Mettl14 
cKO cortex compared to those in WT 3 hr after labeling (Figure S5C-D). Given that FT+ cells at 3 
hr upon labeling are exclusively undifferentiated RGCs [127], these results suggest that Mettl14 
regulates neuronal lineage gene expression directly in RGCs.  
To further assess our model that mRNA decay regulates neuronal lineage gene expression 
in RGCs, we performed in vivo knockdown experiments for the components of CCR4-NOT 
complex (Cnot7 and Cnot1), a major cytoplasmic mRNA deadenylase complex responsible for 
mRNA decay [145, 146]. Both Cnot7 KD and Cnot1 KD led to increased numbers of Tbr2+Pax6+ 
and Neurod1+Pax6+ cells and location closer to the ventricular surface compared to the control 
shRNA (Figure S5E-F), phenotypes resembling Mettl14 cKO (Figure 5C-F).  
Taken together, our results suggest heightened transcriptional coordination and a 
previously unappreciated transcriptional pre-patterning mechanism for mammalian cortical 
neurogenesis, in which late IPC and neuronal genes are already transcribed in cortical neural stem 
cells and these transcripts are down regulated post-transcriptionally by m6A-dependent decay. 
 
METTL14 regulates cell cycle progression of human cortical NPCs 
We next examined whether m6A function is conserved in human cortical neurogenesis. Using a 
previously developed protocol [147], we differentiated human iPSCs into a highly pure population 
of NESTIN+SOX2+ NPCs (hNPCs; 96.4 + 1% among all cells; n = 5; Figure S6A). We co-
expressed GFP and the validated shRNA against human METTL14 in these hNPCs (Figure S6B). 
After 4 days, we labeled cells with EdU for 30 min and performed cell cycle analysis with flow 
cytometer quantification 14 hr later (Figure S6C). Similar to results from mouse Mettl14 cKO NPCs 
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(Figure S2C-D), we found a significant decrease in the percentage of GFP+EdU+ hNPCs that 
divided with METTL14 KD, indicating a delayed cell cycle progression (Figure 6A-B). 
 We recently developed a human iPSC-derived forebrain organoid model, which exhibits 
transcriptome profiles similar to fetal human cortex during development up to the second trimester 
[148]. Around day 47, these forebrain organoids resemble mouse cortical neurogenesis at E13.5 
(Figure S6D). We microinjected plasmids co-expressing GFP and the shRNA against human 
METTL14, or the control shRNA, into the lumen of forebrain organoids and performed 
electroporation to transfect RGCs (Figure S6E). After 7 days, we pulsed organoids with EdU for 1 
hr and performed cell cycle analysis of GFP+ cells 14 hr later (Figure S6F). Similar to findings from 
monolayer hNPC cultures, we observed a significant decrease in the percentage of GFP+EdU+ cells 
that divided with METTL14 KD (Figure 6C-D). Together, these results indicate that m6A mRNA 
methylation plays a conserved role in regulating cortical NPC cell cycle progression in both mouse 
and human.  
 
m6A-seq of human forebrain brain organoids and fetal brain reveals conserved and unique 
m6A landscape features compared to embryonic mouse forebrain  
Finally, we performed m6A-seq of day 47 human forebrain organoids. We detected 11,994 high 
confidence m6A peaks associated with 4,702 transcripts (Figure S7A and Table S5). Our previous 
systematic RNA-seq analyses of human forebrain organoids at different stages revealed that 
transcriptomes of organoids around day 47 were similar to human fetal cortex at 8-12 post-
conception weeks (PCW) [148]. We further performed m6A-seq of PCW11 fetal human brain and 
identified 10,980 high confidence peaks associated with 5,049 transcripts (Figure S7B and Table 
S6). m6A sites were enriched near transcription start sites and stop codons for both human samples 
(Figure S7C-D). Furthermore, m6A profiles from both samples showed significant overlap (Figure 
7B). GO analysis of m6A-tagged transcripts shared in both samples showed enrichment of genes 
related to neurogenesis, neuronal differentiation and development (Figure 7C and Table S7). Many 
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recently identified risk genes for schizophrenia and autistic spectrum disorders have been shown to 
be dynamically expressed and play critical roles during mammalian embryonic brain development 
[149, 150]. Interestingly, disease ontology analysis of these m6A-tagged genes shared in both 
human samples showed enrichment related to mental disorders, mental retardation, schizophrenia 
and bipolar disorder (Figure 7C and Table S7).  
 We further performed comparison among m6A landscapes during mouse and human 
cortical neurogenesis. About 19.3%, 34.7% and 31.4% of detected transcripts exhibited m6A-
tagging in E13.5 mouse brain, day 47 human forebrain organoids, and PCW11 human fetal brain, 
respectively (Figure S7E). Therefore, m6A mRNA methylation appears to be more prevalent in 
human. Among transcripts expressed in all three samples, 856 genes were commonly m6A-tagged 
(Figure 7D). These commonly m6A-tagged transcripts are enriched for genes related to 
neurogenesis and neuronal differentiation (Figure S7F and Table S7). Notably, 1,173 transcripts 
were expressed in both species, but only m6A-tagged in both human samples (Figure 7D). Ontology 
analysis of these human-specific m6A-tagged transcripts showed enrichment of genes related to 
mental disorders and mental retardation (Figure 7E-F and Table S7). In contrast, analysis of the 
gene set of m6A-tagged transcripts shared between mouse and human showed enrichment for 
oncogenic processes (Figure 7E). Notably, among genes associated with the 108 loci recently 
identified for genetic risk of schizophrenia [151], 60 genes were m6A-tagged in human and 21 
genes were uniquely tagged in both human forebrain organoids and fetal brain, but not in mouse 
E13.5 forebrain.  
 
IV.  DISCUSSION 
From flies to mammals, neurogenesis is a highly coordinated process with sequential waves of gene 
expression [152]. Here we revealed a critical role of m6A mRNA methylation in this process in the 
mammalian system in vivo. Our results suggest a model that m6A-tagging of transcripts related to 
neural stem cells, cell cycle, and neuronal differentiation confers their rapid turnover to control the 
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transcriptome composition at different phases of the dynamic cortical neurogenesis process. The 
observation of RGCs expressing markers thought to be expressed only in late IPCs and post-mitotic 
neurons in Mettl14 cKO mice led to the discovery of transcriptional pre-patterning in normal 
cortical neurogenesis and identifies m6A mRNA methylation as a key mechanism to prevent 
precocious expression of genes of later lineage status at the protein level in stem cells. We also 
provide the emerging “epitranscriptomic” field with databases of m6A mRNA landscapes of mouse 
and human cortical neurogenesis and identify intriguing human-specific features.      
 
Transcriptional pre-patterning for cortical neurogenesis 
The concept of pre-patterning initially came from analysis of chromatin states within multipotent 
progenitors to regulate the fate choice for liver and pancreas [153]. Recent genome-wide mapping 
studies have suggested that epigenetic pre-patterning is important for spatio-temporal regulation of 
gene expression and may be a widespread phenomenon in cell fate decision [154]. Our study 
suggests, for the first time, transcriptional pre-patterning in normal cortical neural stem cells in 
vivo. Consistent with our model, Pax6 has been shown to bind and activate both Tbr2 and Neurod1 
promoters [155]. We showed that pre-patterned transcripts are tagged with m6A and subjected to 
rapid decay, therefore most of them are present in low levels among the bulk mRNA preparation 
and little protein under normal conditions – a likely reason why such a mechanism has escaped 
detection in previous studies. While epigenetic mechanisms play a key role in transcriptional 
regulation during neurogenesis [156, 157], epitranscriptomic regulation as a post-transcriptional 
mechanism could provide the speed and additional specificity, while maintaining plasticity of gene 
expression. By working in concert, the epigenetic landscape can permit transcription of certain 
genes, such as genes defining late lineage states, while the epitranscriptome prevents aberrant 
protein production. Future studies are needed to investigate whether transcriptional pre-patterning 
is a general mechanism in fate specification of other stem cells during development.    
 
 45 
Heightened transcriptional coordination of mammalian cortical neurogenesis by m6A 
Our study provides the first in vivo evidence in the mammalian system to support the emerging 
notion that m6A methylation plays a critical role in developmental fate transition. The precise and 
predictable developmental schedule of cortical neurogenesis requires rapid, tightly controlled 
changes in gene expression [119]. Our results suggest that epitranscriptomic m6A-tagging, via 
regulation of mRNA decay, provides a key mechanism for temporal control of dynamic gene 
expression, which in turn regulates cell cycle progression of cortical neural stem cells in both mouse 
and human.  
There are three major categories of m6A-tagged transcripts in the embryonic mouse brain. 
First, many classic transcription factors involved in neural stem cell maintenance and neurogenesis, 
such as Pax6, Sox2, Emx2, and Tbr2, are m6A-tagged and subject to rapid decay. Second, cell 
cycle-related transcripts, such as Cdk9, Ccnh/Cyclin H, and Cdkn1C/p57, are m6A-tagged. 
Functionally, the loss of m6A-tagging leads to prolonged cell cycle progression of cortical NPCs, 
resulting in delayed generation of different neuronal subtypes, extension of cortical neurogenesis 
into postnatal stages and deficits in astrocyte generation in vivo. Third, transcripts that were 
generally thought to be expressed only in later IPCs and post-mitotic neurons, such as Neurod1 and 
Neurod2, are m6A-tagged and expressed in neural stem cells. While expression of transcription 
factors is known to overlap during different stages of mammalian cortical neurogenesis [142], our 
finding suggests a greater degree of transcriptional coordination than previously thought. On the 
other hand, expression of detectable neuronal proteins in a significant number of RGCs located in 
the SVZ in the absence of Mettl14 highlights the critical role of the epitranscriptomic mechanism 
in preventing precocious gene expression during the normal process of mammalian cortical 
neurogenesis.  
 
Conserved and unique features of human m6A landscape during cortical neurogenesis  
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Our study provides databases of m6A mRNA landscapes during mouse and human cortical 
neurogenesis. Consistent with a similar role for m6A mRNA methylation in regulating cell cycle 
progression of cultured human NPCs and mouse NPCs in vitro and in vivo, the shared m6A-tagged 
transcripts in our mouse and human samples are enriched with genes related to neural stem cells, 
cell cycle, and neurogenesis. Notably, many genes associated with genetic risk for mental disorders, 
such as schizophrenia and autistic spectrum disorders, are only m6A-tagged in humans, but not in 
mice, raising the possibility that epitranscriptomic dysregulation may contribute to these human 
brain disorders. So far, one association study found evidence of ALKBH5 in conferring genetic 
risk for major depression disorder [158], and two studies identified association of FTO mutations 
with growth retardation and developmental delay [159, 160].  
 In summary, our study identifies a critical and conserved role of an m6A epitranscriptomic 
mechanism in the temporal control of mammalian cortical neurogenesis via promotion of mRNA 
decay of transcripts related to transcription factors, neural stem cells, cell cycle, and neuronal 
differentiation. Future studies will address how this epitranscriptomic mechanism interacts with 
various epigenetic mechanisms to coordinate dynamic transcriptomes during brain development, 
and how dysregulation of epitranscriptomic mechanisms may contribute to brain disorders.         
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V. STAR METHODS  
 
KEY RESOURCE TABLE 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact Hongjun Song (shongjun@mail.med.upenn.edu). There are no 
restrictions on any data or materials presented in this paper.  
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Animals 
Exons 7, 8, and 9 of mouse Mettl14 were targeted by inserting a single loxP site in intron 6 and an 
FRT-flanked neomycin resistance gene coupled with a loxP site in intron 9, with the consideration 
that they contain the DPWW active motif (Figure S1B). The targeting construct was electroporated 
into 129 mESCs, selected for neomycin resistance, screened for homologous recombination by 
Southern blotting, and selected mESC clones were used to generate chimeric mice by injection into 
C57BL/6J mouse blastocysts. Chimeric mice were bred to wild type C57BL/6J mice to test for 
germline transmission of the mutant allele, which was identified by PCR. The PCR-positive lines 
were crossed with a  -actin promoter-driven Flp recombinase to remove the neomycin resistance 
gene via FRT site recombination. The neomycin cassette-deleted mice were identified by PCR, and 
the resultant Mettl14f/f allele and Nestin-Cre+/Tg mice (Jackson Laboratory stock: 003771) [161] 
were used to generate Nestin-Cre+/Tg; Mettl14+/f mice and Nestin-Cre+/+; Mettl14f/f mice. WT and 
cKO mice were generated by crossing Nestin-Cre+/Tg; Mettl14+/f males and Nestin-Cre+/+; Mettl14f/f 
females.  
For in utero electroporation analysis, timed-pregnant CD1 mice (Charles River Laboratory) 
at E13.5 were used as previously described [147]. Timed pregnant mice were euthanized by 
cervical dislocation, and embryos were euthanized by decapitation before the dissection step. All 
 48 
animal procedures used in this study were performed in accordance with the protocol approved by 
the Institutional Animal Care and Use Committee of Johns Hopkins University School of Medicine. 
 
Primary mouse NPCs 
Mouse NPCs were isolated from Mettl14 WT and cKO mouse embryonic cortices and cultured in 
Neurobasal medium (Gibco BRL) containing 20 ng/ml FGF2, 20 ng/ml EGF, 5 mg/ml heparin, 2% 
B27 (v/v, Gibco BRL), Glutamax (Invitrogen), Penicillin/Streptomycin (Invitrogen) on culture 
dishes pre-coated with Matrigel matrix (2%, Corning). 
 
Human iPSC cultures and fetal brain sample  
The human iPSC line used in the current study (C1) was fully characterized [147, 162]. iPSCs were 
cultured in stem cell medium, consisting of DMEM:F12 (Invitrogen) supplemented with 20% 
Knockout Serum Replacer (Gibco), 1X Non-essential Amino Acids (Invitrogen), 1X 
Penicillin/Streptomycin (Invitrogen), 1X 2-Mercaptoenthanol (Millipore), 1X Glutamax 
(Invitrogen), and 10 ng/ml FGF-2 (Peprotech). Culture medium was changed every day. Human 
iPSCs were passaged every week onto a new plate pre-seeded with irradiated CF1 mouse 
embryonic fibroblasts (Charles River Laboratory). Human iPSCs were detached from the plate by 
treatment of 1 mg/ml Collagenase Type IV (Invitrogen) for 1 hr. iPSC colonies were further 
dissociated into smaller pieces by manual pipetting. All studies were performed under approved 
protocols of Johns Hopkins University School of Medicine. Human iPSCs were differentiated into 
primitive hNPCs according to a previously published protocol (Li et al., 2011). Briefly, iPSCs were 
passaged onto MEF feeders, and after 3 days, induction medium containing Advanced DMEM:F12 
(50%) and Neurobasal medium (50%), CHIR99201 (4 μM, Cellagentech), SB431542 (3 μM, 
Cellagentech), Bovine serum albumin (5 μg/ml, Sigma), hLIF (10 ng/ml, Millipore), Compound E 
(0.1 μM, EMD Millipore), Glutamax (Invitrogen), Pen/Strep, supplemented with N2 and B27 
(Invitrogen), was added to the culture. After 6 days of differentiation, hNPCs were dissociated with 
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Accutase (Invitrogen) and plated, with the aid of a ROCK inhibitor (Y-27632, 3 μM, Cellagentech), 
onto culture dishes pre-coated with Matrigel matrix (2%, Corning).  
 The PCW11 fetal human cortical tissue was used for m6A-seq. All procedures used in this 
study were performed in accordance with the protocol approved by the Institutional Stem Cell 
Research Oversight Committee of Johns Hopkins University School of Medicine and Lieber 
Institute for Brain Development. 
 
METHOD DETAILS 
DNA constructs  
For knockdown experiments for mouse genes, short hairpin RNA sequences (see KEY 
RESOURCE TABLE) were cloned into the retroviral vector expressing GFP under the control of 
the EF1a promoter and a specific shRNA under the control of human U6 promoter (pUEG) as 
previously described [163]. For knockdown experiments for human METTL14, a short hairpin 
RNA sequence was cloned into the lentiviral vector expressing GFP under the control of the human 
ubiquitin C promoter and the specific shRNA under the control of human U6 promoter (cFUGW: 
Addgene plasmid 14883) as previously described [147]. The efficacy of each shRNA was 
confirmed in mouse B16-F10 cells (ATCC), or hNPCs derived from the C1 iPSC line.  
 
In utero electroporation and FlashTag 
In utero electroporation was performed as described previously [147]. In brief, timed-pregnant CD1 
mice (Charles River Laboratory) at E13.5 or E14.5 were anesthetized and the uterine horns were 
exposed and approximately 1 to 2 μl of plasmid DNA, 0.5 μg/μl pCAG-GFP (Addgene plasmid: 
11150) and 2.5 μg/μl cFUGW plasmid with the control shRNA, or the shRNA against mouse 
Mettl3, Cnot1 and Cnot7, was injected manually into the lateral ventricles of embryos using a 
calibrated micropipette. Five pulses (40 V, 50 ms in duration with a 950 ms interval) were delivered 
across the uterus with two 5-mm electrode paddles (CUY650-5, Nepa Gene) positioned on either 
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side of the head by a square wave electroporator (CUY21SC, Nepa Gene). After electroporation, 
the uterus was placed back in the abdominal cavity and the wound was sutured. Mouse embryos 
were analyzed at E17.5. For FlashTag of RGCs, 1 μl of 10 μM of a carboxyfluorescein succinimidyl 
ester (CellTrace CFSE, ThermoFisher) was injected into the lateral ventricle of the E17.5 embryos 
using a calibrated micropipette. Mouse embryos were collected 3 hr later, fixed with with 4% 
paraformaldehyde in PBS overnight at 4°C for analysis. All animal procedures were performed in 
accordance with the protocol approved by the Johns Hopkins Institutional Animal Care and Use 
Committee. 
 
Immunohistology and confocal imaging 
For EdU labeling, timed pregnant mice were injected with EdU (150 mg/kg bodyweight, 
Invitrogen) at defined time points before euthanasia. For immunostaining of tissue sections, brains 
were fixed with 4% paraformaldehyde in PBS overnight at 4°C as previously described [147]. 
Samples were cryoprotected in 30% sucrose in PBS, embedded in OCT compound, and sectioned 
coronally (20 μm-thickness) on a Leica CM3050S cryostat. Brain sections were blocked and 
permeabilized with the blocking solution (5% normal donkey serum, 3% Bovine serum albumin, 
and 0.1% Triton X-100 in PBS) for 1 hr at room temperature, followed by incubation with primary 
antibodies diluted in the blocking solution at 4°C overnight. After washing, secondary antibodies 
diluted in blocking solution were applied to the sections for 1 hr at room temperature. Nuclei were 
visualized by incubating for 10 min with 0.1 μg/ml 4,6-diamidino-2-phenylindole (DAPI, Thermo 
Fisher Scientific) in PBS. For EdU labeling, Click-iT EdU Alexa Fluor 647 Imaging Kit  (Thermo 
Fisher Scientific) was used following the manufacturer’s protocol. Stained sections were mounted 
with ProLong Gold anti-fade reagents (Thermo Fisher Scientific) and analyzed. All the antibodies 




Mouse and human NPC electroporation  
Approximately 1.0 X 106 mouse or human NPCs were resuspended in 100 µL Mouse Neural Stem 
Cell Nucleofector Solution from the Lonza Nucleofector Kit for Mouse Neural Stem Cells (Lonza, 
VAPG-1004). Additionally, 10 µg of the appropriate plasmid was added to the cell solution. The 
solution was then placed in a cuvette provided in the Nucleofector Kit and electroporated using a 
Lonza Nucleofector 2b device (LONZA). Next, the cells were resuspended in NPC media as 
described above with Rock Inhibitor (Y-27632, 3 μM, Cellagentech) to reduce cell death. Cells 
were allowed to grow for at least 3 days before analysis.   
 
Human forebrain organoid culture 
Protocols for generation of forebrain organoids were detailed previously [148]. Briefly, human 
iPSCs were cultured in stem cell medium, consisting of DMEM:F12 (Invitrogen) supplemented 
with 20% Knockout Serum Replacer (Gibco), 1X Non-essential Amino Acids (Invitrogen), 1X 
Penicillin/Streptomycin (Invitrogen), 1X 2-Mercaptoenthanol (Millipore), 1X Glutamax 
(Invitrogen), and 10 ng/ml FGF-2 (Peprotech) on irradiated CF1 mouse embryonic fibroblasts 
(Charles River). On day 1, iPSC colonies were detached by treatment of 1 mg/ml Collagenase Type 
IV (Invitrogen) for 1 hr and transferred to an Ultra-Low attachment 6-well plate (Corning Costar), 
containing 3 ml of stem cell medium (without FGF-2), plus 2 μM Dorsomorphine (Sigma) and 2 
μM A83-01 (Tocris). On days 5-6, half of the medium was replaced with induction medium 
consisting of DMEM:F12, 1X N2 Supplement (Invitrogen), 1X Penicillin/Streptomycin, 1X Non-
essential Amino Acids, 1X Glutamax, 1 μM CHIR99021 (Cellagentech), and 1 μM SB-431542 
(Cellagentech). On day 7, organoids were embedded in Matrigel (Corning) and continued to grow 
in induction medium for 6 more days. On day 14, embedded organoids were mechanically 
dissociated from Matrigel and transferred to each well of a 12-well spinning bioreactor (SpinΩ) 
containing differentiation medium, consisting of DMEM:F12, 1X N2 and B27 Supplements 
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(Invitrogen), 1X Penicillin/Streptomycin, 1X 2-Mercaptoenthanol, 1X Non-essential Amino Acids, 
2.5 μg/ml Insulin (Sigma).   
 
Forebrain organoid electroporation and analysis  
Day 45 forebrain organoids were transferred into PBS solution in a 10 cm petri dish for 
electroporation. A mixture of 0.5 μl of plasmid DNA and 0.05% Fast green was injected into the 
lumen of neural tube structures in forebrain organoids using a calibrated micropipette. About 3-4 
locations on one side of each forebrain organoid were targeted by the injection. The DNA-injected 
side of the organoid was placed toward the positive electrode in the middle of 5 mm gap of electrode 
paddles (CUY650-5, Nepa Gene). Five pulses (40 V, 50 ms in duration with a 950 ms interval) 
were delivered by a square wave electroporator (CUY21SC, Nepa Gene). After electroporation, 
organoids were transferred back to the SpinΩ bioreactor for further culturing.  
 
Analysis of cell cycle progression by EdU pulse labeling 
Analyses of cell cycle progression of mouse NPCs, hNPCs, and dissociated human forebrain 
organoids were performed as described previously [164, 165]. In brief, mouse or human NPCs were 
pulsed by 10 μM EdU (ThermoFisher) for 30 min and washed thoroughly with NPC media. For 
human forebrain organoids, 10 μM EdU directly applied to culture media and organoids were 
incubated in the SpinΩ bioreactor for 1 hr to ensure complete penetrance, then washed thoroughly 
with culture media. After defined time points, cells were dissociated by Accutase, fixed with 4% 
paraformaldehyde in PBS for 20 min at 4°C, stained with Click-iT EdU Alexa 647 Flow Cytometry 
Kits (ThermoFisher) for Flow Cytometry following manufacturer’s protocol. Cells were stained 
with Vybrant DyeCycle Violet (ThermoFisher) or 7-AAD (ThermoFisher) for DNA content and 
applied to flow cytometry using BD LSR II Flow Cytometer (BD Bioscience). EdU+ or GFP+EdU+ 
cells were gated and DNA content of those cells was analyzed compared to that of whole cell 
population. Percentages of divided cells among EdU+ or GFP+EdU+ population (G1 or G0 phase 
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determined by DNA content) during defined time intervals were quantified from four independent 
experiments.  
 
Time-lapse live imaging of mouse NPCs 
96-well glass bottom microplates (655892, Geiner bio-one) were coated with phenol red-free 
Matrigel (356237, Corning). After electroporation of mNPCs with 10 µg CDK2-sensor plasmid 
(pPGK-H2B-mCherry-DHB(aa994-1087)-GFP), cells were plated onto the microplates at a density 
of 3,000 cells per well and allowed to adhere overnight. Cells were imaged using a Nikon Eclipse 
Ti fluorescent microscope controlled by Metamorph microscopy automation software. 
Temperature (37°C), CO2 (5%), and humidity were held constant throughout experiments. Five 
blank positions in a well containing Matrigel and media only were used to flat field mNPC images 
using custom software. ImageJ was used to merge the green and red channels. To quantify the total 
cell cycle length, time was measured from the first cell division to the next cell division of one or 
both daughters. To quantify the G1 phase length, time was measured from one cell division to the 
time point of significant reduction in the ratio of green/red intensity in the nucleus of the cell. S 
phase entry was quantitatively defined as the time when the cytoplasmic/nuclear ratio of green/red 
was approximately 1, as previously described [140]. A nuclear marker, H2B-mCherry, was used in 
the plasmid sensor to accurately segment the cytoplasm and the nucleus. The time point from S 
phase entry through the second cell division was then quantified as S-G2-M length.  
 
RNA purification and quantitative RT-PCR analysis 
For gene expression analysis, total RNA fraction was isolated from cultured NPC samples with 
RNeasy Mini Kit (Qiagen), treated with DNaseI and reverse-transcribed into the first-strand cDNA 
with SuperScript III (Invitrogen). cDNAs were used for SYBR-green based quantitative real-time 
PCR to measure the expression level of target genes with the T method (ABI). All the primers used 
for quantitative PCR were listed in Table S1.   
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Western blot analysis 
Forebrains from E17.5 embryos were quickly dissected out and homogenized in RIPA buffer (50 
mM Tris pH 7.5, 120 mM NaCl, 1% Triton X-100, 0.5% Sodium Deoxycholate, 0.1% SDS, 5 mM 
EDTA, Phosphatase Inhibitor Cocktail (Cell Signaling), protease inhibitor cocktail (Sigma). 
Lysates were incubated for 15 min on ice and centrifuged at 15,000g for 15 min at 4°C. Supernatant 
was collected and boiled for 5 min in Laemmli sample buffer (Biorad), resolved by SDS PAGE, 
transferred to PVDF membrane, and immunoblotted. Primary antibodies are listed in KEY 
RESOURCE TABLE. Quantification of bands was performed using ImageJ software. 
 
m6A dot blot assay 
mRNA was harvested from homogenized forebrains at embryonic stages E15.5 and E17.5 using 
Dynabeads mRNA Direct Purification Kit (61011, Ambion). Four biological replicates were pooled 
for each sample to ensure sufficient concentration of mRNA. Dots were applied to an Amersham 
Hybond-N+ membrane (GE Healthcare) in duplicate as 100 ng mRNA per 1 μl dot. After complete 
drying, the mRNA was crosslinked to the membrane using a UV Stratalinker 2400 by running the 
auto-crosslink program twice. The membrane was then washed in PBST three times and blocked 
with 5% skim milk in PBST for 2 hr. The PBST wash was repeated and the membrane was 
incubated with primary anti-m6A antibody (212B11, Synaptic Systems) at 1:1000 dilution for 2 hr 
at room temperature. After 3 washes in PBST, the membrane was incubated in HRP-conjugated 
anti-mouse IgG secondary antibody for 2 hr at room temperature, then washed again 3 times in 
PBST. Finally, the membrane was visualized using SuperSignal West Dura Extended Duration 
Substrate (34075, Thermo Scientific). To confirm equal mRNA loading, the membrane was stained 
with 0.02% methylene blue in 0.3 M sodium acetate (pH 5.2) and quantified m6A levels were 
normalized to amount of mRNA loaded. Four biological samples in technical duplicates for each 




m6A profiling was performed as previously described [2]. For m6A profiling of mouse developing 
brain, forebrains from WT E13.5 embryos were dissected. For m6A profiling of human organoids, 
25 to 30 forebrain organoids at day 47 were used. For m6A profiling of PCW11 fetal human brain, 
cortex from 2 PCW11 fetuses were dissected. The total RNA was extracted using RNeasy Mini Kit 
(Qiagen). mRNA was isolated using the Dynabeads mRNA Purification Kit (Invitrogen) and 
mRNA was fragmented via sonication to 100-200 base pairs. m6A pull-down was performed using 
a rabbit polyclonal anti-m6A antibody (Synaptic systems), and immunoprecipitation with protein 
G dynabeads (ThermoFisher). m6A-tagged mRNAs were competitively eluted from beads with free 
N6-methyladenosine. cDNA libraries from pulled-down RNA and input RNA were prepared using 
the NEBNext® Ultra™ DNA Library Prep Kit for Illumina®. The experiment was performed with 
three technical replicates. For m6A profiling of day 47 human forebrain organoids, the same 
procedure was followed, with the exception that the experiment was performed with two technical 
replicates because of the amount of samples required. 
 
m6A mRNA immunoprecipitation and q-PCR 
Total RNA from NPCs cultured from WT E13.5 mouse forebrain was extracted using RNeasy Mini 
Kit (Qiagen) and mRNA was isolated using the Dynabeads mRNA Purification Kit (Invitrogen). 
1% of input mRNA was reserved for reverse transcription. Full length m6A tagged transcripts were 
pulled-down using a rabbit polyclonal anti-m6A antibody (Synaptic systems) and a mock pull-down 
was done with normal rabbit IgG (Cell Signaling Technologies). Immunoprecipitation was 
performed with protein G dynabeads (Thermo Fisher). m6A-tagged mRNAs were competitively 
eluted from beads with free N6-methyladenosine. Reverse transcription of input, m6A pull-down 
and mock pull-down mRNA was performed using the SuperScript® III First-Strand Synthesis 
System for RT-PCR (Thermo Fisher). cDNA was used for SYBR-green based quantitative real-
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time PCR. Enrichment of m6A tagged genes in m6A pull-down over input was calculated by 
comparing relative concentrations using Ct values (2-Ct) and dividing each concentration by the 
relative concentration of the input. The concentrations of the immunoprecipitated RNA were then 
divided by the concentration in the input RNA and multiplied by 100, to obtain the percentage of 
transcripts in the m6A immunoprecipitation relative to the input. This value was then normalized 
to enrichment in the mock (IgG) pull-down, which was also calculated using relative concentrations 
to determine a percentage of the input. Primers used are listed in Table S1. 
 
Bioinformatic analyses of m6A-seq 
cDNA libraries from input and m6A pull-down were sequenced on the Illumina Nextseq platform, 
using a 50-cycle single-end run. Pre-processing of reads was performed using the FASTX toolkit 
(http://hannonlab.cshl.edu/fastx_toolkit/), namely adapters were clipped, poor quality reads were 
filtered out, and identical reads were collapsed. Pre-processed reads from E13.5 mouse forebrains 
were aligned to the mouse genome (build GRCm38/mm10), and reads from the human organoids 
and fetal brain to the human genome (build GRCh37/hg19), using Tophat2 [166] with default 
settings. m6A-tagged regions were identified using the MACS2 peak calling algorithm [167], with 
the input library as background. For identifying high confidence m6A regions, peaks were 
intersected in a pairwise fashion among all replicates using the BedTools package [168]. Peaks that 
overlap in at least 50% of their length among 2 or more samples were designated as high confidence 
m6A regions. 
For representative coverage plots of m6A and input libraries, RNA-seq read alignments in 
bam format were transformed to bedGraph format and normalized for library size using the 
genomecov function from the BedTools package [168]. Analysis of m6A peak enrichment was 
performed based on 5 non-overlapping transcript segments defined as follows: Transcription start 
site (TSS) segment [TSS, TSS+200bp], 5’UTR [TSS+201bp, CDS start-1bp], coding region (CDS) 
[CDS start, CDS stop-101bp], stop codon segment [CDS stop-100bp, CDS stop+100bp], 3’ UTR 
 57 
[CDS stop+101bp, TTS]. Each high confidence peak was annotated to one of these regions using 
the BedTools package and fold enrichment was calculated from the ratio between observed peaks 
per region and expected number of peaks normalized by average region size. For analysis of 
correlation between gene expression levels and m6A peak fold change, we calculated RPKMs from 
input RNA seq libraries, using gene counts obtained with the htseq-count function from the HTSeq 
python package [169] that were normalized by library size and gene length defined as the length of 
its longest transcript. Fold changes for m6A peaks were obtained from MACS2 output. 
 
Functional annotation and disease ontology 
To assess enrichment of GO terms specific to a biological process, the ToppFunn module of the 
ToppGene Suite [170] was used. A hypergeometric probability mass function with Benjamini 
Hochberg FDR correction was used to identify significant enrichment for GO terms. Analysis of 
enrichment for Wikipathways terms was performed using ConsensusPathDB (Herwig, 2016), 
which calculates enrichment p-values using the Wilcoxon's matched-pairs signed-rank test, and 
Benjamini Hochberg FDR correction.  
Disease association analysis was performed using WebGestalt [171], which uses a 
hypergeometric method and Benjamini Hochberg FDR correction. Protein interaction network 
figures were generated using Cytoscape 3.3.0 [172], with the Reactome FI plugin. 
 
RNA degradation assay 
cDNA libraries were prepared from cultured NPCs from E13.5 WT and Mettl14 cKO cortex, at 0 
and 5 hr post Actinomycin D treatment, using the NEBNext® Ultra™ DNA Library Prep Kit for 
Illumina®. The experiment was performed with three replicates per condition. Sequencing was 
performed on the Illumina Nextseq platform, using a 100-cycle single-end run. Pre-processing of 
reads was performed using the FASTX toolkit. Gene expression levels were quantified using the 
RSEM package [173], which maps reads to the transcriptome using the aligner tool Bowtie2 [174]. 
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Expected counts per gene per sample were combined into a count matrix, and this matrix was used 
as input for differential expression analysis using the EBSeq package [175], which uses empirical 
Bayesian methods to calculate the posterior probability of a gene being differentially expressed 
(PPDE). Posterior fold changes per gene between cKO and WT were obtained at time 0 and 5 hr 
after Actinomycin D treatment. Fold changes at 5 hr were normalized by fold changes at 0 hr (no 
Actinomycin D treatment) to specifically identify genes that degrade at a different slower rate in 
the cKO compared to WT, regardless of baseline changes in gene expression between two 
conditions. Genes with a normalized fold change higher than 2 in cKO over WT at 5 hr were 
considered as to be differentially degraded (Table S4). 
 
Half-life measurement of m6A-tagged transcripts 
Mouse NPCs were cultured in standard 6 well culture plates to approximately 80% confluence. 
Actinomycin D (Sigma) was added at a concentration of 5 µM. Cells were collected at three time 
points after addition (0, 3 hr, 5 hr) by washing once with PBS, then lysing the cells in Buffer RLT 
from the RNeasy Kit (Qiagen) with 1% β-Mercaptoethanol. A cell scraper was used to remove all 
cells from the well plate. Each sample was normalized for cell number by quantifying DNA content 
using a Quant-IT PicoGreen dsDNA Assay Kit (ThermoFisher) according to manufacturer 
instructions. Equal amounts of cellular contents, as measured by DNA quantity, were taken from 
each sample and 1 pg of luciferase control RNA (Promega) was added to each sample before RNA 
purification. Total RNA was then purified using an RNeasy Kit and reverse transcribed using the 
SuperScript II First-Strand Synthesis System (Thermo Fisher). Real time PCR was performed on a 
Step One Plus cycler from Applied Biosystems with Fast SYBR® Green Master Mix. Standard 
curves were generated by plotting CT values against the known initial concentration of luciferase 
control RNA, and then used to derive mRNA concentration of each target gene at each time point. 
The lnmRNA concentrations at time point 0, 3 and 5 hr were then used to perform a linear regression as a 
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function of time, and identify the slope of said line as the decay rate (k) (Figure S4F). Half life was 
calculated with the following formula: t1⁄2=ln2/kdecay [176]. 
 
Metabolic labeling and purification of nascent RNA 
4sU labeling of nascent RNA was performed as previously described [143]. Mouse NPCs from 
E13.5 WT and Mettl14 cKO forebrain were cultured in standard 6 well culture plates to 
approximately 80% confluence, treated with 500 μM of 4sU (Carbosynth) for 1 hr, washed with 
PBS, and harvested with TRIzol reagent (ThermoFisher). Samples were extracted by chloroform 
twice and precipitated with isopropanol. Biotinylation of 4sU-RNA were carried out in a total 
volume of 250 μl, containing 70 μg total RNA, 10 mM HEPES (pH 7.5), 1 mM EDTA, and 5 μg 
MTSEA biotin- XX (Biotium) freshly dissolved in DMF (final concentration of DMF = 20%). 
Reactions were incubated at RT for 30 min in the dark, and excess biotin reagents were removed 
by chloroform extraction twice. Purified RNA was dissolved in 50 μl RNase-free water and 
denatured at 65°C for 10 min, followed by rapid cooling on ice for 5 min. Biotinylated RNA was 
separated from non-labeled RNA by incubating with 100 μl Streptavidin Magnetic Beads 
(ThermoFisher) for 20 min at RT. Beads were washed twice with high-salt wash buffer (500 μl 
each, 100 mM Tris- HCl pH 7.4, 10 mM EDTA, 1 M NaCl, and 0.1% Tween-20). 4sU-RNA was 
eluted with 100 μl freshly prepared 100 mM DTT followed by a second elution with an additional 
100 μl 5 min later. RNA was recovered using the MinElute Spin columns (Qiagen) according to 
the instructions of the manufacturer, and applied for Q-PCR analysis.  
 
Comparison between human and mouse m6A-seq datasets 
For comparison of m6A sequencing data from day 47 human forebrain organoids, PCW11 fetal 
human cortex, and mouse E13.5 forebrains, we restricted our analysis to expressed genes with a 
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one-to-one ortholog between species. For determining expressed genes, we calculated RPKMs (as 
stated above) from input libraries, and used a threshold of RPKM > 1. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Data in figure panels reflect several independent experiments performed on different days. An 
estimate of variation within each group of data is indicated using standard error of the mean (SEM). 
We performed unpaired Student’s t-test for assessing the significance of differences between two 
treatments (See each figure for details).  
 
Analyses of mouse cortical neurogenesis in vivo  
For quantitative analysis of electroporated neocortices, only GFP+ cells localized within the dorso-
lateral cortex were examined. 3 x 3 tiled images were obtained to cover the electroporated region 
of each coronal section with a 20x or 40x objective by scanning microscope (Zeiss LSM 800) and 
compared with equivalent sections in littermate counterparts. Quantifications were performed using 
Imaris software (Bitplane). Specifically, for quantification of cell fate after in utero electroporation, 
GFP+ cells were marked, and GFP+Pax6+ cells were defined and counted based on the intensity of 
Pax6 immunofluorescence in GFP+ cells measured with the same criteria among different groups 
using Imaris software. For the distribution of GFP+ cells in each layer, the borders between different 
layers were defined by Pax6 immunofluorescence (VZ/SVZ) and DAPI staining (SVZ/IZ and 
IZ/CP). For quantification of cell fate in WT and Mettl14 cKO mice at E17.5, P0 and P5, the regions 
of the primary somatosensory cortex were identified and the numbers of Pax6+, Tbr2+, S100 +, 
Ctip2+, Satb2+ or Tbr1+ cells were counted in each vertical column with 100  m width. For 
distribution plots, the distances between soma of EdU+Pax6+, Pax6+, Tbr2+ or Neurod1+ cells and 
the ventricular surface were calculated. Only EdU+Pax6+ cells within 200 μm distance from the 
ventricular surface were measured, and the histogram of cell location in every 20 μm interval from 
the ventricular surface was plotted as a percentage. For distribution plots of Pax6+Tbr2+ or 
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Pax6+Neurod1+ cells, the distances between soma of cells and the ventricular surface were 
calculated and the numbers of cells per 100 μm2 area in every 20 μm interval from the ventricular 
surface were plotted as density distribution. All quantifications were performed with 4-10 brain 
sections from at least 4 animals. Data are presented as the mean ± SEM and statistical significance 
was assessed using unpaired Student’s t-test.  
 
DATA AND SOFTWARE AVAILABILITY 
The access number for the data for m6A-seq reported in this study is NCBI GEO: GSE99017. 
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Figure 1. Nervous system Mettl14 deletion results in residual radial glia cells and ongoing 
neurogenesis in the postnatal mouse cortex.  
(A-C) Presence of neurogenic RGCs in P5 Nestin-Cre;Mettl14f/f cKO cortices. Shown are sample 
confocal images (A, B) and quantifications (C). Regions in white boxes are shown at a higher 
magnification. Scale bars: 500 m (A, top panel), 50 μm (A, bottom panel), 100 μm (B). Values in 
(C) represent mean + SEM (n = 4-7; ***: P < 0.001; *: P < 0.05; unpaired Student’s t-test).  
(D-E) Preserved IPCs in P5 cKO cortices. Shown are sample confocal images (D; scale bars: 100 
μm) and quantification (E). Values represent mean + SEM (n = 6; ***: P < 0.001; **: P < 0.01; 
unpaired Student’s t-test).  
(F-G) Ongoing neurogenesis in P5 cKO cortices. P5 pups were injected with EdU and analyzed 48 
hr later. Shown in (F) are sample confocal images of the ventricular side of the primary 
somatosensory cortex. Arrows indicate Pax6+EdU+ cells (top) and Tbr2+TuJ1+EdU+ cells (bottom). 
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Scale bars: 100 μm. Quantification of EdU+ cells with different markers is shown in (G). Values 
represent mean + SEM (n = 6; ***: P < 0.001; unpaired Student’s t-test).  
(H-K) Reduced production of upper-layer neurons and astrocytes in cKO cortices. Pregnant mice 
were injected with EdU at E15.5 and analyzed at P5. Shown are sample confocal images (H, J; 
scale bars: 100 μm) and quantification (I, K). Values represent mean + SEM (n = 6; ***: P < 0.001; 
unpaired Student’s t-test).  





Figure 2. Mettl14-/- RGCs and NPCs exhibit prolonged cell cycle progression.  
(A-B) Abnormal INM of RGCs in Mettl14 cKO cortices. Pregnant mice were injected with EdU at 
E17.5 and analyzed 0.5 or 6 hr later. Shown are sample confocal images (A; scale bars: 50 μm) and 
quantification of the distance from Pax6+EdU+ nuclei to the ventricular surface (B). Values for the 
percentages of nuclei in each 20 μm bin represent mean + SEM (n = 4; ***: P < 0.001; **: P < 
0.01; *: P < 0.05; unpaired Student’s t-test).  
(C-D) Delayed S to M phase transition of RGCs in Mettl14 cKO mice. Pregnant mice were injected 
with EdU at E17.5 and analyzed 2 hr later. Shown in (C) are sample confocal images. Arrowheads 
point to Pax6+pH3+EdU+ cells and arrows point to Pax6+pH3+EdU- cells. Scale bar: 50 μm. Shown 
in (D) is the quantification of the percentage of Pax6+pH3+EdU+ cells, representing cells proceeded 
from S to M phase during the 2 hr chase, among total Pax6+pH3+ cells. Values represent mean + 
SEM (n = 5 for WT and n = 8 for cKO; ***: P < 0.001; unpaired Student’s t-test).  
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(E-F) Delayed cell cycle exit of neural progenitors in Mettl14 cKO mice. Pregnant mice were 
injected with EdU at E17.5 and analyzed 24 hr later. Shown in (E) are sample confocal images. 
Arrowheads point to Ki67-EdU+ cells and arrows point to Ki67+EdU- cells. Scale bar: 50 μm. 
Shown in (F) is the quantification of the percentage of Ki67-EdU+ cells, representing cells exited 
from cell cycle, among total EdU+ cells. Values represent mean + SEM (n = 6; ***: P < 0.001; 
unpaired Student’s t-test).  
(G-J) Time-lapse imaging analysis of mouse NPCs showing prolonged S-G2-M phase length in the 
absence of Mettl14. WT and cKO mouse NPCs were electroporated with plasmid co-expressing a 
Cdk2 sensor (green) and the H2B-mCherry nuclear marker (red), cultured for 2 days, and imaged 
for 48 hr. Shown in (G) are sample time-lapse images with time stamps. Scale bars: 10 μm. Also 
shown are box plots of quantifications for the total cell cycle length (H; n = 38 for WT and n = 30 
for cKO), G1 phase length (I; n = 20), and S-G2-M phase length (J; n = 20). Each dot represents 
data from one NPC (***: P < 0.001; unpaired Student’s t-test).  





Figure 3. Mettl3 regulates cell cycle progression of NPCs and maintenance of embryonic 
cortical RGCs.  
(A) Depletion of m6A-tagging on mRNAs purified from E15.5 and E17.5 Mettl14 cKO mouse 
forebrain. Shown in the left panels are sample images of m6A dot blot and methylene blue staining 
(for loading controls). Data were normalized to the averaged levels of WT samples and 
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quantification is shown in the right panel. Values represent mean + SEM (n = 3; **: P < 0.01; 
unpaired Student’s t-test). 
(B) Depletion of m6A-tagging on mRNAs purified from Mettl14 cKO NPCs. Values represent 
mean + SEM (n = 3; **: P < 0.01; unpaired Student’s t-test). 
(C-D) Flow cytometry analysis of cell cycle status of mouse NPCs. NPCs were electroporated to 
co-express GFP and the control shRNA, or the shRNA against Mettl3. At day 4, NPCs were pulse-
labeled with EdU (10 μM) for 30 min, cultured for 9 hr, followed by EdU and DNA content 
(DyeCycle Violet) staining and flow cytometry analysis. Shown are sample histograms of DNA 
content from GFP+EdU+ cells and the total cell population (as a reference; C) and quantification 
(D). Values in (D) represent mean + SEM (n = 4; **: P < 0.01; unpaired Student’s t-test). 
(E-G) Embryonic mouse cortices were electroporated in utero at E13.5 to co-express GFP and 
shRNA-control, or GFP and shRNA-Mettl3, and analyzed at E17.5. Shown in (E) are sample 
confocal images. Scale bars: 50 μm. The distribution of GFP+ cells in each zone (F) and the 
percentage of GFP+Pax6+ cells among total GFP+ cells (G) were quantified. VZ: ventricular zone; 
SVZ: subventricular zone; IZ: intermediate zone; CP: cortical plate. Values represent mean + SEM 
(n = 4; ***: P < 0.001; **: P < 0.01; unpaired Student’s t-test). 





Figure 4. m6A tags transcripts related to transcription factors, cell cycle, and neuronal 
differentiation in the embryonic mouse brain, and promotes their decay.  
(A) Coverage plots from m6A-seq of E13.5 mouse forebrains showing representative examples of 
m6A-tagged (Sox1, Emx2, and Cdk9) and non m6A-tagged (Rad17) transcripts. Top and middle 
panels show read coverages normalized by library sizes from m6A pulled-down and input libraries, 
respectively, and bottom panels show gene structures (arrows point to the direction of transcription; 
S.C.: stop codon). 
(B-C) GO analysis of m6A-tagged genes reveals enrichment for biological process terms related to 
transcription factors, neurogenesis, cell cycle, and stem cell differentiation. Also shown is 
Wikipathways gene set enrichment analysis. FDR: false discovery rate. 
(D) Cumulative distribution of Log2(gene expression ratios) at time 5 hr post ActD over time 0 hr 
for m6A tagged genes (purple line) and non-m6A tagged genes (black line) for WT and Mettl14 
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cKO NPCs. D = value of Kolmogorov Smirnov test statistic corresponding to maximum difference 
between methylated and non-methylated distributions. 
(E) Cumulative distribution of log2(fold change in ratios of gene expression) at 5 hr post ActD 
treatment over time 0 hr upon Mettl14 deletion. Top panel shows cumulative distribution for non-
targets (black line) and transcripts with 1-1.9 m6A sites on average (bright red line), or 2 or more 
sites on average (dark red line). Bottom panel shows cumulative distribution for non-targets (black 
line) and m6A-tagged transcripts with 1-2, 2-3, 3-4, and 4 or more sites on average (red, yellow, 
blue, and green lines, respectively).  
(F) Summary of half-life of a group of transcripts in WT and Mettl14 cKO NPCs. Values represent 
mean + SEM (n = 4; ***: P < 0.001; **: P < 0.01; unpaired Student’s t-test   





Figure 5. Post-transcriptional regulation of pre-patterning gene levels and protein production 
by m6A signaling in cortical neural stem cells. 
(A) Coverage plots from m6A-seq of E13.5 mouse forebrains showing representative examples of 
m6A-tagged IPC (Tbr2 and Neurog2) and neuronal (Neurod1 and Neurod2) genes.  
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(B) Q-PCR analysis of total mRNA and 4sU-purified nascent mRNA from WT and Mettl14 cKO 
NPCs. All Ct values were first normalized to Gapdh control (not m6A-tagged), which were similar 
in both WT and cKO NPCs. The ratio (cKO over WT) was calculated for each experiment and 
values represent mean + SEM (n = 3 cultures; ***: P < 0.001; **: P < 0.01; *: P < 0.05; unpaired 
Student’s t-test).  
(C-F) Precocious expression of Tbr2 and Neurod1 proteins in RGCs in E17.5 Mettl14 cKO mice 
in vivo. Shown are sample confocal images (C, E; scale bars: 50 μm) and quantifications of the 
percentage of Tbr2+Pax6+ cells (D), or Neurod1+Pax6+ cells (F), among total Pax6+ cells (top 
panels, n = 6) and the density distribution of Tbr2+Pax6+ (D), or Neurod1+Pax6+ cells (F), from the 
ventricular surface (bottom panels, n = 4). Arrows indicate Tbr2+Pax6+ (C) or Neurod1+Pax6+ cells 
(E). Values in (D, F) represent mean + SEM (***: P < 0.001; **: P < 0.01; *: P < 0.05; unpaired 
Student’s t-test). 





Figure 6. METTL14 regulates cell cycle progression of human NPCs.  
(A-B) Flow cytometry analysis of cell cycle progression of hNPCs with METTL14 KD. Human 
NPCs were electroporated to co-express GFP and shRNA-control, or shRNA-METTL14. After 4 
days, hNPCs were pulse-labeled with EdU (10 μM) for 30 min, incubated for 14 hr, followed by 
EdU and DNA content (DyeCycle Violet) staining and flow cytometry analysis, similarly as in 
Figure 3C-D. Values represent mean + SEM (n = 4; **: P < 0.01; unpaired Student’s t-test).  
(C-D) Flow cytometry analysis of cell cycle progression with METTL14 KD in human forebrain 
organoids. Day 45 forebrain organoids were electroporated to co-express GFP and shRNA-control, 
or shRNA-METTL14. After 7 days, forebrain organoids were pulse-labeled with EdU (10 μM) for 
1 hr, cultured further for 14 hr, followed by dissociation and analysis similarly as in Figure 3C-D. 
Values represent mean + SEM (n = 4; ***: P < 0.001; unpaired Student’s t-test).  
See also Figure S6.  
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Figure 7. Conserved and unique features of m6A mRNA methylation in human forebrain 
organoids, human fetal brain and embryonic mouse forebrain. 
(A) Representative plots of two m6A-tagged transcripts in day 47 human forebrain organoids and 
PCW11 human fetal brain, but not in mouse E13.5 forebrain. 
(B) Venn diagram showing shared m6A-tagged transcripts between day 47 human forebrain 
organoids and PCW11 fetal human brain.  
(C) GO and disease ontology analyses of shared m6A-tagged genes in day 47 human forebrain 
organoids and PCW11 human fetal brain.  
(D) Venn diagram showing shared and unique m6A-tagged transcripts among mouse E13.5 
forebrain, day 47 human forebrain cortex, and PCW11 fetal human brain. Only ortholog genes 
expressed in all three samples were used for analysis.  
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(E-F) Disease ontology analysis of transcripts uniquely m6A-tagged in human shows enrichment 
for neurodevelopmental diseases, whereas disease ontology analysis of commonly m6A-tagged 
transcripts showed enrichment for oncogenic processes.  
See also Figure S7, Table S5, Table S6 and Table S7.  
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Figure S1: Nervous System Mettl14 Deletion in Mice Results in Postnatal Lethality and 
Deficits in Timely Production of Cortical Neuron Subtypes, Related to Figure 1 
(A) Expression of molecular mediators of m6A signaling based on a published single-cell RNA-
seq dataset of embryonic mouse cortical neurogenesis (Telley et al., 2016). Shown are the 
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expression profiles of selected genes as violin plots, generated using the Seurat package of R 
(http://genebrowser.unige.ch/science2016/) (Macosko et al., 2015). AP: Apical progenitors/RGCs; 
BP: daughter basal progenitors/IPCs; EN: early neurons; LN: late neurons. 
(B) Depletion of Mettl14 protein in the forebrain of Nestin-Cre;Mettl14f/f cKO mice. Shown are 
the genetic deletion strategy (left) and sample western blot images from WT or cKO E17.5 
forebrain lysates (right). Because Mettl14 was only deleted in the nervous system, the minor non-
neural cells contributed to the residual Mettl14 proteins (faint bands). 
(C) Appearance of WT and cKO pups at P5 and P14. Note the impairment in the P14 cKO pup to 
maintain body balance. Scale bars, 1 cm. 
(D) Survival curve of WT (n = 45), Het (n = 23) and cKO (n = 22) pups. 
(E and F) Deficits in the production of upper-layer neurons in cKO cortices at P5. Shown in (E) are 
sample confocal images of staining for Satb2 (layer 2/3), Ctip2 (layer 5) and DAPI, or Ctip2 (layer 
5), Tbr1 (layer 6) and DAPI. Scale bars, 100 μm. Quantification is shown in (E). Values represent 
mean ± SEM (n = 6; ∗∗: p < 0.01; unpaired Student’s t test). 
(G and H) Deficits in the production of lower-layer neurons in cKO cortices at E17.5. Shown in 
(E) are sample confocal images of staining for Ctip2 and DAPI. Scale bar, 100 μm. Quantification 




Figure S2: Flow Cytometry Analysis Reveals Delayed Cell-Cycle Progression of Mettl14 cKO 
NPCs, Related to Figure 2 
(A) Schematic diagrams of the dual reporter system used to track cell cycle status by time-lapse 
imaging. Nuclear localized H2B-mCherry and a GFP-tagged Cdk2 substrate DHB are co-expressed 
in the individual cell. Cdk2 becomes active during the G1-S transition and phosphorylates DHB-
GFP, which is then translocated from the nucleus to the cytoplasm. The presence of GFP in the 
mCherry+ nucleus indicates cells in the G1 phase, whereas translocation to the cytoplasm indicates 
the initiation of the S phase, and continual buildup of cytoplasmic GFP occurs until mitosis. 
(B–D) Flow cytometry analysis of cell cycle progression of WT and Mettl14 cKO NPCs. NPCs 
were pulse-labeled with EdU (10 μM) for 30 min, cultured for 0 or 5 hr, followed by EdU and DNA 
content (7AAD) staining and flow cytometry analysis. Shown in (B) are sample dot plots at 0 and 
5 hr after EdU pulsing. Cells in a specific cell cycle phase were marked in a box. Note that EdU+ 
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cells (S phase at 0 hr) were segregated into divided (G1∗) and non-divided (S/G2∗/M∗) populations. 
Shown in (C) are sample histograms of DNA content from EdU+ cells and the total cell population 
(as a reference). Quantification is shown in (D). Values represent mean ± SEM (n = 4; ∗∗∗: p < 0.01; 




Figure S3: Mettl3 Is Essential for m6A mRNA Methylation and Proper Cell-Cycle 
Progression of Mouse NPCs, Related to Figure 3 
(A) Efficacy of the shRNA against mouse Mettl3. Mouse B16F10 cells were transfected with 
shRNA-control and shRNA-Mettl3. The amount of Mettl3 mRNA was assessed by Q-PCR 3 days 
later. Values represent mean ± SEM (n = 3; ∗∗∗: p < 0.001; unpaired Student’s t test). 
(B and C) Depletion of m6A mRNA methylation by Mettl3 KD. Shown are sample images of m6A 
dot blot and methylene blue staining (as loading controls; B) and quantification (C). Data were 
normalized to the averaged levels of WT samples. Values represent mean ± SEM (n = 3; ∗∗∗: p < 
0.01; unpaired Student’s t test). 
(D) Flow cytometry analysis of cell cycle status of mouse NPCs. Mouse NPCs were electroporated 
to co-express GFP and shRNA-control, or shRNA-Mettl3. After 4 days, NPCs were pulse-labeled 
with EdU (10 μM) for 30 min, cultured for 9 hr, followed by EdU and DNA content (DyeCycle 
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Violet) staining and flow cytometry analysis. GFP+ and GFP− cells were gated separately and 






Figure S4: m6A-Seq Analysis of Mouse Embryonic Forebrain, Related to Figure 4 
(A) Venn diagram showing intersection among m6A peaks identified in 3 independent m6A-seq 
experiments. 4,055 high confidence peaks shared by 2 out of 3 replicates, corresponding to 2,059 
genes, were used for downstream analysis. 
(B) Enrichment of m6A peaks in 5 non-overlapping transcript segments. Pie chart shows percentage 
of peaks annotated to each segment. Bar plot shows fold enrichment of peaks for each segment, 
normalized for the segment length. 
(C) m6A peaks do not correlate with transcript expression levels. Scatterplot shows gene expression 
levels (lnRPKM) of m6A-tagged genes plotted against m6A peak lnfold change. Histogram shows 
distribution of gene expression levels (lnRPKM) for all transcripts detected in 3 RNA-seq input 
libraries. 
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(D) Validation of m6A-tagging in specific transcripts in cortical NPCs. The enrichment of m6A-
tagged transcripts by IP with anti-m6A antibodies over lgG was quantified by Q-PCR. Values 
represent mean ± SEM (n = 3; ∗∗∗: p < 0.01; ∗∗: p < 0.01; ∗: p < 0.05; unpaired Student’s t test). 
(E) Representative coverage plots from the RNA-seq analysis at 0 or 5 hr after treatment with ActD 
showing increased stability of m6A-tagged genes (Sox1 and Emx2), but not a non m6A-tagged gene 
(Rad17) in Mettl14 cKO compared to WT NPCs. 
(F) Representative plot for calculating half-life of transcripts in WT and cKO NPCs. Data for Emx2 
is plotted as an example. The ln of the transcript concentration at each time point, (0, 3, and 5 hr 
after Actinomycin D treatment) was plotted, and a linear regression was used to determine the slope 
of the resultant line. The half-life was then calculated as the ln2 divided by the absolute value of 




Figure S5: Expression of Neuronal Genes in RGCs of Embryonic Cortex In Vivo, Related to 
Figure 5 
(A) Q-PCR analysis of pre-mRNA from WT and Mettl14 cKO NPCs using pre-mRNA specific 
primers. All Ct values were first normalized to the Actin control (not m6A-tagged), which were 
similar in both WT and cKO NPCs. The ratio (cKO over WT) was calculated for each experiment 
and values represent mean ± SEM (n = 4 cultures; ∗∗: p < 0.01; ∗: p < 0.05; unpaired Student’s t 
test). 
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(B) Single-cell transcriptome analysis (Telley et al., 2016) reveals the expression of neuronal 
lineage genes in mouse embryonic cortical RGCs in vivo. Shown are the expression profiles of 
neural lineage genes as violin plots, similarly as in Figure S1A. 
(C and D) Increased expressions of neuronal lineage genes in FlashTag+ (FT+) RGCs 3 hr after 
pulse labeling. Shown are sample confocal images (C; scale bars, 20 μm) and quantifications of the 
percentage of FT+Tbr2+Pax6+ cells, or FT+Neurod1+Pax6+ cells (D), among total FT+ cells. Values 
represent mean ± SEM (n = 5 sections from 2 animals; ∗∗∗: p < 0.01; unpaired Student’s t test). 
(E and F) Precocious expression of Tbr2 and Neurod1 proteins in RGCs upon KD of mRNA 
deadenylase components in vivo. Shown are sample confocal images (E; scale bars, 20 μm) and 
quantifications of the percentage of GFP+Tbr2+Pax6+ cells, or GFP+Neurod1+Pax6+ cells, among 
total GFP+Pax6+ cells and the density distribution of GFP+Tbr2+Pax6+, or GFP+Neurod1+Pax6+ 
cells from the ventricular surface (F). Values represent mean ± SEM (n = 5 sections from 3 animals; 





Figure S6: Mettl14 Regulates Cell-Cycle Progression of hNPCs, Related to Figure 6 
(A) Validation of hNPC differentiation from human iPSCs. Shown is a sample confocal image. 
Scale bar, 50 μm. 
(B) Efficacy of the shRNA against METLL14. Human NPCs were electroporated to co-express 
GFP and shRNA-control, or shRNA-METLL14, and dissociated 3 days later. Amount of METLL14 
mRNA in FACS-purified GFP+ cells was assessed by Q-PCR. All Ct values were first normalized 
to the GAPDH control. Values represent mean ± SEM (n = 3; ∗∗∗: p < 0.01; unpaired Student’s t 
test). 
(C) Flow cytometry analysis of cell cycle progression of hNPCs with METTL14 KD. Similar to 
Figure S3D. 
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(D) Comparison of neuronal differentiation among day 47 human forebrain organoids and 
embryonic mouse cortical development at E13.5, E15.5 and E17.5. Shown are confocal images of 
immunostaining for CTIP2 and SATB2 and DAPI. Scale bar, 50 μm. Note that day 47 human 
forebrain organoids exhibit a differentiation pattern most similar to E13.5 mouse cortex. 
(E) Electroporation of human forebrain organoid with shRNA-expressing plasmid. Day 45 
forebrain organoids were electroporated to co-express GFP and shRNA-control, or shRNA-
METTL14, by microinjection into the lumen of organoids. After 7 days, organoids were pulse-
labeled with EdU (10 μM) for 30 min, and cultured further for 14 hr. Shown are sample confocal 
images at day 52. Scale bar, 100 μm. 
(F) Flow cytometry analysis of cell cycle progression with METTL14 KD in human forebrain 
organoids. Shown are sample dot plots 14 hr after EdU pulse. Cells in a specific cell cycle phase 





Figure S7: Comparison of m6A mRNA Landscaped among Human Forebrain Organoids, 
Fetal Brain, and Mouse Embryonic Forebrain, Related to Figure 7 
(A) Venn diagram showing intersection between m6A peaks identified in 2 independent m6A-seq 
of day 47 human forebrain organoids. 11,994 high confidence peaks corresponding to 4,702 genes 
were used for downstream analysis. 
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(B) Venn diagram showing intersection between m6A peaks identified in 3 independent m6A-seq 
of PCW11 human fetal brain. 10,980 high confidence peaks corresponding to 5,049 genes were 
used for downstream analysis. 
(C and D) Enrichment of m6A peaks in 5 non-overlapping transcript segments for day 47 human 
forebrain organoids (C) and PCW11 fetal human brain (D). Same as in Figure S4B. 
(E) Pie charts showing the percentage of m6A-tagged genes among all expressed genes in each 
samples. 
(F) GO analysis for m6A-tagged genes shared between human forebrain organoids and fetal brain, 
but not in mouse E13.5 forebrain (left panel), and GO analysis of m6A-tagged genes shared among 











Table S2. PAGE ONE OF: Dataset from m6A-Seq of E13.5 Mouse Forebrain, Day 47 Human 
Forebrain Organoids, and PCW11 Fetal Human Cortex, Related to Figures 4, 7, and S7 
The full table can be accessed online at:  
https://www.cell.com/cms/10.1016/j.cell.2017.09.003/attachment/5f286d35-a275-46d5-b3a0-
d1ae0b2d7224/mmc2.xlsx 
peakID chr start stop meanFC meanPval meanQval geneName
ID1 chr1 3214882 3215013 4.885505 7.144255 3.405425 Xkr4
ID2 chr1 6240085 6240331 6.51085 9.2955933 5.1929033 Rb1cc1
ID3 chr1 6248531 6248661 5.634675 8.129175 4.25045 Rb1cc1
ID4 chr1 6249794 6249894 6.327155 8.442 4.39114 Rb1cc1
ID5 chr1 6802929 6803028 4.80461 5.94877 2.32011 St18
ID6 chr1 9546255 9546398 5.292365 8.94584 4.93985 Rrs1
ID7 chr1 9546444 9546819 5.99214 10.708588 6.444145 Rrs1
ID8 chr1 9724471 9724834 7.9892433 13.681413 8.8992233 Vcpip1
ID9 chr1 9745930 9746319 5.8125425 8.6134775 4.6057125 Vcpip1
ID10 chr1 9746596 9747079 6.3882867 9.8628467 5.7024433 NR_040462
ID11 chr1 9747630 9747696 6.737455 11.317705 6.945735 NR_040462
ID12 chr1 12858937 12859343 6.4784633 8.9697333 4.9565467 Sulf1
ID13 chr1 12871905 12871987 6.43611 9.365985 5.2686 Slco5a1
ID14 chr1 13174157 13174705 8.7181 15.320307 10.337557 Ncoa2
ID15 chr1 17400649 17400786 7.7674033 13.21216 8.5102133 Intergenic
ID16 chr1 23369807 23370144 7.50186 11.301963 6.8837933 Ogfrl1
ID17 chr1 24029040 24029248 6.45373 9.63832 5.532795 Fam135a
ID18 chr1 25068028 25068219 7.2368967 10.797927 6.4428 Adgrb3
ID19 chr1 25093899 25094215 7.4681533 11.96079 7.4731333 Adgrb3
ID20 chr1 30803731 30804295 6.3815 11.735687 7.28807 Phf3
ID21 chr1 30804874 30804971 5.9861133 9.5155467 5.3768333 Phf3
ID22 chr1 30805176 30805390 5.38401 8.87386 4.8424067 Phf3
ID23 chr1 30805645 30805794 5.5632567 8.6078533 4.6190967 Phf3
ID24 chr1 30829998 30830245 5.4420333 7.5544467 3.7387033 Phf3
ID25 chr1 30830831 30831163 5.42348 8.3669167 4.4087033 Phf3
ID26 chr1 30943043 30943222 3.6231133 7.2170167 3.4469733 NR_002688
ID27 chr1 30946409 30946546 5.225235 10.83373 6.514255 NR_002688
ID28 chr1 33801390 33801610 5.746565 8.30492 4.387885 Zfp451
ID29 chr1 33801702 33802801 6.612605 11.645972 7.204995 Zfp451
ID30 chr1 33802901 33803036 5.3768867 8.6878967 4.6977133 Zfp451
ID31 chr1 34227850 34227951 5.21634 7.048465 3.31287 Dst
ID32 chr1 34589558 34589689 6.187915 8.303105 4.3928 Amer3
ID33 chr1 36103647 36104428 6.4859875 10.31531 6.0129225 Hs6st1
ID34 chr1 36335920 36336229 8.691475 15.27857 10.37783 Kansl3
ID35 chr1 36512050 36512116 6.353905 8.425765 4.513445 Cnnm3
ID36 chr1 36549270 36549551 6.7809367 11.964663 7.4776767 Sema4c
ID37 chr1 36549791 36550123 5.54133 8.30883 4.3625067 Sema4c
ID38 chr1 38088169 38088610 6.2676667 9.18391 5.1259067 Rev1
ID39 chr1 38209602 38209730 7.232315 10.498825 6.24031 Aff3
ID40 chr1 38864624 38864742 6.01264 8.18334 4.284375 Chst10
ID41 chr1 38865519 38865840 6.872175 10.21248 6.026315 Chst10
ID42 chr1 42695814 42696910 5.3170667 21.51013 15.646773 Pou3f3
ID43 chr1 42697319 42697646 3.9989233 14.439783 9.5828833 Pou3f3
ID44 chr1 42697783 42699903 4.5423975 19.395915 13.81438 Pou3f3
m6A-seq of E13.5 mouse forebrain
Peaks identified by MACS2 in 2 or 3 replicate m6A sequencing experiments
meanFC= mean fold change per peak 
meanPval= mean log10 of pvalue per peak




Table S3:  
GO Analysis of m6A-Tagged Genes in E13.5 Mouse Forebrain, Related to Figure 4  
Category ID Name p-value q-value Bonferroniq-value FDR B&H q-value FDR B&YHit Count in Query ListHit Count in Genome
GO: Biological ProcessGO:0006357 regulation of transcription from RNA polymerase II promoter5.72E-33 4.77E-29 4.77E-29 4.58E-28 369 1922
GO: Biological ProcessGO:0048699 generation of neurons 9.24E-29 7.71E-25 2.95E-25 2.83E-24 303 1538
GO: Biological ProcessGO:0030182 neuron differentiation 5.57E-27 4.65E-23 1.16E-23 1.12E-22 279 1405
GO: Biological ProcessGO:0007049 cell cycle 8.74E-20 7.30E-16 2.52E-17 2.42E-16 307 1771
GO: Biological ProcessGO:0060284 regulation of cell development 1.66E-17 1.39E-13 3.01E-15 2.90E-14 192 989
GO: Biological ProcessGO:0045595 regulation of cell differentiation 1.25E-13 1.05E-09 1.66E-11 1.60E-10 275 1706
GO: Biological ProcessGO:0050768 negative regulation of neurogenesis 1.99E-13 1.66E-09 2.52E-11 2.42E-10 74 287
GO: Biological ProcessGO:0000278 mitotic cell cycle 1.09E-11 9.11E-08 1.14E-09 1.09E-08 177 1019
GO: Biological ProcessGO:0048863 stem cell differentiation 2.03E-08 1.69E-04 1.26E-06 1.21E-05 65 303
p-value q-value pathway source external_id Hit in query list members_input_overlap_geneidssize effective_size
7.44E-10 9.78E-08 TGF-beta Signaling Pathway WikipathwaysWP366 TGFB1; PTK2; SNIP1; JUND; MAP2K6; DCP1A; MAP2K4; SKI; PIAS2; RBL2; PPM1A; BCAR1; JUN; MAP3K7; STRAP; SUMO1; PIK3R2; PIK3R1; RNF111; PJA1; COL1A2; ZEB2; CUL1; SRC; TRAF6; HGS; PML; SKIL; EP300; ZEB1; YAP1; LIMK2; TAB1; NUP153; EID2; PAK2; CREBBP5747; 6714; 9839; 537 ; 9564; 9063; 5062; 7040; 1387; 10454; 5494; 9146; 5608; 55802; 8454; 6935  64219; 79753; 10413; 7341; 163126; 9972; 54778; 6885; 3725; 3727; 6497; 5296; 5295; 6498; 11171; 6416; 2033; 1278; 7189; 5934; 3985132 132
1.80E-07 1.58E-05 Mesodermal Commitment PathwayWikipathwaysWP2857 NOG; TCF4; ZFHX4; MACF1; JARID2; SMAD1; BMPR1A; LATS1; SOX2; ARL4A; AHDC1; EMSY; AXIN2; FZD8; CCDC88A; MEIS1; EOMES; PLCH1; JAK2; ZIC2; ACVR2A; ACVR2B; ACACA; EXT2; EXT1; CEP250; DLL1; SETD2; YAP1; PPP2CA; MBTD1; TOX3; PHF6; CTBP2; ELP4; FOXC111190; 3717; 92; 5515; 6657; 23499; 8320; 101 4; 4211; 84295; 31; 26610; 7546; 10413; 9241; 8313; 2296; 6925; 27245; 54799; 657; 273 4 93; 3720; 79776; 23007; 4086; 83 ; 1488; 2132; 131; 55704; 29072; 9113; 28514; 56946153 153
2.53E-07 1.66E-05 Ectoderm Differentiation WikipathwaysWP2858 NUMA1; TRIM33; HMGB2; SPRY2; SOX2; RGMA; GLI3; FZD8; TFAP2C; UBTF; NR2F2; PDE7A; CDH8; ZFHX4; CDH6; ZBTB2; JAKMIP1; TCF3; NLGN1; TSC22D1; MECP2; SOCS2; CELSR2; ASTN1; SKIL; FGFR2; ROR2; BMPR1A; OGT; ST8SIA4; TTC14; TOX3; PLXNA2; CLVS11952; 6657; 7343; 5150; 3148; 4204; 2263; 51592; 7022; 7026; 7903; 152789; 1006; 1004; 151613; 6929; 22871; 10253; 657; 27324; 460; 8473; 56963; 79776; 8835; 2737; 6498; 8325; 4920; 4926; 8848; 157807; 5362; 576212 142
4.18E-07 2.20E-05 Wnt Signaling Pathway and PluripotencyWikipathwaysWP399 PPP2R1B; PPP2R3A; NFYA; CTNND1; MAP2K4; SOX2; FZD1; FZD3; AXIN2; FZD8; FZD9; JUN; MAP3K7; CSNK1E; FBXW2; PPP2R2A; PRKCE; APC; EP300; LRP5; PPP2CA; CCND2; WNT5B; CTBP2; WNT7A; CREBBP; WNT7B6416; 5581; 55 9; 5515; 6657; 1387; 8325; 7976; 8321; 4800; 4041; 81029; 8 26  1500; 6885; 37 5; 1454; 5520; 5523; 1488; 26190; 2033; 3 4; 7476; 7477; 894; 8313101 101
6.02E-07 2.64E-05 ESC Pluripotency Pathways WikipathwaysWP3931 PDGFRB; PDGFRA; SMAD5; HRAS; SMAD1; IL6ST; BMPR1A; BMPR1B; MAP2K6; FZD1; FZD3; FZD8; FZD9; JUN; HNF1A; MAPK6; MAPK7; PIK3R2; PDGFA; MTOR; APC; MDM2; FGFR2; LRP5; PTPN11; NOG; WNT5B; WNT7A; WNT7B3572; 324; 5597; 5598 5159; 2475; 5154; 5156; 8325; 8326; 8321; 5608; 4041 81029; 2263; 4193 3265; 9241; 6927; 657; 5781; 658; 3725; 4086; 5296; 7976; 7476; 7477; 4090115 11
1.53E-06 5.75E-05 Androgen receptor signaling pathwayWikipathwaysWP138 PTK2; SUMO1; SMARCE1; NCOR2; NCOR1; NCOA2; DAXX; NCOA4; PARK7; UBE3A; JUN; LIMK2; PIK3R2; PIK3R1; BRCA1; SRC; CREB1; RHOB; MDM2; EP300; ROCK2; PIAS2; ZMIZ1; CREBBP9475  5747; 3725; 9063; 672; 6714; 1385; 1387; 4193  388; 6605; 7341; 10499; 57178; 9612; 9611; 5296  5295; 1616; 8031; 2033; 11315; 7337; 398589 89
1.78E-06 5.86E-05 Notch Signaling Pathway WikipathwaysWP61 EP300; RBPJ; MAPT; APH1B; NOTCH2; PSEN1; HES6; SRC; CUL1; SPEN; DLL1; JAK2; PIK3R2; PIK3R1; TLE1; FBXW7; NCOR2; NCOR1; HEY123462; 5295; 3717; 5663; 9612; 5296; 55294; 3516; 23013; 2033; 83464; 8454  285 4; 6714; 9611; 7088; 55502; 4137; 48536
6.17E-06 0.000180415 EGF-EGFR Signaling Pathway WikipathwaysWP437 PTK2; CRKL; LIMK2; RPS6KB1; HRAS; JUND; SPRY2; PLCE1; FOXO4; ABL1; CRK; STAM; JUN; ARF6; MAP3K4; JAK2; MAPK7; PIK3R1; USP6NL; PIK3R2; SRC; RALGDS; HGS; CREB1; MTOR; BCAR1; RASA1; GJA1; NCK1; NCK2; GRB10; PTPN11; PTPN12; RALA4303; 3717; 25; 5900; 9564; 6714; 8027; 5598  1385 2475; 5747 9712; 9146; 51196; 1399; 1398; 4216; 382; 3265; 10253; 2887; 5781; 5782; 5898; 3725; 3727; 2697; 8440; 6198; 5296; 5295; 4690; 5921; 398516 162
1.05E-05 0.000274906 Wnt Signaling Pathway Netpath WikipathwaysWP363 CSNK1G1; TCF4; SOX1; AXIN2; CSNK1D; LRP5; MAP3K7; TCF3; CSNK1A1; CSNK1E; MTOR; APC; BCL9; GJA1; ROR2; TSC1607; 2475  6925; 7248; 4920; 4041  831  324; 2697; 6885; 6656; 1454; 1452; 1453; 53944; 692951 51
m6A tagged genes expressed in mouse E13.5 forebrain
Data from ConsensusPathDB
Gene ontology analysis: Biological Process
m6A tagged genes expressed in mouse E13.5 forebrain




Table S4. PAGE ONE OF: Dataset from RNA Decay Assay of WT and Mettl14 cKO NPCs, 
Related to Figure 4 
The full table can be accessed online at:  
https://www.cell.com/cms/10.1016/j.cell.2017.09.003/attachment/f95a05d1-d62d-40b1-9fc2-
82a5ab485838/mmc4.xlsx  
ensembl_gene_id external_gene_name PPEE PPDE PostFC RealFC Mettl14 cko MeanWT Mean
ENSMUSG00000069045 Ddx3y 0 1 661.3558639 33853.081 338.52081 0
ENSMUSG00000069049 Eif2s3y 0 1 353.3876231 18065.584 180.64584 0
ENSMUSG00000056673 Kdm5d 0 1 311.597793 15923.296 159.22296 0
ENSMUSG00000068457 Uty 0 1 85.18610441 137.376 111.37241 0.8007851
ENSMUSG00000026327 Serpinb11 5.24E-05 0.99994757 58.15789406 69.500337 176.02876 2.5229195
ENSMUSG00000052551 Adarb2 0.026696801 0.973303199 16.52368243 18.99762 59.907957 3.1439718
ENSMUSG00000045672 Col27a1 0.004603385 0.995396615 9.014428334 9.1614658 250.9828 27.386577
ENSMUSG00000091952 Gm17709 0.000169554 0.999830446 8.934921913 11.362691 18.656731 1.632809
ENSMUSG00000070867 Trabd2b 0.046485083 0.953514917 8.919503801 13.413006 11.872037 0.8758593
ENSMUSG00000053469 Tg 8.73E-05 0.999912707 8.811245231 12.134044 14.327506 1.1715934
ENSMUSG00000037621 Atoh8 0.000257702 0.999742298 8.568148964 10.339664 22.192558 2.1373191
ENSMUSG00000101316 Gm12663 0.006771125 0.993228875 7.971177771 9.1691678 26.808511 2.9148576
ENSMUSG00000023391 Dlx2 0.00096234 0.99903766 6.872296796 7.1297572 81.72801 11.454347
ENSMUSG00000026922 Agpat2 8.17E-12 1 6.647117931 6.8902664 80.424654 11.663664
ENSMUSG00000027971 Ndst4 0.026988506 0.973011494 6.193448558 6.4241905 72.667411 11.303085
ENSMUSG00000067276 Capn6 0.037784514 0.962215486 6.017105324 7.641535 11.852731 1.5424017
ENSMUSG00000103945 Gm38228 0.006237365 0.993762635 5.815841352 7.3459468 11.611184 1.5719859
ENSMUSG00000022297 Fzd6 5.31E-09 0.999999995 5.29855075 5.6771728 32.386648 5.6964755
ENSMUSG00000075272 Ttc30a2 0.000383808 0.999616192 5.207635347 5.9001694 18.008275 3.0438571
ENSMUSG00000022546 Gpt 0.001076145 0.998923855 4.838108343 4.988827 63.845824 12.789767
ENSMUSG00000096929 A330023F24Rik 0.042070073 0.957929927 4.831648535 5.2619523 23.540992 4.4657137
ENSMUSG00000051067 Lingo3 8.85E-05 0.999911493 4.649694531 4.6657686 532.47206 114.11526
ENSMUSG00000057886 Cbx3-ps6 0.000916068 0.999083932 4.518289442 4.7720038 33.251284 6.9600875
ENSMUSG00000038451 Spsb2 6.94E-09 0.999999993 4.474860959 4.5449339 113.27348 24.91522
ENSMUSG00000035580 Kcnh8 0.018836966 0.981163034 4.335887746 4.6783948 22.892902 4.8854615
ENSMUSG00000074811 Hps6 1.32E-07 0.999999868 4.333772398 4.3735735 184.12209 42.091063
ENSMUSG00000086043 Gm12473 9.25E-05 0.999907491 4.250686451 4.5130587 28.094768 6.2174324
ENSMUSG00000083307 AA414768 2.10E-06 0.9999979 4.200242619 4.3991146 35.571678 8.0783727
ENSMUSG00000025880 Smad7 0.005336329 0.994663671 4.128047604 4.2617552 50.103839 11.748967
ENSMUSG00000043556 Fbxl7 1.65E-05 0.999983499 4.063230768 4.1524428 71.65577 17.248701
ENSMUSG00000042510 AA986860 0.000136325 0.999863675 4.057386127 4.1735348 55.209445 13.220858
ENSMUSG00000039556 Ppp1r3f 0 1 4.015593778 4.0627951 130.45532 32.102207
ENSMUSG00000049734 Trex1 0.000601225 0.999398775 4.013245443 4.1075856 65.93418 16.044244
ENSMUSG00000106928 Gm43860 1.98E-05 0.999980202 3.993784985 4.2383705 26.065973 6.1423581
ENSMUSG00000038704 Aspdh 5.44E-06 0.999994565 3.923252186 3.9911501 86.359345 21.630215
ENSMUSG00000050830 Vwc2 0.001166433 0.998833567 3.895870618 3.9430607 121.61253 30.834702
ENSMUSG00000034463 Scara3 0.000389111 0.999610889 3.753139417 3.7694112 320.55651 85.034187
ENSMUSG00000025735 Rhbdl1 0.003635341 0.996364659 3.751745891 3.9558777 26.793552 6.7656271
ENSMUSG00000060572 Mfap2 0 1 3.739919735 3.765596 201.96207 53.62615
ENSMUSG00000030862 Cpxm2 0.005579672 0.994420328 3.716664829 4.0353587 17.280052 4.2746382
ENSMUSG00000078611 Gm5901 0.003590197 0.996409803 3.600486195 3.7287388 37.991608 10.181544
ENSMUSG00000074890 Lcmt2 0 1 3.594551512 3.6099 306.71157 84.956777
ENSMUSG00000028358 Zfp618 0.001864723 0.998135277 3.545784295 3.5891737 105.83842 29.481029
ENSMUSG00000020258 Glyctk 0.000493642 0.999506358 3.489788472 3.6155432 35.970185 9.9415295
ENSMUSG00000033361 Prrg3 0.000611339 0.999388661 3.458975082 3.4707054 365.68135 105.35514
ENSMUSG00000054676 1600014C10Rik 0.000630556 0.999369444 3.432791049 3.5287763 44.944794 12.729485
ENSMUSG00000036006 Fam65b 0 1 3.416447382 3.4313916 278.87539 81.264719
ENSMUSG00000037216 Lipt1 2.03E-06 0.999997965 3.377362428 3.4234425 88.766274 25.921872
ENSMUSG00000036533 Cdc42ep3 0.001154812 0.998845188 3.312380594 3.3494035 105.1396 31.383531
ENSMUSG00000012017 Scarf2 0.001210283 0.998789717 3.292854827 3.3148754 173.47729 52.325991
ENSMUSG00000075502 Kbtbd6 8.88E-16 1 3.262617402 3.2939436 119.57344 36.294034
ENSMUSG00000030600 Lrfn1 0 1 3.252305015 3.2586385 582.46175 178.73697
ENSMUSG00000079429 Mroh2a 0 1 3.227580691 3.2415582 259.65251 80.094226
ENSMUSG00000060260 Pwwp2b 0.000523548 0.999476452 3.189369815 3.2546015 54.894803 16.859901
ENSMUSG00000043687 1190005I06Rik 0.00786559 0.99213441 3.168480303 3.3341885 21.920746 6.5675362
RealFC= Real Fold Change
RNA-seq of cortical neural progenitors from WT and cKO mice at 0 hr after Actinomycin treatment. 
FDR<0.05
PPEE= Posterior Probability of being Equally Expresses
PPDE=Posterior Probability of being Differentially Expressed




Category ID Name p-value q-value Bonferroniq-value FDR B&Hq-value FDR B&Y
GO: Biological Process GO:0022008 neurogenesis 3.67E-34 3.21E-30 2.50E-30 2.41E-29
GO: Biological Process GO:0030182 neuron differentiation 1.04E-33 9.12E-30 3.04E-30 2.94E-29
GO: Biological Process GO:0031175 neuron projection development 3.32E-32 2.90E-28 7.25E-29 7.00E-28
GO: Biological Process GO:0007409 axonogenesis 2.55E-25 2.23E-21 1.86E-22 1.79E-21
GO: Biological Process GO:0051960 regulation of nervous system development2.20E-24 1.92E-20 1.48E-21 1.43E-20
GO: Biological Process GO:0050808 synapse organization 1.84E-21 1.61E-17 1.07E-18 1.03E-17
GO: Biological Process GO:0007416 synapse assembly 7.54E-17 6.59E-13 2.44E-14 2.36E-13
GO: Biological Process GO:0021987 cerebral cortex development 2.07E-09 1.81E-05 2.32E-07 2.24E-06
GO: Biological Process GO:0050890 cognition 7.87E-08 6.88E-04 6.31E-06 6.09E-05
ID Name Size Observed Expected p-value q-value
PA447208 Mental disorders 679 62 32.04 5.79E-11 7.58E-08
PA444929 Mental retardation 494 98 52.57 6.79E-10 5.92E-07
PA443557 Brain neoplasms 253 57 26.92 2.93E-08 1.53E-05
PA447216 Schizophrenia 471 85 50.12 7.05E-07 1.54E-04
PA443319 Alzheimer disease 225 46 23.94 1.00E-05 1.46E-03
PA447199 Bipolar disorder 423 71 45.01 6.76E-05 6.10E-03
PA443660 Cerebellar diseases 162 36 17.24 1.36E-05 1.88E-03
PA444713 Language development disorders 63 17 6.70 2.27E-04 1.69E-02
ID Name Size Observed Expected p-value q-value
PA447208 Mental disorders 679 62 32.04 4.90E-07 1.28E-03
PA444929 Mental retardation 494 48 23.31 1.78E-06 2.33E-03
PA446858 Neurodegenerative diseases 473 45 22.32 6.49E-06 5.39E-03
PA443319 Alzheimer disease 225 27 10.62 8.24E-06 5.39E-03
PA447158 Tauopathies 210 24 9.91 5.71E-05 2.99E-02
PA446959 Gait ataxia 92 14 4.34 9.98E-05 0.0435667
ID Name Size Observed Expected p-value q-value
PA444148 Fasciculation 61 15 2.13 1.95E-09 5.10E-06
PA446836 Craniofacial abnormalities 333 33 11.65 8.03E-08 8.76E-05
PA444750 Leukemia 492 42 17.22 1.00E-07 8.76E-05
PA443728 Chromosome aberrations 418 36 14.63 6.75E-07 4.42E-04
PA443653 Neoplastic cell transformation 284 28 9.94 8.58E-07 4.49E-04
PA444761 Myeloid leukemia 293 28 10.25 1.60E-06 6.97E-04
Category ID Name p-value q-value Bonferroniq-value FDR B&Hq-value FDR B&Y
GO: Biological Process GO:0030182 neuron differentiation 3.16E-15 2.13E-11 1.63E-11 1.53E-10
GO: Biological Process GO:0031175 neuron projection development 4.85E-15 3.26E-11 1.63E-11 1.53E-10
GO: Biological Process GO:0022008 neurogenesis 2.74E-14 1.84E-10 4.60E-11 4.32E-10
GO: Biological Process GO:0048666 neuron development 1.46E-13 9.83E-10 1.64E-10 1.54E-09
GO: Biological Process GO:0061564 axon development 4.90E-10 3.29E-06 2.12E-07 1.99E-06
GO: Biological Process GO:0007010 cytoskeleton organization 5.05E-10 3.39E-06 2.12E-07 1.99E-06
GO: Biological Process GO:0050803 regulation of synapse structure or activity5.16E-09 3.47E-05 1.51E-06 1.42E-05
GO: Biological Process GO:0099536 synaptic signaling 4.22E-08 2.84E-04 1.09E-05 1.02E-04
Category ID Name p-value q-value Bonferroniq-value FDR B&Hq-value FDR B&Y
GO: Biological Process GO:0022008 neurogenesis 4.05E-29 2.39E-25 7.95E-26 7.36E-25
GO: Biological Process GO:0048666 neuron development 1.90E-26 1.12E-22 2.79E-23 2.59E-22
GO: Biological Process GO:0006357 regulation of transcription from RNA polymerase II promoter2.68E-26 1.58E-22 3.16E-23 2.92E-22
GO: Biological Process GO:0031175 neuron projection development 1.80E-25 1.06E-21 1.77E-22 1.64E-21
GO: Biological Process GO:0030030 cell projection organization 1.15E-22 6.78E-19 9.69E-20 8.97E-19
GO: Biological Process GO:0007417 central nervous system development1.56E-22 9.20E-19 1.04E-19 9.65E-19
GO: Biological Process GO:0061564 axon development 7.53E-22 4.44E-18 4.03E-19 3.73E-18
GO: Biological Process GO:0007420 brain development 2.31E-21 1.36E-17 1.05E-18 9.69E-18
shared m6A-tagged genes among human organoid and fetal brain, and mouse E13.5 forebrain
Data from Toppgene Suite
Data from Webgestalt
Figure 7C
Gene ontology analysis: Biological Process
m6A-tagged genes shared in Day 47 human forebrain organoid and PCW11 fetal human brain
Data from Toppgene Suite
Gene ontology analysis: Biological Process
Disease ontology




m6A-tagged genes in both human organoid and fetal brain, but not in mouse E13.5 forebrain 
Disease ontology
shared m6A-tagged genes among human organoid and fetal brain, and mouse E13.5 forebrain
Data from Webgestalt
Figure S7F
Gene ontology analysis: Biological Process
m6A-tagged genes in both human organoid and fetal brain, but not in mouse E13.5 forebrain 
Data from Toppgene Suite
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Table S5. Gene and Disease Ontology Analysis of m6A-Tagged Genes in Mouse and Human, 
Related to Figures 7 and S7 
 
Movie S1 can be accessed online at  
https://www.cell.com/cms/10.1016/j.cell.2017.09.003/attachment/4287e8bd-c9ed-4779-aa24-
a5804a21cc90/mmc6.mp4 
Movie S1. Time-Lapse Imaging of WT NPCs Using a Dual-Fluorescence Reporter System, 
Related to Figure 2 
 
Movie S2 can be accessed online at  
https://www.cell.com/cms/10.1016/j.cell.2017.09.003/attachment/8659ed20-9ae2-41ff-89d9-
1e45f465fa71/mmc7.mp4 
Movie S2. Time-Lapse Imaging of Mettl14 cKO NPCs Using a Dual-Fluorescence Reporter 
System, Related to Figure 2 
 
Category ID Name p-value q-value Bonferroniq-value FDR B&Hq-value FDR B&Y
GO: Biological Process GO:0022008 neurogenesis 3.67E-34 3.21E-30 2.50E-30 2.41E-29
GO: Biological Process GO:0030182 neuron differentiation 1.04E-33 9.12E-30 3.04E-30 2.94E-29
GO: Biological Process GO:0031175 neuron projection development 3.32E-32 2.90E-28 7.25E-29 7.00E-28
GO: Biological Process GO:0007409 axonogenesis 2.55E-25 2.23E-21 1.86E-22 1.79E-21
GO: Biological Process GO:0051960 regulation of nervous system development2.20E-24 1.92E-20 1.48E-21 1.43E-20
GO: Biological Process GO:0050808 synapse organization 1.84E-21 1.61E-17 1.07E-18 1.03E-17
GO: Biological Process GO:0007416 synapse assembly 7.54E-17 6.59E-13 2.44E-14 2.36E-13
GO: Biological Process GO:0021987 cerebral cortex development 2.07E-09 1.81E-05 2.32E-07 2.24E-06
GO: Biological Process GO:0050890 cognition 7.87E-08 6.88E-04 6.31E-06 6.09E-05
ID Name Size Observed Expected p-value q-value
PA447208 Mental disorders 679 62 32.04 5.79E-11 7.58E-08
PA444929 Mental retardation 494 98 52.57 6.79E-10 5.92E-07
PA443557 Brain neoplasms 253 57 26.92 2.93E-08 1.53E-05
PA447216 Schizophrenia 471 85 50.12 7.05E-07 1.54E-04
PA443319 Alzheimer disease 225 46 23.94 1.00E-05 1.46E-03
PA447199 Bipolar disorder 423 71 45.01 6.76E-05 6.10E-03
PA443660 Cerebellar diseases 162 36 17.24 1.36E-05 1.88E-03
PA444713 Language development disorders 63 17 6.70 2.27E-04 1.69E-02
ID Name Size Observed Expected p-value q-value
PA447208 Mental disorders 679 62 32.04 4.90E-07 1.28E-03
PA444929 Mental retardation 494 48 23.31 1.78E-06 2.33E-03
PA446858 Neurodegenerative diseases 473 45 22.32 6.49E-06 5.39E-03
PA443319 Alzheimer disease 225 27 10.62 8.24E-06 5.39E-03
PA447158 Tauopathies 210 24 9.91 5.71E-05 2.99E-02
PA446959 Gait ataxia 92 14 4.34 9.98E-05 0.0435667
ID Name Size Observed Expected p-value q-value
PA444148 Fasciculation 61 15 2.13 1.95E-09 5.10E-06
PA446836 Craniofacial abnormalities 333 33 11.65 8.03E-08 8.76E-05
PA444750 Leukemia 492 42 17.22 1.00E-07 8.76E-05
PA443728 Chromosome aberrations 418 36 14.63 6.75E-07 4.42E-04
PA443653 Neoplastic cell transformation 284 28 9.94 8.58E-07 4.49E-04
PA444761 Myeloid leukemia 293 28 10.25 1.60E-06 6.97E-04
Category ID Name p-value q-value Bonferroniq-value FDR B&Hq-value FDR B&Y
GO: Biological Process GO:0030182 neuron differentiation 3.16E-15 2.13E-11 1.63E-11 1.53E-10
GO: Biological Process GO:0031175 neuron projection development 4.85E-15 3.26E-11 1.63E-11 1.53E-10
GO: Biological Process GO:0022008 neurogenesis 2.74E-14 1.84E-10 4.60E-11 4.32E-10
GO: Biological Process GO:0048666 neuron development 1.46E-13 9.83E-10 1.64E-10 1.54E-09
GO: Biological Process GO:0061564 axon development 4.90E-10 3.29E-06 2.12E-07 1.99E-06
GO: Biological Process GO:0007010 cytoskeleton organization 5.05E-10 3.39E-06 2.12E-07 1.99E-06
GO: Biological Process GO:0050803 regulation of synapse structure or activity5.16E-09 3.47E-05 1.51E-06 1.42E-05
GO: Biological Process GO:0099536 synaptic signaling 4.22E-08 2.84E-04 1.09E-05 1.02E-04
Category ID Name p-value q-value Bonferroniq-value FDR B&Hq-value FDR B&Y
GO: Biological Process GO:0022008 neurogenesis 4.05E-29 2.39E-25 7.95E-26 7.36E-25
GO: Biological Process GO:0048666 neuron development 1.90E-26 1.12E-22 2.79E-23 2.59E-22
GO: Biological Process GO:0006357 regulation of transcription from RNA polymerase II promoter2.68E-26 1.58E-22 3.16E-23 2.92E-22
GO: Biological Process GO:0031175 neuron projection development 1.80E-25 1.06E-21 1.77E-22 1.64E-21
GO: Biological Process GO:0030030 cell projection organization 1.15E-22 6.78E-19 9.69E-20 8.97E-19
GO: Biological Process GO:0007417 central nervous system development1.56E-22 9.20E-19 1.04E-19 9.65E-19
GO: Biological Process GO:0061564 axon development 7.53E-22 4.44E-18 4.03E-19 3.73E-18
GO: Biological Process GO:0007420 brain development 2.31E-21 1.36E-17 1.05E-18 9.69E-18
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m6A-tagged genes in both human organoid and fetal brain, but not in mouse E13.5 forebrain 
Disease ontology
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Foreword:   After establishing that m6A promotes mRNA degradation in neural progenitor cells to 
regulate neurogenesis, I was curious if mRNA degradation results primarily in simple 
downregulation of gene expression, or if it also functions to regulate highly dynamic patterns of 
gene expression. I therefore wrote a research proposal to study the role of m6A in oscillatory 
expression dynamics for fate-determining transcription factors in neural stem cells. This work was 
funded first by a Grass Fellowship courtesy of the Grass Foundation, which I used to start this 
independent research at the Marine Biological Laboratories (MBL) in Woods Hole, MA. My 
summer at the MBL was crucial for my development as a scientist, and gave me experience in 
running my own laboratory space and independent experiments. Next, I was awarded an NSF 
GROW award in concert with the Japanese Society for the Promotion of Science (JSPS) to continue 
this research in Ryoichiro Kageyama’s lab at Kyoto University in Japan. Dr. Kageyama graciously 
accepted me into his lab for a one year visiting scholar position, during which time I learned 
bioluminescent live imaging techniques and gained an appreciation for oscillatory expression 
patterns in developmental processes.   
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I. INTRODUCTION:  
Regulation of gene expression has long been accepted as a major regulator of cell fate. 
However, gene expression does not always occur in a binary “on” or “off” pattern.   In fact, dynamic 
patterns of gene expression often determine downstream functional effects. For example, 
transcription of Notch genes can occur in bursts, which produce a markedly different result than 
sustained transcription [177]. Similarly, several Notch pathway genes are expressed in an 
oscillatory pattern, and this oscillation is necessary to maintain the balance between stem cell self-
renewal and differentiation [178]. Of particular interest is Ascl1, which oscillates with a period of 
approximately 3 hours and regulates neural stem cell (NSC) differentiation into neurons [179, 180]. 
The regulation of Ascl1 oscillatory dynamics is important for NSC fate but remains poorly 
understood.  
While feedback loops at the transcriptional level are important for oscillatory expression 
of transcription factors, mRNA processing is another major regulatory aspect [181]. Recently, 
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methylation at the 6th position of adenosine on mRNA, termed m6A, has been shown to regulate 
mRNA processing, including mRNA degradation in NSCs [88]. My previous work showed that 
many regulatory transcription factors in neural stem cells are tagged with m6A, including Dll1, 
Ascl1, Olig2, Hes1, Hes7, and Neurog2, all of which produce oscillatory patterns of protein 
expression [88, 178, 180, 182, 183]. Loss of m6A in NSCs elongates mRNA half-life and causes 
dysregulated transcription factor expression that impairs timely NSC differentiation [88, 89]. A 
short half-life of mRNA is crucial for oscillatory expression of neural transcription factors, and loss 
of m6A could disrupt this oscillation to impair neural development, as seen in mice lacking m6A. 
While previous studies of m6A have focused on the combined effects of m6A on many gene 
transcripts, we are specifically interested in how loss of m6A alters the expression patterns of 
individual genes. This is especially important for understanding how differential m6A methylation 
across cell types and developmental times can alter expression of individual genes that regulate cell 
fate.  Therefore, in this study we investigated the role of m6A on the period of Ascl1 oscillation and 
its subsequent effects on neurogenesis.  
We used bioluminescence live imaging techniques to visualize rapid dynamics of Ascl1 
expression. Unlike fluorescence markers, which have long maturation and degradation times, 
luciferase is optimal for imaging the 2-3 hour period of Ascl1 with high temporal resolution [184]. 
We used NSCs harvested from transgenic mice that express a functional fusion of Ascl1 and firefly 
luciferase proteins (Ascl1-luc2) [178, 185]. Since single-transcript m6A editing techniques are not 
yet available, we used shRNA against Mettl3 (shMettl3), the m6A methyltransferase, to block m6A 
addition to mRNA. We then examined the effects of m6A loss specifically on Ascl1 expression 
patterns to understand how changes in mRNA dynamics regulate gene expression beyond simply 
increasing or decreasing mRNA abundance.  
 
II. RESULTS:  
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m6A regulates the half-life of Ascl1 mRNA 
Using published m6A sequencing data we identified Ascl1 as an m6A-modified transcript (Figure 
1A). Previous work showed that m6A promotes degradation of modified mRNA in NSCs. To 
confirm that m6A also regulates the half-life of Ascl1-luc2 fusion mRNA, we used previously 
validated shRNA against Mettl3 to knockdown (KD) the methyltransferase to block m6A formation 
(Figure 2B). We then performed half-life analysis on Ascl1-luc2 in control NSCs and Mettl3-KD 
NSCs. Indeed, we found that the half-life of Ascl1-luc2 mRNA was significantly longer upon 
treatment with shMettl3 than the control (Figure 1C). In contrast, shMettl3 treatment had no effect 
on the half-life of a control gene transcript, Rad17, that is not m6A modified (Figure 1D). 
 
m6A regulates the oscillatory period of Ascl1  
We next examined the consequence of loss of m6A on the oscillatory dynamics of Ascl1-luc2. 
NSCs were electroporated with either scrambled control shRNA or shMettl3 and allowed to recover 
for 48 hours before live imaging. Cells treated with control shRNA showed a robust oscillatory 
expression of Ascl1 with a period of approximately 3 hours, as previously described (Figure 2A,B).  
Treatment with shMettl3 caused a significant elongation of the oscillatory period to approximately 
9 hours (Figure 2C-E).  
 
Ascl1 oscillation dynamics depend on m6A-mediated rapid mRNA degradation  
To confirm that the changes in Ascl1 oscillatory period caused by shMettl3 treatment were caused 
by changes in mRNA degradation, we next treated NSCs with shRNA against Ythdf2 (shYthdf2).  
YTHDF2 is the reader protein that binds to m6A to promote degradation of the modified transcript. 
We first confirmed knockdown of Ythdf2 by qPCR (Figure 3A). Next, we electroporated Ascl1-
luc2 NSCs with shYthdf2 and performed live imaging 48 hours later. Ythdf2 knockdown caused a 
comparable elongation of Ascl1’s oscillatory period as treatment with shMettl3 (Figure 3B-D). 
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Loss of m6A impairs neurogenesis in individual cells 
Previous studies have shown that Ascl1 expression regulates differentiation of NSCs into neurons. 
Specifically, Ascl1 oscillates during NSC pluripotency, then builds up to sustained expression 
levels, which induces expression of the differentiation marker DCX (Figure 4A). To study the 
dependency of DCX induction and neurogenesis on the period of Ascl1 oscillation, we harvested 
NSCs from transgenic mice that express Ascl1-luc2 and DCX-DsRed and performed live imaging 
analysis. We treated Ascl1-luc2/DCX-DsRed NSCs with shMettl3, allowed cells to recover for 48 
hours, then added neurogenic media at the onset of live imaging. Indeed, we found that control 
NSCs show oscillations followed by sustained expression and coordinated DCX upregulation 
(Figure 4B). In contrast, loss of m6A caused long Ascl1 oscillatory periods and did not lead to 
sustained expression nor sudden DCX upregulation during 20 hours of live imaging. Instead, there 
was a slow, linear increase in DCX expression over time (Figure 4C). Previous work showed that 
loss of m6A in the developing forebrain slows down the timing of neurogenesis. Therefore, we next 
examined whether Mettl3-KD NSCs would eventually upregulate DCX if given more time. 
Imaging for 35 hours showed that both Ascl1 and DCX are eventually upregulated in Mettl3-KD 




III. FUTURE WORK: 
In order to isolate the importance of the period of Ascl1 oscillation for neurogenesis, we designed 
experiments to optogenetically induce Ascl1 oscillation in NSCs with an inducible knockout of 
endogenous Ascl1 (Ascl1fl/fl NSC) [178, 186]. We will virally transfect Ascl1fl/fl NSC with Cre to 
induce Ascl1 knockout (Ascl1-KO), then transfect constructs containing either light-inducible 
Ascl1-luc2 or control light-inducible ubiquitin-luc2 (ub-luc2) as well as shMettl3. We will induce 
Ascl1 oscillations with a 3 hour period in Mettl3-KD Ascl1-KO NSCs to see if this can rescue the 
observed deficits in neural differentiation caused by Mettl3 KD.  This will help to isolate the role 
of m6A on Ascl1 from the global changes in m6A caused by shMettl3 treatment.  
 
IV. DISCUSSION: 
 m6A is known to regulate neural stem cell behavior and cortical neurogenesis by promoting 
mRNA degradation of modified transcripts. On a global scale this has major consequences on the 
differentiation and proliferation capacity of NSCs, though how individual genes contribute to this 
phenotype is unclear. In this study we show that m6A-mediated mRNA processing significantly 
alters the expression pattern of Ascl1 protein, which regulates neurogenesis. We find that the timing 
of differentiation is delayed upon loss of m6A, and that the delayed timing correlates with an 
elongated oscillatory period of Ascl1. This provides further insight into the previous finding that 
loss of m6A in the developing forebrain delays the timing of NSC differentiation and cortical 
neurogenesis. We therefore conclude that m6A regulates the temporal dynamics of gene expression, 
and that this is especially important for genes that are expressed in a non-binary pattern with tightly 
regulated temporal components. 
 Methylation of Ascl1 mRNA may be necessary in NSCs to allow for oscillatory expression 
of the protein. The significant elongation of Ascl1 mRNA half-life upon knockdown of Mettl3 
confirms that Ascl1 expression is regulated by the m6A system. Indeed, we found significant 
changes in the oscillatory period of Ascl1 when we knocked down Mettl3, showing that m6A does 
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not only mediate mRNA abundance, but also contributes to tightly regulated temporal expression 
patterns at the protein level. The elongated half-life of Ascl1 mRNA upon loss of m6A likely 
increases the availability of mRNA for translation into protein. Previous models of oscillatory gene 
expression consider mRNA abundance, the rate of mRNA synthesis, and the rate of mRNA 
translation to protein, but rarely account for the rate of mRNA degradation.  While the rate of 
mRNA degradation contributes to total abundance, it also has a clear role in allowing for rapid, 
dynamic changes in protein expression, which are necessary for oscillations that occur on the 
timescale of a few hours.  
We further confirmed that the observed change in Ascl1 oscillatory period was due to m6A-
mediated mRNA degradation by knocking down YTHDF2—the m6A reader protein that promotes 
degradation of modified transcripts. Ythdf2 knockdown strongly recapitulated the effects of Mettl3 
knockdown on Ascl1 oscillations, indicating that Ascl1 is indeed regulated by the m6A-YTHDF2 
pathway. An important caveat, however, is that m6A and YTHDF2 likely regulate other oscillatory 
transcription factors as well, including Hes1, which is inversely correlated with Ascl1 oscillation. 
Therefore, some of the observed effects on Ascl1 oscillatory expression patterns may be due to 
changes in oscillation patters of upstream regulators like Hes1. We hope to address this by using 
optogenetic tools that will allow us to alter only Ascl1 expression.  
Finally, we chose to study the expression pattern of Ascl1 specifically because it is a fate-
determining transcription factor. It is known to regulate neurogenesis, and that oscillatory 
expression allows for stem cell self-renewal whereas sustained expression causes differentiation 
into the neurons. The fact that distinct patterns of expression have functional consequences for NSC 
fate spurred our interest in the regulation of its oscillatory expression pattern. We found that Mettl3 
KD and the subsequent elongation of Ascl1’s oscillatory period correlated with abnormal induction 
of DCX expression, indicating impairments in neurogenesis. Control cells in this study and 
previous studies show an abrupt, coordinated upregulation of Ascl1 and DCX. This indicates there 
is likely a threshold of Ascl1 expression necessary to induce DCX expression. In contrast, 
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elongated oscillations often produced a slow, linear increase in low levels of DCX expression. This 
linear increase may be a result of the semi-sustained Ascl1 expression that occurs over the long 
oscillatory period, but does not continue to climb enough to induce truly sustained expression. 
Eventually, Mettl3-KD cells also reached sustained Ascl1 and DCX expression indicative of 
differentiation, though the time to differentiation was almost double that of control cells. This 
reinforces in vivo findings that NSCs lacking m6A are competent to produce neurons, but do so 
much slower than wildtype NSCs [88]. While global changes in m6A contribute to this impairment, 
we hypothesize that temporal dynamics of Ascl1 expression are especially important and that loss 
of m6A on Ascl1 severely hinders the rate of neurogenesis. Our proposed optogenetic experiments 
would further confirm this hypothesis.  
In conclusion, we showed that m6A mRNA methylation can regulate the dynamics of 
oscillatory gene expression in fate-determining transcription factors like Ascl1. This work 
highlights the role of m6A on individual gene expression patterns and its importance for temporal 
regulation of gene expression and NSC differentiation. It further supports the complexity of 
oscillatory expression systems and shows that the dynamics of mRNA processing contribute to 
oscillatory protein expression.       
  
V. METHODS: 
Neural stem cell (NSC) monolayer culture:  
 NSCs previously harvested from embryonic forebrains from transgenic mice were plated 
on well plates coated with Matrigel (Corning), and grown in serum-free culture medium 
DMEM/F12 media (Gibco) plus N2 supplement (R&D systems), 1% penicillin/streptomycin, and 
10 ng/mL of FGF and EGF (Invitrogen).The media was changed every other day and cells were 
passaged prior to confluence.  
 
shRNA constructs:  
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shRNA against Mettl3 was previously constructed and validated [88]. Briefly, short hairpin 
RNA against Mettl3 was cloned into a retroviral vector under control of the human U6 promoter 
(pUEG). shRNA against YTHDF2 was purchased (Millipore Sigma TRCN0000197932) and re-
validated in NSCs by RT-qPCR. 
 
RNA purification and quantitative RT-PCR analysis:  
 RNA for gene expression analysis was purified using a Dynabeads mRNA Direct 
purification kit (Thermo Fisher), followed by reverse transcription into cDNA using reverse 
transcriptase and random hexamer primers (Takara Bio). SYBR green (Sigma Aldrich) was used 
with cDNA and gene-specific primers for quantitative real-time PCR on a StepOnePlus qPCR 
Machine (Applied Biosystems). All reactions were performed in triplicate.  
 
Half-life measurements of m6A-tagged mRNA: 
 Mouse NPCs were cultured with NSC media to 80% confluence, then treated with 5 µM 
Actinomycin D (Sigma) at timepoint zero. Cells were then collected at timepoints 0, 3, and 5 hours 
after Actinomycin D treatment, washed in PBS, then lysed in RNA lysis buffer (Qiagen). Each 
sample was normalized for DNA content using a Quant-IT PicoGreen dsDNA Assay Kit 
(ThermoFisher) and 1 pg of control RNA (Promega) was added to each sample before RNA 
purification. Total RNA was then purified with an RNeasy Kit and reverse transcribed with 
SuperScript II First-Strand Synthesis (Thermo Fisher). RT PCR was performed as described above. 
Standard curves were made by plotting CT values against the known initial concentration of control 
RNA, then used to calculate the concentration of mRNA for each target at each time point. The 
natural log of mRNA concentrations at each time points were then used to calculate a linear 
regression as a function of time, and the slope of this line was used as the decay rate (kdecay). Half-




 Approximately 1.0 X 106 mouse NSCs were resuspended in 100µL Optimem media 
(Gibco) and up to 10 µg total of plasmid DNA. The cells were placed in a cuvette and electroporated 
using a NEPA21 super-electroporator with the following conditions: (1) 5 pore-creating pulses of 
175V for 2.5 ms with an interval of 50 ms and decay rate of 10%, followed by 5 transfer pulses of 
20V for 50 ms at 50 ms intervals and a 40% decay rate. Cells were then re-plated with NSC media 
and Rock Inhibitor (Y-27632, 3 mM, Cellagentech) and imaged 48 hours later.   
 
Bioluminescence live imaging of NSCs:  
 NPCs electroporated with shRNA were plated onto Matrigel-coated 35-mm glass-base 
dishes at 50-60% confluence at least 24 hours prior to imaging. One hour prior to imaging fresh 
media containing 1mM luciferin was added. Images were taken using an upright microscope (IX81; 
Olympus) with a 40X objective and a cooled CCD camera (iKon-M DU934P-BV, Andor). 
Metamorph imaging software (Universal Imaging Corp) was used to adjust filters and camera 
control. The luminescence channel was set to a 5 minute exposure and images were taken at a time 
interval of 10 minutes for 20-40 hours. Fluorescence channels were used on the same microscope 
and exposure times were optimized using Metamorph software.  
 
Image analysis and quantification: 
 Image analysis was performed as previously described [178]. Briefly, image analysis was 
performed in ImageJ using custom plug-ins to remove background noise in luminescence images. 
Custom code is available upon request through the Kageyama Lab. First, a spike-noise filter was 
applied to reduce cosmic ray noise, and a temporal background reduction filter was applied to 
reduce CCD readout noise. Tracking individual cells and quantification of bioluminescence or 




Neurogenic differentiation of NSCs: 
Neuronal differentiation was induced by adding neurogenic NS-A medium (Stemcell 
Technologies) containing 0.5µM retinoic acid (Sigma), N2, and B27 supplement. Live imaging 






Figure 1: Ascl1 mRNA is regulated by m6A  
(A) Coverage plot of m6A on Ascl1 mRNA. m6A IP (green) shows significant enrichment over 
input control (gray). Gene structure is shown below   (B) qPCR confirmation of Mettl3 knockdown 
by shRNA (C) Half-life of Ascl1 mRNA is significantly longer upon Mettl3 knockdown. (D) Half-









Figure 2: m6A regulates the oscillatory period of Ascl1 in NSCs. 
(A) Trace plot of Ascl1-luc2 expression measured by luminescence live imaging in control NSCs. 
(B) Montage image of an individual control NSC. (C) Plot of Ascl1-luc2 expression measured by 
luminescence live imaging of NSCs treated with shMettl3 shows elongation of Ascl1’s oscillatory 
period. (D) Montage image of an individual NSC treated with shMettl3. (E) Quantification of the 
oscillatory period of Ascl1 in control and shMettl3 treated NSCs. Blocking m6A significantly 







Figure 3: YTHDF2-mediated degradation of m6A-modified mRNA regulates Ascl1 
oscillations. 
(A) qPCR confirmation of Ythdf2 shRNA knockdown. (B) Trace plot of Ascl1-luc2 expression 
measured by luminescence live imaging of NSCs treated with shYthdf2 shows elongation of Ascl1’s 
oscillatory period. (C) Montage image of an individual NSC treated with shYthdf2. (D) 
Quantification of the oscillatory period of Ascl1 in control, shMettl3, and shYthdf2 treated NSCs. 
Blocking either m6A addition to mRNA or m6A reading by YTHDF2 significantly increases 








Figure 4: Elongated Ascl1 oscillation impairs the timing of neurogenesis. 
(A) Model of transgenic NSC used to measure the coordination of Ascl1 oscillation and DCX as a 
reporter of neurogenesis. (B) Plot of Ascl1-luc2 expression and DCX induction for 20 hours after 
addition of neurogenic media in NSCs treated with control shRNA. (C) Plot of Ascl1-luc2 
expression and abnormal DCX expression for 20 hours after addition of neurogenic media in NSCs 
treated with shMettl3. (D) Plot of Ascl1-luc2 expression and abnormal DCX expression for 35 
hours after addition of neurogenic media in NSCs treated with shMettl3. (E) Montage image of a 














I contributed to a study on m6A in Fragile X Syndrome in collaboration with Yongchao 
Ma’s lab at Northwestern University, resulting in a second author publication in Cell Reports. In 
this chapter I will include text and figures from the published work only for parts that I contributed 
to and will reference the published manuscript in full for pieces that were performed solely by other 
authors. Therefore, this text is an adaptation of the published manuscript.  
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I. SUMMARY:  
N6 -methyladenosine (m6A) modification of mRNA is emerging as a vital mechanism regulating 
RNA function. Here, we show that fragile X mental retardation protein (FMRP) reads m6A to 
promote nuclear export of methylated mRNA targets during neural differentiation. Fmr1 knockout 
(KO) mice show delayed neural progenitor cell cycle progression and extended maintenance of 
proliferating neural progenitors into postnatal stages, phenocopying methyltransferase Mettl14 
conditional knockout (cKO) mice that have no m6A modification. RNA-seq and m6A-seq reveal 
that both Mettl14 cKO and Fmr1 KO lead to nuclear retention of m6A-modified FMRP target 
mRNAs regulating neural differentiation, indicating both m6A and FMRP are required for the 
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nuclear export of methylated target mRNAs. FMRP preferentially binds m6A-modified RNAs to 
facilitate their nuclear export through CRM1. Importantly, the nuclear retention defect can be 
mitigated by wild-type, but not nuclear export-deficient FMRP, establishing a critical role for 
FMRP in mediating m6 A-dependent mRNA nuclear export during neural differentiation. 
 
II. INTRODUCTION: 
Methylation of RNA on N6 -adenosine (m6A) is emerging as a critical mechanism regulating 
different aspects of RNA metabolism and function, including stability (Du et al., 2016; Ke et al., 
2017; Wang et al., 2014), localization (Roundtree et al., 2017), and translation (Lin et al., 2016; 
Meyer et al., 2015; Wang et al., 2015). In mammals, methyltransferases METTL3 
(methyltransferase-like 3) and METTL14 form a complex that mediates the addition of methyl 
groups to adenosines in target RNAs (Liu et al., 2014). Readers such as the YTH (YT521-B 
homology) domain containing proteins bind and interpret m6A in a sequencedependent manner 
(Dominissini et al., 2012; Wang et al., 2014; Xu et al., 2014). The presence of m6A erasers has also 
been revealed, suggesting the complex and dynamic regulation of m6A (Jia et al., 2011; Wei et al., 
2018). The emerging biological functions regulated by m6A include the proliferation and 
differentiation of embryonic (Batista et al., 2014; Geula et al., 2015) and neural stem cells (Wang 
et al., 2018; Yoon et al., 2017), as well as complex behaviors and processes such as circadian 
rhythms (Fustin et al., 2013), stress response (Engel et al., 2018), and learning (Koranda et al., 
2018). The RNA-binding protein fragile X mental retardation protein (FMRP) is encoded by the 
fragile X mental retardation gene (FMR1), mutations in which result in fragile X syndrome, the 
leading genetic cause of intellectual disability. FMRP contains both a nuclear localization sequence 
(NLS) and a nuclear export sequence (NES), and it is localized in both the nucleus and the 
cytoplasm (Eberhart et al., 1996; Kim et al., 2009). The best-studied function of FMRP is the 
negative regulation of mRNA translation; thus, fragile X syndrome may result in part from the 
aberrant expression of FMRP target genes (Darnell et al., 2011; Richter et al., 2015). Functionally, 
 113 
loss of Fmr1 has been associated with abnormalities in cortical development and dendritic spine 
formation, which may contribute to aberrant learning and behavior in fragile X syndrome (Castrén 
et al., 2005; La Fata et al., 2014; Saffary and Xie, 2011; Shen et al., 2019; Tervonen et al., 2009). 
Here, we report that FMRP binds m6A-modified mRNAs and promotes their nuclear export to 
regulate neural differentiation. Fmr1 knockout (Fmr1KO) mice show delayed cell cycle 
progression and neural differentiation, phenocopying methyltransferase Mettl14 conditional KO 
(Mettl14cKO) mice that are devoid of m6A modification (Yoon et al., 2017). Both Mettl14cKO 
and Fmr1KO lead to the nuclear retention of m6A-modified FMRP target mRNAs regulating neural 
differentiation, including components of Notch and Hedgehog signaling pathways. FMRP 
preferentially binds m6A-modified target mRNAs and cooperates with the nuclear export protein 
CRM1 to facilitate nuclear export. Nuclear retention of methylated FMRP target mRNAs in 
Fmr1KO can be mitigated by wild-type Fmr1 but not NES-lacking Fmr1ΔNES, suggesting that 
FMRP is sufficient to drive the nuclear export of m6A-tagged FMRP target mRNAs, and this 
mechanism requires the NESnuclear export. Our findings establish a role for FMRP in regulating 
m6A-dependent mRNA nuclear export during neural differentiation. 
 
III. RESULTS: 
First, Brittany Edens showed that Frm1 KO mice phenocopy Mettl14 cKO mice in terms of 
impaired NPC proliferation in vivo (Figure 1A-D). I then performed flow cytometry analysis to 
show that purified Fmr1 KO NPCs have comparable delays in cell cycle progression as Mettl14 
cKO NPCs (Figure 1E-F, Figure S1).  Next, Brittany Edens showed that Fmr1 KO mice also 
maintain a population of cortical NPCs into postnatal stages, as seen in Mettl14 cKO mice.  
 
 
FMRP Preferentially Binds m6A-Modified RNAs to Promote Their Nuclear Export during 
Neural Differentiation 
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As previous analyses have suggested that FMRP may bind to consensus RNA methylation motifs 
(Ascano et al., 2012; Edupuganti et al., 2017; Fu et al., 2014), we considered that FMRP could 
serve as an m6A reader to bind and interpret m6A to regulate RNA function. To test this possibility, 
Brittany Edens performed electrophoretic mobility shift assay (EMSA) and Brittany and I both 
performed bio-layer interferometry analysis to assess the binding affinity of purified FMRP to RNA 
oligos containing an endogenous m6A-modified sequence from mouse Dll1 mRNA or a consensus 
m6A motif. In both analyses, FMRP binding to RNA probes was significantly enhanced by m6A 
methylation, suggesting that FMRP preferentially binds to methylated RNAs compared to non-
methylated RNAs (Figures 2A, 2B, S2A, and S2B). As an RNA-binding protein, FMRP localizes 
to both the nucleus and the cytoplasm (Eberhart et al., 1996; Kim et al., 2009). Therefore, we 
hypothesized that FMRP could mediate nuclear RNA export. To test this, Brittany Edens and 
colleagues performed RNA sequencing (RNA-seq) to compare mRNA levels in WT and Fmr1 KO 
NPC nuclear fractions. We found that genes involved in cell differentiation, neural development 
(Figure 2C), and embryonic development (Figure S2C) were enriched in Fmr1 KO nuclear 
fractions, suggesting nuclear retention of these mRNAs upon the loss of Fmr1. To understand how 
the binding of FMRP to m6A affects neural differentiation, I then helped compare genes that are 
differentially expressed in Fmr1 KO NPC nucleus to our previously published m6A-seq dataset of 
mouse embryonic neural progenitors (Figure 2D). Gene Ontology analysis revealed enrichment in 
processes such as neurogenesis, neural differentiation, and regulation of gene expression (Figure 
2E), as well as chromatin and DNA binding (Figure S2D). Furthermore, pathway analysis yielded 
terms related to pluripotency and developmental signaling pathways (Figure 2F). Among the 
mRNAs that are both m6A tagged and differentially expressed in Fmr1 KO NPC nucleus, 
components of the Notch and Hedgehog pathways (Figures 2G and 2H) are particularly interesting, 
as they are involved in regulating the balance between neural stem cell maintenance and 
differentiation and have been genetically associated with intellectual disability (Chaudhry et al., 
2015; Noor et al., 2010). We focused on six of the m6A modified, differentially expressed Notch- 
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and Hedgehog-related mRNAs (Ptch1, Dll1, Dlg5, Fat4, Gpr161, and Spop), all of which are also 
validated FMRP targets (Ascano et al., 2012). We quantified the levels of these six targets in WT 
and Fmr1 KO NPCs by qRT-PCR. Each mRNA showed increased nuclear retention in Fmr1 KO 
NPCs (Figure 2I), suggesting a critical role for FMRP in the nuclear export of these methylated 
target mRNAs. None of these mRNAs showed increased whole-cell levels, indicating that the 
increase in nuclear levels was not caused by increased general transcription (Figure S2E). We next 
tested the effect of the loss of m6A on the nuclear levels of these mRNAs in Mettl14 cKO NPCs. 
The elevated nuclear retention of the FMRP target mRNAs observed in Fmr1KO NPCs was largely 
phenocopied in Mettl14 cKO NPCs (Figure 2J), suggesting a nuclear export mechanism that 
requires both FMRP and m6A. 
 Finally, Edens and colleagues showed that FMRP-mediated nuclear export of m6A-
modified targets occurs through CRM1 (Edens et al. 2019). This solidified the mechanism of 
FMRP-m6A cooperation to regulate embryonic neurogenesis.   
 
IV. DISCUSSION:  
RNA methylation on N6 -adenosine is emerging as a vital mechanism regulating RNA metabolism 
and function (Dominissini et al., 2012; Meyer et al., 2012; Peer et al., 2017). Here, we report that 
FMRP regulates neural differentiation through m6A-dependent mRNA nuclear export. We also 
elucidated the underlying mechanism by which FMRP preferentially binds m6A-modified mRNAs 
and facilitates their nuclear export through CRM1 to regulate neural differentiation. 
In Fmr1KO mice, we discovered delayed cell cycle progression and extended maintenance of 
proliferating neural progenitors into postnatal stages, which are also m6A-dependent phenotypes 
found in methyltransferase Mettl14cKO mice that have no m6A. These findings suggest a 
functional relation between FMRP and m6A in neural differentiation. Our RNAseq and m6A-seq 
show that both Mettl14cKO and Fmr1KO lead to nuclear retention of m6A-modified FMRP target 
mRNAs regulating neural differentiation, indicating that both m6A methylation and FMRP are 
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required for the nuclear export of target mRNAs. To establish the link between FMRP and m6A, 
we first tested the role of m6A in FMRP target mRNA nuclear export by CRM1 RIP in WT and 
Mettl14cKO NPCs. We found significantly reduced CRM1 binding to FMRP target mRNAs in 
Mettl14cKO NPCs that have no m6A (Figures 4G and 4H). This finding highlights the importance 
of m6A in CRM1-mediated nuclear export of FMRP targets. In addition, we also tested whether 
the reintroduction of FMRP could rescue the nuclear retention of m6A-tagged FMRP target 
mRNAs, including components of Notch and Hedgehog signaling pathways that have well-
established roles in regulating neural proliferation and differentiation. We found that only WT 
FMRP, not the NES-lacking and nuclear restricted FMRPΔNES, alleviated nuclear retention 
deficits in Fmr1KO NPCs (Figures 4I and 4J). Thus, FMRP is sufficient to drive the nuclear export 
of m6A-tagged FMRP target mRNAs, and this mechanism requires the NES-nuclear export. Our 
findings establish a critical role for FMRP in regulating m6A-dependent mRNA nuclear export 
during neural differentiation. Recently, in a large-scale screen to establish a global m6A 
interactome using mass spectrometry, FMRP was found to be one of more than 20 candidate 
proteins that may interact with an m6A-modified probe of 4 GGACU repeats with higher affinity 
in cell lines (Edupuganti et al., 2017). However, a separate study found no preferential binding of 
FMRP to m6A-modified RNA probes (Zhang et al., 2018), although specific enrichment of m6A 
in FMRP targets was discovered. The discrepancy could be due to differences in experimental 
conditions, design of RNA probes, or the quality of purified FMRP protein used. We used full-
length FMRP iso1 purified from Sf9 cells and probe RNA sequences from mouse Dll1 mRNA 
containing both consensus FMRP-binding sites and RNA methylation motifs to show that FMRP 
preferentially binds to methylated RNA in both EMSA and bio-layer interferometry analysis. Our 
data establish the role of FMRP as an m6A reader both in vivo and in vitro. The nuclear export of 
mRNAs related to Notch and Hedgehog signaling was found in our study to require both FMRP 
and m6A. Delta-like (Dll) binding to the Notch receptor drives the expression of Hes1 to maintain 
stem cell pluripotency and suppress differentiation (Ishibashi et al., 1995). Notch has also been 
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shown to cross-talk with additional pathways, including Hedgehog, to regulate neural stem cell 
proliferation and differentiation. Hedgehog-induced maintenance of stem cell pluripotency relies 
in part on the activation of Notch to balance proliferation with differentiation (Dave et al., 2011; 
Kong et al., 2015). We found increased nuclear retention of m6A-modified FMRP targets related 
to Notch and Hedgehog pathways in both Fmr1KO and Mettl14cKO NPCs. Our findings suggest 
that a disruption in the balance between proliferation and differentiation regulated by FMRP-m6A-
dependent nuclear export may underlie the aberrant neural differentiation phenotypes observed in 
Fmr1KO and Mettl14cKO mice, eventually leading to defects in neuronal function. We discovered 
the extended maintenance of neural progenitors into postnatal stages, accompanied by delayed cell 
cycle progression and neural differentiation in Fmr1KO mice. Cell cycle phase and duration are 
tightly coupled to neurogenic potential (McConnell and Kaznowski, 1991; Pilaz et al., 2016). 
Moreover, there is a strong association between neuronal birth-date and identity (Rakic, 1988). 
Therefore, the temporal aberrations in neural progenitor cell cycle and differentiation observed in 
Fmr1KO mice may influence cortical development by affecting neuron subtype specification, 
contributing to functional deficits in fragile X syndrome. Consistent with our observations, 
alterations of layer-specific neuron migration and localization have been found in Fmr1KO mice 
(La Fata et al., 2014; Tervonen et al., 2009). In addition, delayed cell cycle exit in Fmr1KO 
progenitors may deregulate the excitatory-inhibitory balance in the developing neural circuitry, as 
inhibitory interneuron integration into the cortex follows and depends upon pyramidal neuron 
differentiation and patterning (Bartolini et al., 2013). Defects in these processes in Fmr1KO mice 
could drive the altered synaptic landscape that is characteristic of fragile X syndrome. Our study 
elucidates a mechanism by which FMRP reads and facilitates the nuclear export of m6Amodified 
mRNAs to regulate neural differentiation, defects in which may contribute to functional deficits in 




 LEAD CONTACT AND MATERIALS AVAILABILITY: Further information and requests for 
resources and reagents should be directed to and will be fulfilled by the Lead Contact, Yongchao 
C. Ma (ma@northwestern.edu).  
EXPERIMENTAL MODEL AND SUBJECT DETAILS: All animal experiments conducted 
within this study have been approved by the Institutional Animal Care and Use Committee 
(Protocol #IS6359), and performed in accordance with federal regulations governing the use of 
animals in laboratory research. All animals were maintained in standard housing conditions with 
12-hour light/dark cycle and food and water available ad libitum. Fmr1 mice (B6.129P2-Fmr1 
tm1Cgr/J Jackson Laboratory #003025), originally generated by the Dutch-Belgian Fragile X 
Consortium (1994), were obtained through Dr. Anis Contractor from Dr. David Nelson’s 
laboratory, where the original knockout line was backcrossed onto C57/BL6 background. 
Heterozygous Fmr1 female mice were bred with C57/BL6 males to yield wild-type and knockout 
littermates for all FMRP experiments at indicated time points (E17.5, P0, P5, or P7), or utilized for 
generation of neural precursor cells (NPCs) at E13.5. Because Fmr1 is an X-linked gene, only males 
were used for knockout analysis with the mating scheme described.  
 
METHOD DETAILS  
Cell Culture—Dorsal forebrains from timed-pregnant E13.5 mouse embryos were digested with 
Accutase (Fisher) to yield dissociated cortical neural precursor cells (NPCs) for culture. NPCs were 
carried on plates coated with Matrigel (Corning) at 80 μg/ml and maintained in DMEM-F12 
medium (GIBCO) supplemented with B27 (GIBCO), N2 (GIBCO), and Glutamax (GIBCO). A 
growth factor cocktail containing EGF (PeproTech) (20ng/ml) and basic FGF (PeproTech) 
(20ng/ml) in Heparin (5 μg/ml) was added to the medium fresh. Cells were carried at densities not 
exceeding 80%, and all experiments were performed on density- and passage-matched NPC 
cultures. Cells were incubated in standard conditions: 37°C with 5% CO2. Multiple lines of NPCs 
were generated from independent litters of Fmr1 wild-type and knockout embryos. 
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Flow Cytometry—NPCs were exposed to EdU for a duration of thirty minutes, and then either 
fixed immediately or incubated for five hours and then fixed, and incorporation was detected with 
the Click-iT Plus EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Invitrogen) according to 
manufacturer’s protocol. DNA was labeled with 7-AAD (Thermo/ Fisher). Data were collected 
using a BD LSR II Flow cytometer (BD Biosciences). Flow cytometry data were visualized with 
FlowJo software. 
 
Nuclear RNA Extraction and Quality Control—NPCs were harvested at ~80% confluency with 
Accutase (Fisher), and nuclear fractions were prepared as described in the NE-PER Nuclear and 
Cytoplasmic Extraction Kit (Thermo/Fisher) manufacturer’s protocol, with minor modifications. 
0.5U/μl of RNase inhibitor (Ambon/Fisher) was added to the CERI reagent to prevent degradation. 
After separation from the cytoplasmic fraction, the nuclear pellet was washed twice with PBS 
(prepared in DEPC water), and resuspended in an appropriate volume of TRIzol reagent 
(Invitrogen). The nuclear pellet was homogenized with a Polytron PT 1200E (Kinematica). RNA 
was purified using the TRIzol reagent manufacturer’s protocol, and quantified using the Quant-iT 
RNA HS Assay Kit (Invitrogen). The efficiency of separation was determined by measuring 
nuclear and cytoplasmic RNA fractions by qRT-PCR for the relative quantities of nuclear (U1) or 
cytoplasmic (beta-actin) control genes. Only nuclear RNA preparations with high U1 expression 
(~8-fold nuclear increase over cytoplasm) and low beta-actin expression (~7-fold cytoplasmic 
increase over nucleus) were utilized (Figure S4). For qPCR analysis of Leptomycin B (LMB) 
treated NPCs, a concentration of 20nM was used for 20 hours. 
 
qRT-PCR—RNAs, prepared as described, were reverse-transcribed to produce cDNAs using the 
QuantaBio qScript cDNA SuperMix (VWR) according to manufacturer’s protocol, and the 
QuantaBio PerfeCTa SYBR® Green SuperMix (VWR) was used for quantitative real-time PCR 
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(qRT-PCR). All reactions were run on the Applied Biosystems 7500 Fast Real-Time PCR System. 
The Delta-Delta-Ct method was used to compare relative transcript levels between groups. 
Unaffected control genes used for normalization are noted in the figure legends for each 
experiment.  
 
RNA Sequencing and Analysis—RNAs were first subjected to Bioanalyzer analysis (Agilent) to 
assess RNA quality and concentration prior to sequencing. Libraries of nuclear fraction RNAs were 
prepared according to the TruSeq RNA-Seq Library protocol (Illumina). Sequencing was 
performed using the Illumina NextSeq500, 75SE High Output (100 million reads). Gene ontology 
analysis was performed using the TOPPFUN module of TOPPGENE (Chen et al., 2009). Pathway 
analysis was performed using Consensus PathDB (Herwig et al., 2016). The gene interaction 
network schematic was generated using GENEmania (Warde-Farley et al., 2010). Gene sets 
displayed in heatmaps were obtained from the GO term gene list as indicated within the figures. 
m6A sequencing data used to generate the list of overlapping Fmr1/m6A-tagged genes was reported 
previously (Yoon et al., 2017). 
 
Electrophoretic Mobility Shift Assay (EMSA)—Full-length FMRP isoform 1 protein, tagged with 
six histidine on the amino-terminus, was purified from codon-optimized baculovirus-infected Sf9 
cells by Dr. Yang Xiang at ABclonal. Biotinylated oligos were synthesized containing mouse 
Dll1mRNA sequence,  
5′- GAACACCAACAAGAAGGCGGXCUUUCACGGGGXCCAUGGAGCCGA-3′ or a 
consensus RNA methylation sequence, 5′-CGUGGXCUGGCU-3′ (X = A or m6A). In addition, 
oligos containing a mutated consensus sequence were synthesized 5′- GAUACXGAGAAG-3′. 
RNA probes were resuspended in DEPC-treated water and denatured by heating to 65°C for ten 
minutes. Recombinant FMRP protein was diluted in binding buffer (10mM HEPES, pH 8.0; 50mM 
KCl; 1mM EDTA; 0.05% Triton X-100; 5% glycerol; 10 μg/ml salmon sperm DNA; 1mM DTT; 
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40U/ml RNasin) to produce graded concentrations. One part RNA probe (20nM final 
concentration) was then mixed with one part protein (0nM, 125nM, 250nM, 500nM, and 1000nM 
final concentrations) and incubated at room temperature for thirty minutes. A rabbit anti-FMRP 
antibody (Cell Signaling Technology) or control rabbit IgG was added to binding reactions to 
induce supershift. The RNA probe-protein mixtures were run on a 4%–20% TBE gradient gel 
(Novex) and transferred onto a BioDYNE B nylon membrane (Fisher) using a Trans-Blot Turbo 
semi-dry transfer system (BioRad). The membrane was crosslinked using a UV Staratlinker 2400 
(Stratagene) set to 180mg/cm2 for 45 to 60 s. Binding was detected using the Chemiluminescent 
Nucleic Acid Detection Module (Fisher). Densitometry measurements of all bands were made 
using the measurement log feature in Adobe Photoshop to calculate the dissociation constant (Kd). 
Results are averaged from three independent experiments. 
 
Bio-Layer Interferometry Analysis—Bio-layer interferometry analysis of FMRP binding to the 
short m6A-modified and non-modified RNA oligos was assessed using the BLItz system (Forte 
Bio). Purified His-tagged FMRP (isoform 1) was loaded onto penta-His biosensors. Binding to 
m6A-modified and non-modified RNA probes was recorded at the following RNA concentrations: 
5000nM, 2500nM, 500nM, 150nM, and 0nM. Reagents were prepared in binding buffer containing 
100mM KCl, 20mM HEPES, 1mM EDTA, 0.05% Triton-X, 5% glycerol, and 1mM DTT. Each 
reaction was performed using 30 s for all baselines, 120 s for loading, 120 s for association, and 
120 s for dissociation. KD was analyzed using MATLAB’s nonlinear curve-fit function as described 
above, and reported data represent three replicates. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS  
Statistical analysis was performed using Prism7 software (Graphpad). Non-linear curve fitting, 
used to determine the dissociation constant in Figure 3B, was performed using MATLAB 
(MathWorks). Specific details regarding the statistical test used, number of samples (n), and 
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number of experimental replicates are in the figure legends. All graphs present mean + SEM. For 
all experiments, an alpha of 0.05 was used and significance level is indicated as follows: ns p > 
0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. The distributions of all datasets were 
analyzed prior to analysis to confirm the applicability of the statistical approach (i.e., verify Normal 
distribution of data subjected to t test). 
 
DATA AND CODE AVAILABILITY  
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VI. FIGURES:  
 
 
Figure 1: Genetic Knockout of Fmr1 Leads to Delayed Neural Progenitor Cell Cycle 
Progression 
(A) Analysis of cell cycle exit in WT and Fmr1KO E17.5 cortical progenitors. EdU (24 h) staining 
is shown in red and Ki-67 in green. Enlarged sections (bottom) highlight Ki-67+EdU+ cells 
(arrows). Scale bars, 25 μm. 
(B) Significantly fewer EdU+ cells exit the cell cycle during the 24-h EdU exposure in Fmr1KO 
cortex (∗∗∗∗p ≤ 0.0001; n = 5 WT, 6 KO mice). Data are presented as mean + SEM. 
(C) Analysis of M phase entry in WT and Fmr1KO cortical progenitors. pH3 staining is shown in 
red, Pax6 in green, and EdU in blue. Scale bar, 25 μm. 
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(D) Significantly fewer EdU+ RGCs entered mitosis within the 2-h EdU exposure in Fmr1KO 
cortex (∗∗p = 0.0017; n = 6 WT, 6 KO mice). Data are presented as mean + SEM. 
(E) FACS analysis of cell cycle dynamics in WT and Fmr1KO NPCs. Cells labeled by EdU are 
shown in the upper quadrants. Cells that divided during the 5-h incubation are shown in green and 
cells remaining in G2/M are in red. 
(F) Histograms comparing 2n (divided) and 4n (undivided) NPCs between WT and Fmr1KO. 
(G) Significantly fewer Fmr1KO EdU+ NPCs completed division by the end of 5 h compared to 






Figure 2: FMRP Preferentially Binds m6A-Modified RNAs to Promote Their Nuclear Export 
in Regulating Neural Differentiation  
(A) EMSA comparing FMRP binding to non-methylated (left) or methylated (right) RNA. 
(B) Steady-state analysis of FMRP binding to methylated or non-methylated RNA using bio-layer 
interferometry. Results are averaged from three independent experiments. 
(C) Heatmaps comparing WT and Fmr1KO NPC nuclear expression of genes related to cell 
differentiation (left) and nervous system development (right). 
(D) Venn diagram showing RNAs that are m6A modified and differentially expressed in Fmr1KO 
nucleus. 
(E) Gene Ontology (GO) analysis of RNAs that are both differentially expressed in Fmr1KO 
nucleus and m6A modified. Biological processes (top) and disease associations (bottom) are shown. 
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(F) Pathway analysis of RNAs that are both differentially expressed in Fmr1KO nucleus and m6A 
modified. 
(G) Gene interaction network of Hedgehog- and Notch-related signaling components and their 
cross-talk. m6A-tagged FMRP targets are outlined in yellow. 
(H) Coverage plot of m6A modification of Dll1 mRNA. 
(I) RNAs of Hedgehog- and Notch-related components are retained in Fmr1KO nucleus quantified 
by qRT-PCR: Dlg5 (∗p = 0.0324), Dll1 (∗p = 0.0433), Fat4 (∗∗p = 0.0065), Gpr161 (∗∗p = 0.0020), 
Ptch1 (∗p = 0.0262), and Spop (∗∗∗p = 0.0006); n = 5 WT, 3 KO biological replicates. Normalization 
is to U1. Data are presented as mean + SEM. 
(J) RNAs of Hedgehog- and Notch-related components are retained in Mettl14cKO nucleus 
quantified by qRT-PCR: Dlg5 (∗p = 0.0180), Dll1 (∗∗p = 0.0016), Fat4 (∗∗p = 0.0021), Gpr161 (∗p = 
0.0361), Ptch1 (∗p = 0.0164), and Spop (∗∗∗∗p < 0.0001); n = 3 WT, 4 cKO biological replicates. 
Normalization is to U1. Data are presented as mean + SEM. 
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VII. SUPPLEMENTAL FIGURES: 
 
Figure S1: EdU incorporation does not differ between WT and Fmr1KO NPCs, Related to 
Figure 1. 
A. FACS analysis of EdU uptake in WT and Fmr1KO NPCs. Cells labeled during a 30 minute EdU 
pulse are shown in blue. B. Histograms comparing WT and Fmr1KO NPCs. The number and 
distribution of NPCs following a 30 minute EdU pulse is similar between WT and Fmr1KO. C. 
There is no significant difference in the number of EdU+ cells following a thirty-minute pulse 




Figure S2: Binding and gene expression analysis, Related to Figure 2.  
A. and B. Bio-layer interferometry kinetic association analysis of FMRP binding to methylated (A) 
or nonmethylated (B) RNA. Results are averaged from three independent experiments. C. Heat 
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map comparing WT and Fmr1KO nuclear expression of genes related to embryo development. D. 
Gene ontology analysis of transcripts that are both m6 A-modified and differentially expressed in 
Fmr1KO nucleus. Molecular function (top) and mouse phenotypes (bottom) are shown. E. RT-
qPCR analysis of m6 A-tagged FMRP target mRNAs in whole cell WT and Fmr1KO RNAs 








Hypoxia-inducible factors repress translation via 
ALKBH5-mediated m6A demethylation in hypoxic 




Foreword: Dr. Gregg Semenza graciously accepted me into his lab for the second half of my PhD. 
Based on a previous study of m6A in the lab, I met with Dr. Semenza to propose a more in-depth 












Hypoxia-inducible factors repress translation via ALKBH5-mediated m6A demethylation in 
hypoxic breast cancer cells 
 
Caroline Vissersa,b, Debangshu Samantab,c, Tina Huangb,d, and Gregg L. Semenzab,c,d,e,f,g,h 
 
a Biochemistry, Cellular, and Molecular Biology Graduate Program, Johns Hopkins University 
School of Medicine, Baltimore, Maryland 21205, USA; b Institute for Cell Engineering, Johns 
Hopkins University School of Medicine, Baltimore, Maryland 21205, USA; c Department of 
Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA;  d 
Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, 
Maryland 21205, USA; e Department of Pediatrics, Johns Hopkins University School of Medicine, 
Baltimore, Maryland 21205, USA; f Department of Medicine, Johns Hopkins University School of 
Medicine, Baltimore, Maryland 21205, USA; g Department of Radiation Oncology, Johns Hopkins 
University School of Medicine, Baltimore, Maryland 21205, USA; and h Department of Biological 




N6-methyladenosine (m6A) is a post-transcriptional modification of mRNA that alters mRNA and 
protein expression with emerging roles in cancer. Intratumoral hypoxia is a driving force for cancer 
progression, and expression of the m6A demethylase ALKBH5 is strongly induced by hypoxia-
inducible factors (HIFs), leading to global changes to the m6A landscape in hypoxic cancer cells. 
However, the relationship between transcriptional and post-transcriptional regulation by HIFs and 
ALKBH5, respectively, and downstream functional consequences of global changes in m6A have 
not been examined. We report that in hypoxic MCF7 breast cancer cells the majority of HIF-
dependent genes are also ALKBH5 dependent at both the mRNA and/or protein levels. 
Additionally, the repression of cell cycle-promoting genes is both HIF- and ALKBH5- dependent, 
and knockdown of HIF-1α/HIF-2α or ALKBH5 causes increased levels of cancer cell proliferation 
in hypoxia. Loss of either HIF-1α/HIF-2α or ALKBH5 expression also causes increased levels of 
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m6A+ RNA. Through m6A-RNA sequencing we found that transcripts that promote translation 
initiation are consistently methylated in control cells, while transcripts encoding proteins mediating 
oxidative metabolism are dynamically demethylated in response to hypoxia. Loss of HIF-1α/HIF-
2α or ALKBH5 broadly alters m6A coverage patterns on mRNA, and specifically prevents 
demethylation of oxidative metabolism gene transcripts, which impairs the switch from aerobic to 
glycolytic metabolism in hypoxia. We also found that the most highly expressed m6A reader protein 
in MCF7 cells is YTHDF1, which promotes translation of m6A-modified mRNA. Indeed, m6A+ 
mRNAs produce significantly more protein in response to hypoxia than do m6A- mRNAs. 
Therefore, HIFs and ALKBH5 work in concert to limit translation, restrict cancer cell proliferation, 
and upregulate glycolytic metabolism in response to hypoxia. 




Low intratumoral O2 levels in breast cancer are associated with a significantly increased risk of 
metastasis and patient mortality [187]. Hypoxia occurs when O2 consumption exceeds O2 supply, 
due to rapid tumor growth and the formation of intratumoral blood vessels that are structurally and 
functionally abnormal. The mean pO2 in advanced breast cancers is 10 mmHg (~1.5% O2), which 
induces hypoxic stress in cancer cells that causes broad changes in cell motility, metabolism, and 
proliferation [188]. At the molecular level, cellular responses to hypoxia are mediated by hypoxia-
inducible factors (HIFs), which are heterodimers consisting of an O2-regulated HIF-1α or HIF-2α 
subunit and a constitutively expressed HIF-1β3.  Previous studies have shown that HIF-1 and HIF-
2 play central roles in cancer progression, as they regulate the transcription of genes involved in 
tumor growth, angiogenesis, cell metabolism, invasion, metastasis, immune evasion, and resistance 
to chemotherapy [187, 189-193]. 
In parallel with the role of hypoxia in the tumor microenvironment, changes in epigenetic 
regulation of gene expression play a key role in cancer progression [187]. Recently, several groups 
have shown an interplay between hypoxia and a new gene regulatory pathway—chemical 
modifications of mRNA—called epitranscriptomics [194-197]. Methylation of the N6 position in 
adenine, termed m6A, is the most common modification in mRNA, and is a powerful regulator of 
mRNA and protein expression. Hypoxia-inducible factors (HIFs) directly induce expression of the 
m6A demethylase AlkB homolog 5 (ALKBH5), causing global changes in m6A in human breast 
cancer cells exposed to hypoxia [196, 198]. 
m6A is added to mRNA by a methyltransferase complex that includes methyltransferase-
like 3 (METTL3), METTL14, and Wilms tumor 1 associated protein (WTAP), whereas m6A is 
removed from mRNA by ALKBH5, making m6A a dynamic modification that changes according 
to external and internal stimuli [199]. Fat mass and obesity associated protein (FTO) may also be 
an m6A demethylase, although recent reports suggest it does not act on m6A in vivo [21, 200, 201]. 
A variety of “reader” proteins can interact with m6A to determine the fate of the modified RNA 
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transcript, which includes altered transcript half-life, alternative splicing, nuclear export, and 
increased translation [199, 202]. The m6A modification has been implicated in a variety of cancers, 
including glioblastoma, acute myeloid leukemia, lung cancer, and breast cancer [92, 203, 204]. The 
m6A eraser ALKBH5 is induced in breast cancer cells exposed to hypoxia. We have previously 
examined the role of ALKBH5 in breast cancer cells and found that HIF-dependent induction of 
ALKBH5 expression promoted the cancer stem cell phenotype through increased expression of 
pluripotency factors [196]. However, the role of ALKBH5 in modulating global gene expression 
to regulate breast cancer cell responses to hypoxia is unknown. 
In this study, we compared MCF-7 subclones with stable expression of short hairpin RNA 
(shRNA) targeting HIF-1α and HIF-2α for double knockdown (HIF-DKD), shRNA targeting 
ALKBH5 for knockdown (ALK-KD), and shRNA serving as a non-targeting control (NTC). We 
used RNA sequencing, m6A+ RNA immunoprecipitation and sequencing, and proteomic analysis 
of MCF-7 breast cancer cells to identify HIF- and ALKBH5-dependent changes in mRNA and 




HIFs and ALKBH5 coordinately regulate mRNA expression in hypoxic human breast cancer 
cells.  
We first confirmed the knockdown of HIF-1α in HIF-DKD cells and the knockdown of ALKBH5 
in ALK-KD cells using sequence-specific short hairpin RNAs (shRNAs) (Supplementary Figure 
1a-b). We used reverse transcription and quantitative real-time PCR (RT-qPCR) to investigate the 
HIF- and ALKBH5- dependency of genes known to be induced in response to hypoxia. Some 
genes, such as CA9, are HIF-dependent but not ALKBH5-dependent (Supplementary Figure 1c), 
whereas others, such as VEGFA, are both HIF and ALKBH5-dependent (Supplementary Figure 
1d).  To delineate the global regulatory roles of HIFs and ALKBH5 in breast cancer cells, we 
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performed RNA sequencing of HIF-DKD, ALK-KD, and NTC subclones of MCF-7 cells exposed 
to 20% or 1% O2 for 24 h. We identified 1,353 mRNAs whose induction in response to hypoxia 
was HIF-dependent, and 1,221 mRNAs whose repression was HIF-dependent as well as 1,277 
mRNAs whose induction in response to hypoxia was ALKBH5-dependent, and 1,033 mRNAs 
whose repression was ALKBH5-dependent (Supplementary Figures 2-4). Remarkably, 921 
mRNAs lost hypoxic induction in both the HIF-DKD and ALK-KD subclones (Figure 1a), 
indicating coordinated regulation of mRNA expression by HIFs and ALKBH5. 
Gene ontology (GO) analysis confirmed that HIF-dependent mRNAs were significantly 
associated with “response to oxygen levels”, “response to hypoxia”, and “glucose catabolism to 
pyruvate” (Supplementary Figure 5a). ALKBH5-dependent mRNAs were significantly associated 
with “epigenetic regulation” and “regulation of cellular differentiation” (Supplementary Figure 5b).  
GO analysis of mRNAs that were both HIF- and ALKBH5-dependent for induction were associated 
with “morphogenesis” and “organelle and vesicle fusion” (Figure 1b). 
In addition to the broad induction of genes in response to hypoxia, cells repress expression 
of many genes, particularly those involved in cell proliferation, to conserve energy under hypoxic 
conditions. Again, the overlap of genes that were repressed in a HIF- and ALKBH5-dependent 
manner was remarkably high, with 733 genes losing repression in both groups (Figure 1c). These 
genes, which are repressed in response to hypoxia in NTC cells but not in HIF-DKD or ALK-KD 
cells, were significantly associated with cell cycle-related GO terms (Figure 1d and Supplementary 
Figure 5c-d). 
To assess the functional relevance of impaired repression of cell cycle mRNAs, we exposed 
MCF-7 subclones to 20% or 1% O2 and counted the number of live cells at 24, 48, and 72 h. 
Compared to NTC cells, the number of HIF-DKD, and especially ALK-KD cells, were significantly 
increased under hypoxic as compared to non-hypoxic conditions (Figure 1e). To determine whether 
these differences in cell number were attributable to differences in cell proliferation, we analyzed 
DNA synthesis by treating cells with 5-ethynyl-2-deoxyuridine (EdU) after 48 h of exposure to 1% 
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O2. Whereas hypoxia inhibited EdU incorporation by 12% in NTC cells, this reduction in DNA 
synthesis was significantly impaired in HIF-DKD, and especially ALK-KD, cells (Figure 1f). These 
results demonstrate that HIFs and especially ALKBH5 are necessary to inhibit DNA replication 
and cell division under hypoxic conditions. 
 
m6A levels in RNA are dynamically regulated by HIFs and ALKBH5 in response to hypoxia.  
Recent reports show that FTO does not demethylate m6A in vivo [21, 201], suggesting that 
ALKBH5 is the only m6A demethylase, whereas the role of FTO is unclear. Nonetheless, 
expression of FTO is much less than ALKBH5 in MCF-7 cells and is not induced in response to 
hypoxia (Supplementary Figure 6). We therefore moved forward with our analysis of ALKBH5 as 
the major regulator of m6A demethylation in response to hypoxia.  HIF-dependent ALKBH5 
expression leads to increased demethylase activity and decreased m6A+ RNA levels (as determined 
by ELISA) in hypoxic NTC cells; in contrast, m6A levels remain static in hypoxic HIF-DKD cells, 
whereas in ALK-KD cells, baseline m6A levels are significantly increased, and rise further in 
response to hypoxia (Figure 2a). 
We used an antibody that specifically recognizes m6A to perform methylated-RNA 
immunoprecipitation and sequencing (MeRIP-Seq) [1, 205] in order to identify mRNAs that are 
methylated in NTC, HIF-DKD, and ALK-KD cells exposed to 20% or 1% O2 for 24 h. In particular, 
we identified mRNAs that are dynamically methylated or demethylated in response to hypoxia. 
The number of unique transcripts tagged with m6A specifically under hypoxic conditions increased 
from 543 in NTC to 903 in HIF-DKD and 1564 in ALK-KD cells (Figure 2b). This finding suggests 
that the methyltransferase complex becomes more promiscuous in response to hypoxia and that 
ALKBH5 normally limits this response. 
GO analysis revealed that in non-hypoxic NTC cells, mRNAs modified with m6A were 
significantly associated with mRNA processing and translation (Figure 2c). m6A+ mRNAs in 
hypoxic NTC cells are also enriched for these same GO terms (Supplementary Figure 7). In 
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contrast, many more unique gene transcripts are aberrantly methylated in HIF-DKD and ALK-KD 
cells. 360 mRNAs were m6A-modified in both HIF-DKD and ALK-KD, but not in NTC, cells in 
response to hypoxia, indicating that these transcripts are normally demethylated by upregulated 
ALKBH5, and GO analysis revealed that these mRNAs were associated with chromatin and 
nucleosome organization (Figure 2d). Another study also found that m6A mRNA modification can 
broadly influence gene expression by modifying transcripts involved in epigenetic regulation [89]. 
62 mRNAs were specifically demethylated in hypoxic NTC cells, but remain methylated 
in hypoxic HIF-DKD cells and in both hypoxic and non-hypoxic ALK-KD cells. These mRNAs 
were significantly associated with mitochondrial regulation and oxidative metabolism (Figure 2e), 
suggesting that ALKBH5-dependent mRNA demethylation contributes to the switch from 
oxidative to glycolytic metabolism in hypoxic breast cancer cells. Changes in cancer cell 
metabolism in response to hypoxia are known to be HIF-dependent [206], but have never been 
studied in relation to ALKBH5. Considering the targeted, ALKBH5-dependent demethylation of 
oxidative metabolism genes in response to hypoxia, we tested changes in mitochondrial respiration 
in response to hypoxia in each subclone. We measured oxygen consumption rate (OCR) as a 
measure of mitochondrial respiration and extracellular acidification rate (ECAR) as a measure of 
glycolysis. As expected, NTC cells significantly shifted toward glycolytic metabolism (decreased 
OCR/ECAR ratio) after 72 h of exposure to hypoxia (Figure 2f). In contrast, both HIF-DKD and 
ALK-KD cells have significantly higher OCR/ECAR ratios compared to NTC cells in hypoxia. 
This confirms that HIF and ALKBH5 both regulate the shift toward glycolytic metabolism in 
hypoxic MCF-7 cancer cells.  
 
ALKBH5 is necessary to maintain the normal distribution of m6A on mRNAs in hypoxic cells.  
Some mRNAs, such as IFT20, are methylated in hypoxic conditions in HIF-DKD and ALK-KD, 
but not NTC, cells. This provides an example of transcripts that become aberrantly methylated 
when HIF or ALKBH5 are expression is silenced (Figure 3a).  Other transcripts, such as TSFM, 
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are specifically demethylated in response to hypoxia in NTC cells but remain methylated in HIF-
DKD and ALK-KD cells (Figure 3b). 
A growing body of experimental evidence suggests that m6A in the 5’-untranslated region 
(5’-UTR), coding sequence (CDS) and 3’-UTR may be associated with distinct regulatory functions 
[1, 207, 208]. m6A coverage on introns remains fairly constant in all subclones between normoxia 
and hypoxia, while coverage of the UTRs and CDS is more dynamic (Figure 3c). In NTC cells, 
hypoxia is associated with decreased 5’-UTR methylation and increased 3’-UTR methylation, 
whereas in both HIF-DKD and ALKBH5-KD cells, hypoxia is associated with increased 5’-UTR 
methylation and decreased CDS methylation (Figure 3d). Increased 5’-UTR methylation was also 
observed in mouse embryo fibroblasts subjected to heat shock and was associated with increased 
m6A-mediated translation [209]. ALK-KD cells show the most dramatic changes in m6A coverage, 
with increased methylation in both the 5’-UTR and especially in the 3’-UTR in response to hypoxia. 
Thus, ALKBH5 appears to preferentially demethylate the UTRs of mRNAs in MCF-7 breast cancer 
cells. 
 
HIFs mediate multiple aspects of post-transcriptional regulation via ALKBH5.  
The fate of m6A-modified transcripts in a cell depends largely on the particular “reader” proteins 
that are expressed, which varies across cell types and developmental stages [26, 202, 210]. To 
address this issue, we analyzed our RNA sequencing data to determine the relative expression levels 
of mRNAs encoding known m6A readers in MCF-7 cells (Figure 4a). The most highly expressed 
reader was YTHDF1, which increases the translation of m6A-modified transcripts [202, 211]. 
Expression of YTHDF1 has been correlated with malignant tumor behavior and decreased patient 
survival in colorectal cancer [212]. YTHDC1, which was also highly expressed, regulates 
alternative splicing, although its function appears to vary across cell types [202, 210, 213, 214]. 
We found examples of hypoxia-induced alternative splicing that correlated with m6A status as well 
as alternative splicing that was independent of m6A status. For example, ANKZF1 mRNA is 
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alternatively spliced in hypoxic cells [215]. In NTC cells, ANKZF1 mRNA was not m6A-modified 
and alternative splicing was induced by hypoxia, whereas in HIF-DKD and ALK-KD cells, hypoxia 
induced aberrant m6A modification and alternative splicing of ANKZF1 mRNA was not induced 
(Supplementary Figure 8a). In contrast, although CYR61 mRNA was aberrantly m6A-modified in 
HIF-DKD and ALK-KD cells, hypoxia-induced alternative splicing [216] was not affected 
(Supplementary Figure 8b). 
Expression of YTHDF2, which regulates mRNA degradation, was mildly increased in 
MCF-7 cells exposed to hypoxia in a HIF- and ALKBH5-independent manner (Figure 4a). Among 
mRNAs with hypoxia-induced expression in NTC cells, 132 mRNAs were only m6A-modified at 
1% O2 compared to 31 mRNAs that were only m6A-modified at 20% O2, whereas among hypoxia-
repressed mRNAs, 91 were m6A-modified only at 20% O2 as compared to 43 that were m6A-
modified only at 1% O2 (Supplementary Figure 8c), suggesting that m6A modification is actually 
correlated with increased mRNA abundance (p < 0.001, Χ2 test). This indicates that YTHDF2-
mediated mRNA degradation is not the primary mechanism of m6A action in MCF-7 breast cancer 
cells. However, there is currently very little understanding of how m6A reader proteins selectively 
bind particular transcripts, and how co-expressed reader proteins might compete with one another. 
The expression of YTHDF2 suggests that it has specific mRNA targets in MCF-7 cells, and its 
specificity and competition with YTHDF1 warrants future investigation. 
As described above, YTHDF1 binding to m6A+ mRNA facilitates translation of mRNA 
into protein. Under hypoxic conditions, many new proteins need to be synthesized, but cellular 
resources must also be conserved, leading to an overall decrease in mRNA and protein synthesis. 
This led us to examine an often-overlooked category of mRNAs: those that show no significant 
differential expression in NTC cells in response to hypoxia, but gain significant induction in HIF-
DKD and ALK-KD cells. We found 786 HIF-regulated and 1,107 ALKBH5-regulated mRNAs that 
are aberrantly induced in response to hypoxia, of which 593 genes are both HIF- and ALKBH5-
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dependent (Figure 4b). The top gene ontology term for these genes is “translation initiation” (Figure 
4c). 
Analysis of the fold-induction of mRNAs classified under the GO terms “translation 
initiation” (GO:0006413) and “ribosome” (GO:0005840) revealed that there was a large skew 
toward significant induction of translation-related genes in both HIF-DKD and ALK-KD as 
compared to NTC cells (Figure 4d). We next investigated the functional consequences of this 
induction by quantifying levels of translation initiation in response to hypoxia using L-
homopropargylglycine (HPG)-Alexa Fluor 488 to label newly synthesized proteins 
(Supplementary Figure 8d). At 20% O2, there was no significant difference in the levels of 
translation initiation between the NTC and HIF-DKD subclones, whereas translation initiation was 
significantly higher in the ALK-KD subclone (Figure 4e), which is consistent with the observed 
changes in m6A levels (Figure 2a). At 1% O2, translation initiation was significantly greater in HIF-
DKD and especially in ALK-KD cells (Figure 4f). 
 
HIF and ALKBH5 regulate differential protein expression through m6A.  
Dysregulated translation initiation in HIF-DKD and ALK-KD cells implied changes in the 
proteome in response to hypoxia and/or loss of HIF or ALKBH5 expression. To test this hypothesis, 
we performed mass spectrometry analysis of the MCF-7 subclones after incubating the cells at 20% 
or 1% O2 for 48 h. Proteomic analysis revealed that 263 proteins were hypoxia-induced (Figure 5a) 
and 471 proteins were hypoxia-repressed (Figure 5B) in NTC cells but not in HIF-DKD or ALK-
KD cells (Figure 5a-b). Many of the differentially expressed proteins were not differentially 
expressed at the mRNA level (Supplementary Figure 9a), which is consistent with a specific effect 
of m6A modification on mRNA translation. Several studies have previously reported a low 
correlation between mRNA and protein expression and identified multiple contributing factors 
[217, 218]. In our study, stringent selection criteria for high-confidence HIF- and ALKBH5-
dependent mRNA and protein expression, the use of independently prepared samples for RNA and 
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protein analysis, and the number of biological replicates likely contributed to the limited overlap 
between differentially expressed mRNAs and proteins. Furthermore, growing awareness of the 
epitranscriptome is helping to explain the common discordance between mRNA and protein levels, 
reinforcing the necessity to look beyond only RNA sequencing results to understand which genes 
are being dynamically expressed in a cell [219]. 
GO analysis of proteins that are hypoxia-induced in a HIF- and ALKBH5-dependent 
manner revealed that they are significantly associated with metabolic processes and cellular 
respiration (Figure 5c). Proteins that are hypoxia-repressed in a HIF- and ALKBH5-dependent 
manner are associated with a variety of biochemical processes, including “catabolic processes”, 
“protein stabilization”, and “protein glycosylation” (Figure 5d). Additionally, loss of ALKBH5 
reduces the number of significantly downregulated proteins to approximately half as many as in 
controls (Supplementary Figure 9b). Next, we quantified the log2 fold-change of proteins encoded 
by m6A+ or m6A- mRNA. We found that proteins with corresponding m6A+ modified mRNA are 
induced at significantly higher levels in hypoxia than proteins made from unmethylated mRNA 
(Figure 5e). This supports our model that hypoxic stress causes HIF-dependent induction of 
ALKBH5, which demethylates many mRNAs to limit their translation (Figure 5f). 
In accordance with the increase in methylated transcripts in hypoxic HIF-DKD and ALK-
KD cells compared to NTC cells (Figure 2a-b) and global increases in translation (Figure 4f), some 
proteins become aberrantly induced in response to hypoxia in HIF-DKD and ALK-KD cells. 397 
proteins in HIF-DKD and 269 proteins in ALK-KD cells are significantly (p < 0.05) induced in 
response to hypoxia that are not induced in NTC cells (Supplementary Figure 10a). These proteins 
fall into diverse gene ontologies including oxidative processes, mitosis, antigen presentation, and 
mitochondrial RNA modification (Supplementary Figure 10b-d). Furthermore, proteins that 
mediate translation initiation (GO:0045948) are more highly expressed in HIF-DKD and ALK-KD 
cells than NTC cells under hypoxic conditions (Supplementary Figure 10e), providing examples of 





Hypoxia and HIF-dependent transcriptional activation are crucial for cancer progression 
[187], and are known to induce expression of the m6A demethylase ALKBH5 [196, 198]. However, 
the extent to which HIFs functions through ALKBH5 to alter gene expression in breast cancer was 
unknown. In the present study, we showed that the genes regulated by HIFs in response to hypoxia 
are largely also ALKBH5-dependent. We found that loss of HIFs or ALKBH5 causes highly 
overlapping changes in the response to hypoxia compared to controls, indicating that the action of 
HIFs extend beyond their direct DNA binding targets by inducing changes in the m6A system via 
ALKBH5. To this end, induction of ALKBH5 is necessary for global reduction of m6A levels in 
response to hypoxia. We found that MCF-7 cells most strongly express the m6A reader YTHDF1, 
which increases the translation of m6A+ mRNA [220].  In accordance with this, we showed that 
loss of HIF or ALKBH5 expression, and corresponding increases in m6A levels cause significant 
increases in global translation levels compared to control cells in hypoxia. This indicates, for the 
first time, that HIF also regulates translation via ALKBH5. Upon loss of HIF or ALKBH5, genes 
that mediate translation initiation are upregulated at both the mRNA and protein level in hypoxia, 
which may lead to global increases in translation beyond the specific m6A-mediated translation of 
individual transcripts. Though diverse categories of genes are up- and down-regulated, of particular 
interest are the genes that regulate mitosis. Hypoxia-induced inhibition of DNA synthesis, mediated 
by HIF/ALKBH5 activity, enables cancer cells to survive cytotoxic chemotherapy, which targets 
dividing cells. 
m6A has recently garnered significant interest as a major regulator of gene expression, and 
it appears to be especially relevant in cancer [221, 222]. However, multiple distinct downstream 
functions of m6A have been shown to be at play in different types of cancers or cell lines [92, 223-
225]. As we showed here, multiple reader proteins can be co-expressed within one cell type. It is 
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still largely unclear how m6A reader proteins compete with one another, though it is likely that each 
protein has specific target transcripts that are determined by secondary RNA structure and/or 
protein binding partners [226]. We have previously found that m6A-mediated degradation of Nanog 
mRNA reduces formation of breast cancer stem cells [196], and in the present study we found a 
correlation between m6A and alternative splicing of ANKZF1 RNA. Others have shown that 
altering methyltransferase activity can drive changes in cancer proliferation and progression [221, 
227, 228]. However, the highly dynamic nature of m6A and limitations in detection efficiency make 
it difficult to attribute functional consequences to m6A-mediated effects on individual transcripts. 
Therefore, we chose to analyze broader patterns of m6A+ mRNA fate to determine HIF- and 
ALKBH5-dependent effects on mRNA and protein expression. To this end, we found that increases 
in m6A most strongly correspond to increases in translation in MCF-7 cells, and m6A+ transcripts 
have significantly higher corresponding protein abundance than m6A- transcripts. We also found a 
significant correlation between m6A modification and increased transcript abundance, which could 
be due to RNA stabilization mediated by YTHDF1 binding [211]. 
Finally, the localization of m6A on mRNA has traditionally been attributed to 
methyltransferase activity [10]. However, we found that loss of ALKBH5 also regulates the pattern 
of m6A within transcripts, especially in response to hypoxia. In control cells, the distribution pattern 
of m6A is fairly constant between normoxia and hypoxia. Knockdown of ALKBH5 reveals that 
methylation patterns drastically change in response to hypoxia, and that ALKBH5 is necessary to 
selectively prevent increases in methylation in the 5’UTR and 3’UTR. This, along with an increase 
in the number of unique transcripts that are m6A-modified in response to hypoxia, indicates that 
the methyltransferase complex likely becomes more promiscuous under hypoxic stress. This 
finding warrants further investigation, as the specificity of how m6A is added onto particular mRNA 
transcripts is still largely unknown. Clearly, there is some balance between the action of the 
methyltransferase and the demethylase, but the extent to which their actions are independent from 
one another and how each selects its binding targets is an interesting avenue to pursue further. 
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Overall, studies of m6A in cancer have shown that it is an important regulator of gene 
expression. However, the notable differences in m6A function across cell types and physiological 
conditions means that the role of m6A will likely not be straightforward, even in a single type of 
cancer. Therefore, it is critical to understand that m6A is highly dynamic, and its function must be 
carefully analyzed in a case-by-case basis. In this study we show that the demethylase, ALKBH5, 
is especially relevant in hypoxia, and that the majority of HIF-dependent genes are also ALKBH5-
dependent. Furthermore, this pathway significantly alters protein expression beyond the expected 
changes based on transcriptional dynamics. The coupling of HIF and ALKBH5 activity provides a 
mechanism to rapidly respond to hypoxia by coordinated increases in transcription, mRNA 
stabilization, and synthesis of proteins that mediate adaptation to reduced O2 availability, and to 
downregulate the expression of mRNAs and proteins involved in cell proliferation. Inhibiting HIFs 
or ALKBH5 results in a remarkable degree of aberrant mRNA expression that may contribute to 




HIF and ALKBH5 knockdown in MCF7 cells. 
Lentiviral vectors encoding shRNAs targeting HIF-1α and HIF-2α were previously described 
[229]. pLKO.1-puro lentiviral vectors encoding shRNA targeting ALKBH5 mRNA (clone ID, 
NM_017758.2–1625s1c1 and NM_017758.2–1176s1c1) were purchased from Sigma-Aldrich, 
packaged using 293T cells, then transfected into MCF-7 cells [229]. Successfully transduced cells 
were selected for and maintained by supplementation of the culture medium with puromycin (0.5 
μg/mL).  
 
MCF7 cell culture. 
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Cells were cultured in Dulbecco’s Modified Eagle Medium (Gibco) supplemented with 10% fetal 
bovine serum, 1% penicillin-streptomycin (Invitrogen). The medium was changed every other day, 
and cells were passaged prior to reaching confluence.  For cell culture at 1% O2, plates were placed 
in a modular incubator chamber (Billups-Rothenberg) and flushed for 2 min at 2 psi with a gas 
mixture containing 1% O2, 5% CO2, and 94% N2. 
 
Cell cycle analysis by cell counting and EdU pulse labeling. 
Analysis of cell proliferation was performed by live cell counting over 72 h, using trypan blue to 
distinguish between live and dead cells. DNA synthesis analysis was performed by pulsing cultured 
cells with 10 µM EdU (ThermoFisher) for 45 mi. Cells were then dissociated using trypsin, washed 
with PBS, and fixed with 4% paraformaldehyde in PBS for 15 min on ice. Cells were permeabilized 
and stained with the Click-iT EdU Alexa 647 Flow Cytometry Kit (ThermoFisher) as per the kit 
protocol, and analyzed using a BD LSR II Flow Cytometer (BD Bioscience). EdU+ and EdU- cells 
were gated and calculated as a percentage of the total cell number. Experiments were done with 
three replicates per experimental group. 
 
RNA purification and RT-qPCR. 
Total RNA was purified using RNA mini-prep purification columns (Zymo Research R1054), then 
equal quantities of purified RNA were reverse transcribed using random primers and the Invitrogen 
Superscript IV First-Strand Synthesis System (ThermoFisher 18091200). cDNA was measured 
using quantitative PCR with Fast SYBR Green Master Mix (ThermoFisher 4385610). qPCR 



















mRNA was purified using a Dynabeads mRNA Direct Purification Kit (ThermoFisher 61011). 100 
ng of mRNA purified from each subclone cultured at 20% or 1% O2 for 48 h was loaded onto an 
EpiQuik m6A ELISA plate (Epigentek P-9005-48) in triplicate. Signal intensity was quantified 
using a plate reader set to read at 450 nm. Absolute m6A levels were calculated based on a standard 
curve as per kit instructions. 
 
Metabolic analysis by Seahorse assay. 
4000 cells of each subclone type were plated on day 1. The next day the cells were incubated under 
20% or 1% O2 for 72 h, then the Agilent Seahorse assay was performed as per manufacturer’s 
protocol. 
 
Quantification of translation initiation. 
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Cells were cultured in 20% or 1% O2 for 48 h, and protein synthesis was quantified using a Click-
iT HPG Alexa Fluor 488 Protein Synthesis Assay Kit (ThermoFisher C10428) per the 
manufacturer’s instructions. Briefly, cells were treated with HPG in L-methionine-free medium for 
30 min. Hypoxic cells were exposed to 1% O2 during treatment in a hypoxia workstation. Cells 
were then washed in PBS, fixed in 3.7% formaldehyde in PBS, and permeabilized using 0.5% 
Triton X-100. HPG was detected using the Click-iT reaction cocktail supplied in the kit along with 
NuclearMask Blue Stain for DNA staining. Cells were then scanned on a plate reader to measure 
DAPI for DNA stain detection and FITC for Alexa Fluor 488 detection. FITC levels were 
normalized to DAPI to quantify normalized levels of translation initiation in each cell type. 
Additionally, cells were grown, treated, and stained in glass slide chambers (Thermo Scientific 
Nunc 154526) and visualized under a confocal microscope. 
 
RNA sequencing. 
Three technical replicates of cells for each experimental group and control were collected in Trizol, 
from which total RNA was purified [230]. mRNA was then purified using the Dynabeads mRNA 
Purification Kit (Invitrogen). cDNA libraries were prepared using the Illumina NEBNext Ultra 
DNA Library Prep Kit, then sequenced with a 75-cycle single-end run on the Illumina Nextseq 
platform. 
 
m6A-RNA immunoprecipitation and sequencing. 
m6A sequencing was performed as previously described [2]. Briefly, triplicate samples of mRNA 
for each experimental group and controls were purified as in RNA sequencing. m6A pull-down was 
performed with a rabbit polyclonal anti-m6A antibody (Synaptic Systems), then mRNA was 
immunoprecipitated with protein G Dynabeads (ThermoFisher) using competitive elution with free 




Bioinformatic analysis of sequencing data. 
RNA and m6A-RNA sequencing results were processed using the FASTX toolkit 
(http://hannonlab.cshl.edu/fastx_toolkit/) to clip adaptors, filter out low quality reads, and collapse 
identical reads. Reads were mapped to the hg19 human genome using Tophat2 [166] with default 
settings. Differential expression analysis was performed using the DESEQ2 package in R [231]. 
Significance was calculated as padj ,which corrects the p-value for multiple testing using the 
Benjamini-Hochberg correction method. Genes with significant (padj<0.05) induction or repression 
in response to hypoxia in NTC cells were deemed “hypoxia-induced” and “hypoxia-repressed,” 
respectively. HIF- and ALKBH5-dependent genes were then identified as those that lose 
significance (padj>0.05) in HIF-DKD or ALK-KD cells in hypoxic over normoxic conditions or 
genes that are significantly (padj<0.05) higher and have |Log2FoldChange| > 0.5 in hypoxic NTC 
cells over hypoxic HIF-DKD or hypoxic ALK-KD cells. Expression levels for individual 
transcripts were calculated as log2(transcripts per million +1), and expression heat maps were 
plotted using the Heatmapper online tool [232]. m6A peaks were identified using MACS2[167] 
peak calling using total RNA sequencing data as the input control. The BedTools package [168] 
was used to filter for high-confidence m6A peaks; peaks from the triplicate samples were compared 
in a pairwise manner to identify peaks that overlap in at least 2 out of 3 samples. Representative 
m6A coverage plots were made by converting aligned reads in bam format to bedGraph format 
using the BedTools package genomecov function, then plots were made in R with the 
GenomicRanges [233], rtracklayer [234], BSgenome.Hsapiens.UCSC.hg19, and biomaRt [235] 
packages. The distribution of m6A peaks over gene bodies was analyzed using the 
assignChromosomeRegion function of the ChIPpeakAnno [236] package in R. The peak 




Functional annotation and gene ontology. 
Enrichment for gene ontology terms in biological processes was tested using the ToppFunn 
application in the ToppGene Suite [170]. Significant enrichment was determined using a 
hypergeometric probability mass function and Benjamini Hochberg FDR correction with a p-value 
cutoff of 0.05. Redundant gene ontology terms were filtered and the parent term was kept. 
 
 
Proteomic analysis by mass spectrometry. 
Subclones were cultured at 20% or 1% O2 for 48 h and proteins were purified for mass spectrometry 
analysis. Cells were washed with ice cold PBS five times to remove serum proteins, then lysed 
using 0.5 mL of 2% SDS containing 1 mM EDTA and 1 mM phenylmethyl sulfonyl fluoride. Cells 
were sonicated on ice until the cloudy cell lysate became clear. The lysates were then centrifuged 
to remove any pellet and diluted. Protein content and quality were tested with a SilverQuest Silver 
Staining Kit (ThermoFisher LC6070) before sending samples to the Johns Hopkins Mass 
Spectometry Core Facility for analysis, where a Fusion mass spectrometer was used alongside 







Figure 1. HIF regulation of transcriptional changes in response to hypoxia largely occurs 





(a) Overlap of genes that are HIF- and ALKBH5- dependent for induction in response to hypoxia. 
(b) Gene ontology of the 921 genes that are HIF- and ALKBH5-dependent for induction in response 
to hypoxia. (c) Overlap of genes that are HIF- and ALKBH5- dependent for repression in response 
to hypoxia. (d) Gene ontology of the 733 genes that are HIF- and ALKBH5-dependent for 
repression in response to hypoxia. (e) Live cell counts of NTC, HIF-DKD, and ALKBH5-KD 
MCF-7 cells over 72 h of hypoxia. Data are presented as the ratio of counts in live cells cultured at 
1% O2/20% O2 (mean ± SEM, n = 3; *p < 0.05 relative to NTC, **p < 0.01 compared to NTC, $p 
< 0.05 relative to DKD). (f) Percent reduction in cells that incorporate EdU after 48 h of hypoxia 
in the NTC, HIF-DKD, and ALKBH5-KD subclones (mean ± SEM, n = 3; **p < 0.01 vs NTC, 






Figure 2. Dynamic changes in m6A transcript coverage depend on HIF and ALKBH5 
expression. 
(a) ELISA showing the percentage of mRNAs that are m6A+ after 24 h at 20% (teal) or 1% (peach) 





of unique transcripts tagged with m6A in NTC, HIF-DKD, and ALKBH5-KD cells incubated for 
48 h in 20% (teal) or 1% (peach) O2.  (c) Gene ontology of transcripts that are methylated in NTC 
cells at 20% O2.  (d) Gene ontology of transcripts that are not methylated in NTC cells at 20% or 
1% O2, but are methylated in HIF-DKD and ALKBH5-KD cells after exposure to 1% O2 for 48 h. 
(e) Gene ontology of transcripts that are demethylated in NTC cells after exposure to 1% O2 for 48 
h, but remain methylated in hypoxic HIF-DKD and ALKBH5-KD cells. (f) Measurement of O2 
consumption rate (OCR) and extracellular acidification rate (ECAR) to analyze aerobic and 
glycolytic metabolism, respectively (mean ± SEM, n = 4; * p < 0.05 vs OCR of NTC at 20% O2, 








Figure 3. HIF and ALKBH5 mediate m6A methylation patterns across the epitranscriptome. 
(a-b) Sample coverage plots showing enrichment in m6A+ RNA immunoprecipitation and 
sequencing (m6A RIP-seq; black) compared to input total RNA sequencing (gray) for IFT20 (a) 
and TSFM (b) RNA. The bottom panel shows the gene structure, with the position of the 
transcription start site shown in green, the stop codon shown in red, exons shown as large 





KD cells exposed to 1% O2 for 24 h. (c) Distribution of m6A peaks over 5’-UTR (yellow), CDS 
(blue), introns (gray) and 3’-UTR (purple) of RNA from all protein-coding genes. Percentages were 
calculated from peaks that occur in at least two out of three m6A RIP-seq replicates. (d) Gene body 
coverage distribution of m6A RIP-seq peaks in cells exposed to 20% or 1% O2 for 24 h. Gene body 








Figure 4. HIF regulates global translation via ALKBH5 and m6A. 
(a) Heat map showing relative expression levels of mRNAs encoding known m6A readers in NTC, 
HIF-DKD, and ALKBH5-KD cells incubated at 20% or 1% O2 for 48 h. Values are calculated as 





< 0.05) induced in response to hypoxia in HIF-DKD and ALKBH5-KD cells, but not in NTC cells.  
(c) Gene ontology of the 593 shared significantly induced genes (from panel B) show that 
translation is upregulated in HIF-DKD and ALKBH5-KD cells in response to hypoxia. (d) Volcano 
plots showing differential expression of genes in the “translation initiation” and “ribosome” gene 
ontologies in NTC, HIF-DKD, and ALKBH5-KD cells incubated at 1%/20% O2. Red dots 
represent genes that are significantly differentially expressed (padj < 0.05). Dots outside the blue 
dashed lines at Log2(FoldChange) = 1 represent genes that are up- or down- regulated greater than 
2-fold. (e) Translation initiation after incubation at 20% O2 for 48 h, calculated by intensity of a 
GFP linked methionine analog (HPG) added to cells for 30 minutes before harvesting and 
normalized to cell number by DAPI intensity, then normalized to NTC (mean± SEM, n = 4; ****p 
< 0.0001 vs NTC, !!!!p < 0.0001 vs HIF-DKD; n.s., no significance vs NTC). (f) Translation 
initiation levels after incubation at 1% O2 for 48 h, calculated as in panel E (mean± SEM, n = 4; *p 







Figure 5. HIFs and ALKBH5 regulate protein expression via increased translation of m6A-
modified mRNA. 
(a) Venn diagram showing overlap of proteins that are HIF- (yellow) and ALKBH5- (violet) 





are HIF- and ALKBH5- dependent for repression in response to hypoxia. (c) Gene ontology of 
proteins that are HIF- and ALKBH5- dependent for induction. (d) Gene ontology of proteins that 
are HIF- and ALKBH5-dependent for repression. (e) Violin plot showing proteins with cognate 
mRNA that is m6A+ have significantly higher Log2(Fold-Change) in expression in response to 
hypoxia than proteins with cognate mRNA that is m6A-. Red dots represent the mean Log2(Fold-
Change) in expression of all proteins. Height of the plot represents the total distribution of 
expression values, and width of the plot represents the frequency distribution of expression values 
(****p < 0.0001). (f) Graphic summary: hypoxic stress induces HIF-dependent induction of 
ALKBH5, which demethylates m6A from mRNA to reduce translation of modified transcripts. 
Many transcripts encoding proteins that promote translation are demethylated, which in turn 







VII. SUPPLEMENTAL FIGURES: 
 
Supplementary Figure 1. Confirmation of knockdown efficiency and mRNA 
expression. Confirmation of HIF-1α (a) and ALKBH5 (b) shRNA knockdown by RT-
qPCR at 20% O2 (red) and 1% O2 (blue) (mean ± SEM, n = 3; ****p < 0.0001; n.s., p > 
0.05). (c) Analysis of HIF-dependent and ALKBH5-independent CA9 mRNA induction 
by RT-qPCR (mean ± SEM, n=3; ****p < 0.0001; n.s., p > 0.05). (d) Confirmation of HIF-
dependent and ALKBH5-dependent VEGFA mRNA induction by RT-qPCR (mean ± 







Supplementary Figure 2. Differential mRNA expression in MCF-7 NTC subclone 
exposed to 1% or 20% O2 for 24 h. Log2FoldChange of mRNA expression at 1% O2 vs 
20% O2. Red dots represent a significant (padj < 0.05) change in gene expression. The top 






Supplementary Figure 3. Differential mRNA expression between MCF-7 NTC and 
HIF-DKD subclones exposed to 1% O2 for 24 h. Log2FoldChange of mRNA expression 
in NTC vs HIF-DKD subclone at 1% O2. Red dots represent a significant (padj < 0.05) 






Supplementary Figure 4. Differential mRNA expression between MCF-7 NTC and 
ALK-KD subclones exposed to 1% O2 for 24 h. Log2FoldChange of mRNA expression 
in NTC vs ALK-KD subclone at 1% O2. Red dots represent significant (padj < 0.05) 






Supplementary Figure 5. Gene ontology analysis of HIF- and ALKBH5-dependent 
mRNAs. (a) Gene ontology of mRNAs that are HIF-dependent for induction in response 
to hypoxia. (b) Gene ontology of mRNAs that are ALKBH5-dependent for induction in 
response to hypoxia. (c) Gene ontology of mRNAs that are HIF-dependent for repression 
in response to hypoxia. (d) Gene ontology of mRNAs that are ALKBH5-dependent for 







Supplementary Figure 6. Comparison of FTO and ALKBH5 mRNA expression levels 
in cells exposed to 20% or 1% O2 for 48 h. Data are RPKM (reads per kilobase of 
transcript, per million mapped reads) and normalized to FTO expression in normoxia 







Supplementary Figure 7. Gene ontology of mRNAs that are methylated in NTC cells 







Supplementary Figure 8. Potential m6 A functions mediated by known YTH domain-
containing reader proteins. (a) Expression of alternatively spliced versions of ANKZF1 
RNA in NTC, HIFDKD, and ALKBH5-KD cells incubated at 20% or 1% O2 for 24 h, as 
determined by RT-qPCR. Red bars represent gene transcripts that are m6 A-modified in 
hypoxia. Alternative splicing of ANKZF1 correlates with m6 A status (mean± SEM, n = 
3; ***p < 0.001 vs NTC at 20% O2). (b) Expression of alternatively spliced versions of 
CYR61 mRNA in NTC, HIF-DKD, and ALKBH5-KD cells incubated at 20% or 1% O2 





in hypoxia. CYR61 mRNA alternative splicing does not correlate with m6 A 3 status 
(mean± SEM, n = 3; ***p < 0.001 vs expression at 20% O2). (c) Venn diagrams showing 
that more upregulated mRNAs are m6 A-modified than not at 1% O2, whereas fewer 
downregulated mRNAs are m6 A-modified at 1% O2. Χ2 analysis demonstrated 
significant (p < 0.001) enrichment in hypoxic cells of upregulated mRNAs that are m6 A-
modified. (d) Confirmation of translation initiation assay by confocal imaging of cells 
incubated at 1% O2 for 48 h and treated with AlexaFluor488-linked methionine analog 
HPG for 30 min before fixation. Increased levels of nascent protein (green) are seen in the 







Supplementary Figure 9. Analysis of differentially expressed proteins in MCF-7 cells. 
(a) Venn diagrams showing the overlap between differentially expressed mRNA and 
protein in NTC, HIFDKD and ALKBH5-KD cells exposed to 1% O2 for 24 h (for RNA 
analysis) or 48 h (for protein analysis). Values determined from RNA sequencing (n = 3) 
and mass spectrometry (n = 4). (b) Plot of the number of proteins that are significantly (p 
< 0.05) upregulated (turquoise) or downregulated (violet) in NTC, HIF-DKD, and 







Supplementary Figure 10. HIF and ALKBH5 prevent aberrant translation under 
hypoxic conditions. (a) Venn diagram of proteins that are significantly (p < 0.05) induced 
in response to hypoxia in HIF-DKD (yellow) and ALK-KD (violet), but not in NTC cells, 





DKD cells. (c) Gene ontology of aberrantly induced proteins in ALK-KD cells. (d) Gene 
ontology of aberrantly induced proteins shared between HIF-DKD and ALK-KD cells. (e) 
Violin plot showing fold-change of expression in response to hypoxia of proteins in the 
“positive regulation of translation initiation” gene 4 ontology (*p < 0.05 vs NTC). Red dots 
represent the mean Log2(Fold-Change) in expression of all proteins. Height of the plot 
represents the total distribution of expression values, and width of the plot represents the 



















 Working in different systems throughout graduate school, from neuroscience to breast 
cancer, highlighted the fact that m6A has incredibly different functions in distinct contexts. It also 
made it clear that m6A likely does not have a single function even within a singular cell type. The 
current state of the field is focused on identifying the central function of m6A in one cell type at a 
time. Moving forward, however, I am interested in understanding the upstream regulation of the 
system that allows it to be so specialized and dynamic in distinct contexts.  
 For example, different cell types in the nervous system express different levels of various 
m6A machinery proteins (Figure 1). Moving forward, I’m interested in understanding what 
regulates the expression of different m6A reader proteins, as well as identifying upstream regulators 
of methyltransferase or demethylase activity.  
 In addition to understanding the dynamics of m6A, I’m excited by the prospects of studying 
other epitranscriptomic marks. As detection technologies improve, other modifications will become 
easier to study. For example, pseudouridine, m5C, and m1A 
are emerging as additional important regulators of mRNA 
processing and require studies in vivo. I’m also interested 
in the interaction  
of epitranscriptomic marks on mRNA, tRNA, and rRNA 
that could clarify some of the uncertainties in how the 
epitranscriptome functions.  I am honored and excited to 
contribute to our understanding of the epitranscriptome in 
the coming years.   
Figure 1: Differential Expression of m6A Machinery 
Fragments per kilobase (FPKM) as a measure of gene expression from RNA sequencing data shows 
highly differential expression of m6A methyltransferase components (green,) reader proteins 
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